WO2004072051A1 - Isoxazole compounds as inhibitors of heat shock proteins - Google Patents

Isoxazole compounds as inhibitors of heat shock proteins Download PDF

Info

Publication number
WO2004072051A1
WO2004072051A1 PCT/GB2004/000506 GB2004000506W WO2004072051A1 WO 2004072051 A1 WO2004072051 A1 WO 2004072051A1 GB 2004000506 W GB2004000506 W GB 2004000506W WO 2004072051 A1 WO2004072051 A1 WO 2004072051A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
isoxazole
carboxylic acid
dihydroxy
acid ethylamide
Prior art date
Application number
PCT/GB2004/000506
Other languages
French (fr)
Inventor
Martin James Drysdale
Brian William Dymock
Harry Finch
Paul Webb
Edward Mcdonald
Karen Elizabeth James
Kwai Ming Cheung
Thomas Peter Mathews
Original Assignee
Vernalis (Cambridge) Limited
Cancer Research Technology Ltd
The Institute Of Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0303105A external-priority patent/GB0303105D0/en
Priority claimed from GBGB0306560.4A external-priority patent/GB0306560D0/en
Priority claimed from GB0313751A external-priority patent/GB0313751D0/en
Priority to US10/544,443 priority Critical patent/US7705027B2/en
Priority to JP2006502254A priority patent/JP4921162B2/en
Priority to SI200431954T priority patent/SI1611112T1/en
Priority to CA2515726A priority patent/CA2515726C/en
Priority to ES04709273T priority patent/ES2393483T3/en
Priority to AU2004210779A priority patent/AU2004210779B2/en
Priority to MXPA05008335A priority patent/MXPA05008335A/en
Priority to NZ541479A priority patent/NZ541479A/en
Priority to CN2004800093392A priority patent/CN1771235B/en
Application filed by Vernalis (Cambridge) Limited, Cancer Research Technology Ltd, The Institute Of Cancer Research filed Critical Vernalis (Cambridge) Limited
Priority to EP04709273A priority patent/EP1611112B1/en
Priority to BRPI0407403-3A priority patent/BRPI0407403B1/en
Priority to EA200501272A priority patent/EA009919B1/en
Priority to KR1020057014738A priority patent/KR101166749B1/en
Priority to DK04709273.9T priority patent/DK1611112T3/en
Publication of WO2004072051A1 publication Critical patent/WO2004072051A1/en
Priority to NO20054195A priority patent/NO335001B1/en
Priority to HK06112447.8A priority patent/HK1091831A1/en
Priority to US12/708,686 priority patent/US8507480B2/en
Priority to US13/525,409 priority patent/US8450310B2/en
Priority to US13/929,098 priority patent/US9718793B2/en
Priority to US15/631,059 priority patent/US10413550B2/en
Priority to US16/528,278 priority patent/US11234987B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • This invention relates to substituted isoxazoles having HSP90 inhibitory activity, to the use of such compounds in medicine, in relation to diseases which are responsive to inhibition of HSP90 activity such as cancers, and to pharmaceutical compositions containing such compounds.
  • HSPs Heat Shock Proteins
  • HSPs multigene families of HSPs exist, with individual gene products varying in cellular expression, function and localization. They are classified according to molecular weight, e.g., HSP70, HSP90, and HSP27.
  • Several diseases in humans can be acquired as a result of protein misfolding (reviewed in Tytell et al., 2001 ; Smith et al., 1998).
  • therapies which disrupt the molecular chaperone machinery may prove to be beneficial.
  • misfolded proteins can cause protein aggregation resulting in neurodegenerative disorders.
  • misfolded proteins may result in loss of wild type protein function, leading to deregulated molecular and physiological functions in the cell.
  • HSPs have also been implicated in cancer. For example, there is evidence of differential expression of HSPs which may relate to the stage of tumour progression (Martin et al., 2000; Conroy et al., 1996; Kawanishi et al., 1999; Jameel et al., 1992; Hoang et al., 2000; Lebeau et al., 1991).
  • HSP90 in various critical oncogenic pathways and the discovery that certain natural products with anticancer activity are targeting this molecular chaperone
  • the first molecular chaperone inhibitor is currently undergoing clinical trials.
  • HSP90 HSP90 constitutes about 1-2% of total cellular protein, and is usually present in the cell as a dimer in association with one of a number of other proteins (see, e.g., Pratt, 1997). It is essential for cell viability and it exhibits dual chaperone functions (Young et al., 2001 ). It plays a key role in the cellular stress response by interacting with many proteins after their native conformation has been altered by various environmental stresses, such as heat shock, ensuring adequate protein folding and preventing non-specific aggregation (Smith et al., 1998).
  • HSP90 may also play a role in buffering against the effects of mutation, presumably by correcting the inappropriate folding of mutant proteins (Rutherford and Lindquist, 1998).
  • HSP90 also has an important regulatory role. Under normal physiological conditions, together with its endoplasmic reticulum homologue GRP94, HSP90 plays a housekeeping role in the cell, maintaining the conformational stability and maturation of several key client proteins.
  • steroid hormone receptors e.g., ERBB2, RAF-1, CDK4, and LCK
  • Ser/Thr or tyrosine kinases e.g., ERBB2, RAF-1, CDK4, and LCK
  • a collection of apparently unrelated proteins e.g., mutant p53 and the catalytic subunit of telomerase hTERT. All of these proteins play key regulatory roles in many physiological and biochemical processes in the cell. New HSP90 client proteins are continuously being identified.
  • HSP90 The highly conserved HSP90 family in humans consists of four genes, namely the cytosolic HSP90 ⁇ and HSP90 ⁇ isoforms (Hickey et al., 1989), GRP94 in the endoplasmic reticulum (Argon et al., 1999) and HSP75/TRAP1 in the mitochondrial matrix (Felts et al., 2000). It is thought that all the family members have a similar mode of action, but bind to different client proteins depending on their localization within the cell.
  • ERBB2 is known to be a specific client protein of GRP94 (Argon et al., 1999) and type 1 tumour necrosis factor receptor (TNFR1) and RB have both been shown to be clients of TRAP1 (Song et al., 1995; Chen et al., 1996).
  • HSP90 participates in a series of complex interactions with a range of client and regulatory proteins (Smith, 2001 ). Although the precise molecular details remain to be elucidated, biochemical and X-ray crystallographic studies (Prodromou et al., 1997; Stebbins et al., 1997) carried out over the last few years have provided increasingly detailed insights into the chaperone function of HSP90.
  • HSP90 is an ATP-dependent molecular chaperone (Prodromou et al, 1997), with dimerization of the nucleotide binding domains being essential for ATP hydrolysis, which is in turn essential for chaperone function (Prodromou et al, 2000a). Binding of ATP results in the formation of a toroidal dimer structure in which the N terminal domains are brought into closer contact with each other resulting in a conformational switch known as the 'clamp mechanism' (Prodromou and Pearl, 2000b).
  • HSP90 Inhibitors The first class of HSP90 inhibitors to be discovered was the benzoquinone ansamycin class, which includes the compounds herbimycin A and geldanamycin. They were shown to reverse the malignant phenotype of fibroblasts transformed by the v-Src oncogene (Uehara et al., 1985), and subsequently to exhibit potent antitumour activity in both in vitro (Schulte et al., 1998) and in vivo animal models (Supko et al., 1995).
  • 17-Allylamino, 17-demethoxygeldanamycin retains the property of HSP90 inhibition resulting in client protein depletion and antitumour activity in cell culture and xenograft models (Schulte et al, 1998; Kelland et al, 1999), but has significantly less hepatotoxicity than geidanamycin (Page et al, 1997). 17AAG is currently being evaluated in Phase I clinical trials.
  • Radicicol is a macrocyclic antibiotic shown to reverse the malignant phenotype of v-Src and v-Ha-Ras transformed fibroblasts (Kwon et al, 1992; Zhao et al, 1995). It was shown to degrade a number of signalling proteins as a consequence of HSP90 inhibition (Schulte et al., 1998). X-ray crystallographic data confirmed that radicicol also binds to the N terminal domain of HSP90 and inhibits the intrinsic ATPase activity (Roe et al., 1998). Radicicol lacks antitumour activity in vivo due to the unstable chemical nature of the compound.
  • a purine-based HSP90 inhibitor, PU3 has been shown to result in the degradation of signalling molecules, including ERBB2, and to cause cell cycle arrest and differentiation in breast cancer cells (Chiosis et al., 2001 ).
  • HSP90 as a Therapeutic Target Due to its involvement in regulating a number of signalling pathways that are crucially important in driving the phenotype of a tumour, and the discovery that certain bioactive natural products exert their effects via HSP90 activity, the molecular chaperone HSP90 is currently being assessed as a new target for anticancer drug development (Neckers et al., 1999).
  • geidanamycin, 17AAG, and radicicol The predominant mechanism of action of geidanamycin, 17AAG, and radicicol involves binding to HSP90 at the ATP binding site located in the N-terminal domain of the protein, leading to inhibition of the intrinsic ATPase activity of HSP90 (see, e.g., Prodromou et al., 1997; Stebbins et al., 1997; Panaretou et al., 1998).
  • HSP90 ATPase activity prevents recruitment of co-chaperones and encourages the formation of a type of HSP90 heterocomplex from which these client proteins are targeted for degradation via the ubiquitin proteasome pathway (see, e.g., Neckers et al., 1999; Kelland et al., 1999).
  • HSP90 inhibitors Treatment with HSP90 inhibitors leads to selective degradation of important proteins involved in cell proliferation, cell cycle regulation and apoptosis, processes which are fundamentally important in cancer.
  • HSP90 function has been shown to cause selective degradation of important signalling proteins involved in cell proliferation, cell cycle regulation and apoptosis, processes which are fundamentally important and which are commonly deregulated in cancer (see, e.g., Hostein et al., 2001).
  • An attractive rationale for developing drugs against this target for use in the clinic is that by simultaneously depleting proteins associated with the transformed phenotype, one may obtain a strong antitumour effect and achieve a therapeutic advantage against cancer versus normal cells.
  • These events downstream of HSP90 inhibition are believed to be responsible for the antitumour activity of HSP90 inhibitors in cell culture and animal models (see, e.g., Schulte et al., 1998; Kelland et al., 1999).
  • the present invention relates to the use of a class of substituted isoxazole compounds as HSP90 inhibitors, for example for inhibition of cancer cell proliferation.
  • the invention also includes novel isoxazole compounds per se, and pharmaceutical compositions containing them
  • Ri is a group of formula (IA):
  • Ar 1 is an optionally substituted aryl or heteroaryl radical
  • Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical
  • R 2 is (i) a group of formula (IA) as defined in relation to R ;
  • R 3 is hydrogen, optionally substituted cycloalkyl, cycloalkenyl, Ci-C ⁇ alkyl, C ⁇ -C 6 alkenyl, or C ⁇ -C 6 alkynyl; or a carboxyl, carboxamide, or carboxyl ester group.
  • the class of compounds defined above in relation to formula (I) is believed to be novel, and the invention includes all novel members of that class and their salts, hydrates and solvates, and prodrugs thereof.
  • carboxyl group refers to a group of formula -COOH
  • carboxyl ester group refers to a group of formula -COOR, wherein R is a radical actually or notionally derived from the hydroxyl compound ROH;
  • carboxamide group refers to a group of formula -CONR a Rb, wherein -NR a R b is a primary or secondary (including cyclic) amino group actually or notionally derived from ammonia or the amine HNR a R b .
  • (C a -C b )alkyl wherein a and b are integers refers to a straight or branched chain alkyl radical having from a to b carbon atoms.
  • a 1 and b is 6, for example, the term includes methyl, ethyl, n- propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl and n-hexyl.
  • divalent (C a -C b )alkylene radical wherein a and b are integers refers to a saturated hydrocarbon chain having from a to b carbon atoms and two unsatisfied valences.
  • (C a -C b )alkenyl wherein a and b are integers refers to a straight or branched chain alkenyl radical having from a to b carbon atoms and containing at least one double bond of E or Z configuration, including for example, ethenyl and allyl.
  • divalent (C a -C b )alkenylene radical wherein a and b are integers refers to a hydrocarbon chain having from a to b carbon atoms, at least one double bond, and two unsatisfied valences.
  • (C a -C b )alkynyl wherein a and b are integers refers to a straight or branched chain alkenyl radical having from a to b carbon atoms and containing at least one triple bond, including for example, ethynyl and prop-2-ynyl.
  • divalent (C a -C b )alkynylene radical wherein a and b are integers refers to a straight or branched chain alkynyl radical having from a to b carbon atoms and containing at least one triple bond, and two unsatisfied valencies.
  • cycloalkyl refers to a saturated carbocyclic radical having from 3-8 carbon atoms and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
  • cycloalkenyl refers to a carbocyclic radical having from 3-8 carbon atoms containing at least one double bond, and includes, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl.
  • aryl refers to a mono-, bi- or tri-cyclic carbocyclic aromatic radical. Illustrative of such radicals are phenyl, biphenyl and napthyl.
  • Carbocyclic refers to a cyclic radical whose ring atoms are all carbon, and includes monocyclic aryl, cycloalkyl and cycloalkenyl radicals.
  • heteroaryl refers to a mono-, bi- or tri-cyclic aromatic radical containing one or more heteroatoms selected from S, N and O.
  • Illustrative of such radicals are thienyl, benzthienyl, furyl, benzfuryl, pyrrolyl, imidazolyl, benzimidazolyl, thiazolyl, benzthiazolyl, isothiazolyl, benzisothiazolyl, pyrazolyl, oxazolyl, benzoxazolyl, isoxazolyl, benzisoxazolyl, isothiazolyl, triazolyl, benztriazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl and indazolyl.
  • heterocyclyl or “heterocyclic” includes “heteroaryl” as defined above, and in particular means a mono-, bi- or tricyclic non-aromatic radical containing one or more heteroatoms selected from S, N and O, and to groups consisting of a monocyclic non-aromatic radical containing one or more such heteroatoms which is covalently linked to another such radical or to a monocyclic carbocyclic radical.
  • radicals are pyrrolyl, furanyl, thienyl, piperidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, pyrazolyl, pyridinyl, pyrrolidinyl, pyrimidinyl, morpholinyl, piperazinyl, indolyl, morpholinyl, benzfuranyl, pyranyl, isoxazolyl, benzimidazolyl, methylenedioxyphenyl, ethylenedioxyphenyl, maleimido and succinimido groups.
  • substituted as applied to any moiety herein means substituted with up to four compatible substituents, each of which independently may be, for example, (C ⁇ -C 6 )alkyl, (CrC 6 )alkoxy, hydroxy, hydroxy(C ⁇ -C 6 )alkyl, mercapto, mercapto(C ⁇ -C 6 )alkyl, (C -C ⁇ jalkylthio, halo (including fluoro, bromo and chloro), trifluoromethyl, trifluoromethoxy, nitro, nitrile (-CN), oxo, phenyl, - COOH, -COOR A , -COR A , -SO 2 R A , -CONH 2l -SO 2 NH 2 , -CONHR A , -SO 2 NHR A , -CONR A R B , -SO 2 NR A R B , -
  • an “optional substituent” may be one of the foregoing substituent groups.
  • substituents C ⁇ -C 6 )alkyl, halo, trifluoromethyl, trifluoromethoxy, trifluoromethylsulfonyl, and phenyl are those most commonly regarded as lipophilic.
  • substituents listed which contain alkyl groups may be lipophilic depending on the particular alkyl groups present.
  • salt includes base addition, acid addition and quaternary salts.
  • Compounds of the invention which are acidic can form salts, including pharmaceutically or veterinarily acceptable salts, with bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. N-methyl-D-glucamine, choline tris(hydroxymethyl)amino- methane, L-arginine, L-lysine, N-ethyl piperidine, dibenzylamine and the like.
  • bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. N-methyl-D-glucamine, choline tris(hydroxymethyl)amino- methane, L-arginine, L-lysine, N-
  • Those compounds (I) which are basic can form salts, including pharmaceutically or veterinarily acceptable salts with inorganic acids, e.g. with hydrohalic acids such as hydrochloric or hydrobromic acids, sulphuric acid, nitric acid or phosphoric acid and the like, and with organic acids e.g. with acetic, tartaric, succinic, fumaric, maleic, malic, salicylic, citric, methanesulphonic, p-toluenesulphonic, be4nzoic, benzenesunfonic, glutamic, lactic, and mandelic acids and the like.
  • hydrohalic acids such as hydrochloric or hydrobromic acids, sulphuric acid, nitric acid or phosphoric acid and the like
  • organic acids e.g. with acetic, tartaric, succinic, fumaric, maleic, malic, salicylic, citric, methanesulphonic, p-toluene
  • lipophilic as used herein in relation to a substituent means that it has a positive substituent hydrophobicity constant ( ⁇ ).
  • ⁇ hydrophobicity constant
  • Some compounds of the invention contain one or more actual or potential chiral centres because of the presence of asymmetric carbon atoms.
  • the presence of several asymmetric carbon atoms gives rise to a number of diastereoisomers with R or S stereochemistry at each chiral centre.
  • the invention includes all such diastereoisomers and mixtures thereof.
  • An aspect of the invention includes compounds of formula (A) or (B) above and a salts, N-oxides, hydrates or solvates thereof and prodrugs thereof, except the following three compounds (X), (Y) and (Z) which are commercially available:
  • the invention particularly includes those wherein the substituents Ri , R 2 and R 3 are as discussed and specified in the following sections headed "The radical R “, "The radical R 2 ", and "The radical R 3 ", Another aspect includes the use of such compounds for the treatment of diseases responsive to inhibition of HSP90 activity.
  • the radical Ar 1 present in the Ri group is optionally substituted phenyl, preferably with one of the optional substituents being a hydroxy group in position 2 relative to the point of attachment of the phenyl ring to isoxazole ring.
  • the group Ri preferably has formula (IB)
  • Alk 1 , Alk 2 , p, r, s, Z and Q are as defined above in relation to Ri, and R represents one or more optional substituents.
  • R represents one or more optional substituents.
  • the ring carbon atom adjacent the hydroxyl group be unsubstituted.
  • each of p, r and s may be 0, and Q may be hydrogen, so that Ri is optionally substituted aryl or heteroaryl.
  • R may be, for example, optionally substituted phenyl, preferably 2-hydroxyphenyl which may be further substituted, for example by one or more of hydroxy, methyl, ethyl, methoxy, ethoxy , chloro, or bromo.
  • Ri is 2,4-dihydroxyphenyl, substituted in the 5-position by a small lipophilic substituent, for example having a molecular volume equal to or less than that of tert-butyl, such as methyl, ethyl, isopropyl, isobutyl, tert-butyl, chloro, or bromo, especially ethyl, isopropyl, or chloro.
  • a small lipophilic substituent for example having a molecular volume equal to or less than that of tert-butyl, such as methyl, ethyl, isopropyl, isobutyl, tert-butyl, chloro, or bromo, especially ethyl, isopropyl, or chloro.
  • the hydroxyl groups may be protected by groups which are cleaved in the body to release the hydroxyl groups.
  • prodrug-type groups of this kind which are cleaved to hydroxyls include alkylcarbonyloxy groups such as methylcarbonyloxy, and alkylaminocarbonyloxy groups such as dialkylamino- or isopropylamino- carbonyloxy.
  • p, r and s may again each be 0, and Q may be an optionally substituted carbocyclic or heterocyclic ring, for example a phenyl or pyridyl ring.
  • Q is a direct substituent in the optionally substituted Ar 1 ring
  • one or more of p, r and s may be 1 , and Q may be hydrogen or an optionally substituted carbocyclic or heterocyclic ring.
  • p and/or s may be 1 and r may be 0, so that Q is linked to Ar 1 by an alkylene or alkenylene radical, for example a C C 3 alkylene radical, which is optionally substituted.
  • each of p, r, and s may be 1, in which cases, Q is linked to Ar 1 by an alkylene or alkenylene radical which is interrupted by the hetero atom- containing Z radical.
  • p and s may be 0 and r may be 1 , in which case Q is linked to Ar 1 via the hetero atom-containing Z radical.
  • R 2 is of type (i), i.e. a group of formula (IA)
  • examples include phenyl, 2-, 3-, or 4-pyridyl, 2- or 3-furanyl, 2- or 3-thienyl, and thiazolyl wherein optional substituents include any of those listed above in the definition of "substituted", for example methoxy , ethoxy, methylenedioxy, ethylenedioxy, fluoro, chloro, bromo, and trifluoromethyl.
  • R 2 may be phenyl substituted in the 4 position by C C 6 alkoxy such as methoxy or ethoxy, or by fluoro, chloro, bromo, piperazinyl, N-methylpiperazinyl, or piperidinyl.
  • R 2 substituents include those having the partial structure:
  • solubilising groups are known in medicinal chemistry. Examples include morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, ethylamino, isopropylamino, diethylamino, cyclohexylamino, cyclopentylamino, methoxyethylamino, piperidin-4-yl, N-acetylpiperazinyl, methylsulfonylamino, thiomorpholinyl, thiomorpholinyldioxide, 4-hydroxyethylpiperidinyl, and 4-hydroxypiperidinyl.
  • n O or 1
  • R B is hydrogen or a C C 6 alkyl or C 2 -C 6 alkenyl group, for example methyl, ethyl, n- or iso-propyl, or allyl,
  • R A is hydroxy or optionally substituted carbocyclic, for example hydroxy and/or chloro-substituted phenyl and 3,4 methylenedioxyphenyl; or heterocyclyl, for example pyridyl, furyl, thienyl, N-piperazinyl, or N- morpholinyl any of which heterocyclic rings may be substituted,
  • N-heterocyclic ring which may optionally contain one or more additional hetero atoms selected from O, S and N, and which may optionally be substituted on one or more ring C or N atoms, examples of such N-heterocyclic rings including morpholino, piperidinyl, piperazinyl and N-phenylpiperazinyl.
  • R 3 may be, for example, hydrogen, methyl, ethyl, n- or iso-propyl, trifluoromethyl, hydroxyethyl, methylsulfonaminomethyl, or a carboxamide group -CONR B (Alk) n R A as discussed above for R 2 .
  • a carboxamide group is presently preferred, especially ethylaminocarbonyl and isopropylaminocarbonyl.
  • a particular sub-set of the compounds with which this invention is concerned consists of those of formula (ID), and the formula B regioisomers thereof, and their salts, solvates and hydrates, and prodrugs thereof:
  • each R independently represents an optional substituent and R 3 represents a carboxamide group.
  • a preferred sub-set of the compounds with which this invention is concerned consists of those of formula (IE), and the formula (B) regioisomers thereof, and their salts, solvates and hydrates, and prodrugs thereof:
  • R 9 represents -CH 2 NR 10 R 11 or-NR 10 R 11 wherein the substituted amino group -NR 10 R 11 is a solubilising group, (such as morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, ethylamino, isopropylamino, diethylamino, cyclohexylamino, cyclopentylamino, methoxyethylamino, piperidin-4-yl, N-acetylpiperazinyl, N- methylpiperazinyl, methylsulfonylamino, thiomorpholinyl, thiomorpholinyl- dioxide, 4-hydroxyethylpiperidiny
  • some compounds of formula (IA) may be prepared by reaction of hydroxylamine and a compound of formula (III)
  • ring A corresponds to the group Ri of compounds (IA) and R 2 and R3 are as defined in relation to formula (I).
  • Compounds prepared in this way may then be chemically modified to introduce desired substituents, to produce other compounds of formula (A)
  • Ri is a phenyl ring, optionally already carrying substituents
  • the introduction of a bromo substituent will often enable introduction of other substituents at the bromo site by sp2 coupling.
  • the isoxazole ring is formed by the reaction of a comound (IV) with hydroxylamine
  • R' ⁇ and R' 3 are members of the substutuent classes Ri and R 3 defined above, to produce the isoxazole (V)
  • isoxazole regioisomers (B) may be prepared from the isoxazoles (A) by reaction with trimethyloxonium boron trifluoride, and again compounds prepared in this way may then be chemically modified to introduce desired substituents, to produce other compounds of formula (IA).
  • the compounds of the invention are inhibitors of HSP90 and are thus useful in the treatment of diseases which are responsive to inhibition of HSP90 activity such as cancers; viral diseases such as Hepatitis C (HCV) (Waxman, 2002); Immunosupression such as in transplantation (Bijlmakers, 2000 and Yorgin, 2000); Anti-inflammatory diseases (Bucci, 2000) such as Rheumatoid arthritis, Asthma, MS, Type I Diabetes, Lupus, Psoriasis and Inflammatory Bowel Disease; Cystic fibrosis (Fuller, 2000); Angiogenesis-related diseases (Hur, 2002 and Kurebayashi, 2001 ): diabetic retinopathy, haemangiomas, psoriasis, endometriosis and tumour angiogenesis.
  • an Hsp90 inhibitor of the invention may protect normal cells against chemotherapy-induced toxicity and be useful in diseases where failure to undergo apoptosis is an underlying factor.
  • Such an Hsp90 inhibitor may also be useful in diseases where the induction of a cell stress or heat shock protein response could be beneficial, for example, protection from hypoxia-ischemic injury due to elevation of Hsp70 in the heart (Hutter, 1996 and Trost, 1998) and brain (Plumier, 1997 and Rajder, 2000).
  • Hsp90 inhibitor could also be useful in diseases where protein misfolding or aggregation is a major causal factor , for example, scrapie/CJD, Huntingdon's and Alzheimer's (Sittler, 2001 ; Trazelt, 1995 and Winklhofer, 2001 ).
  • the invention also provides:
  • a pharmaceutical composition comprising a compound of formula (A) or (B) as defined and specified above, together with a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier for example aqueous saline.
  • a suitable dose for orally administrable formulations will usually be in the range of 0.1 to 3000 mg once, twice or three times per day, or the equivalent daily amount administered by infusion or other routes.
  • optimum dose levels and frequency of dosing will be determined by clinical trials as is conventional in the art.
  • the compounds with which the invention is concerned may be prepared for administration by any route consistent with their pharmacokinetic properties.
  • the orally administrable compositions may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical, or sterile parenteral solutions or suspensions.
  • Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, fragacanth, or polyvinyl-pyrrolidone; fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricant, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants for example potato starch, or acceptable wetting agents such as sodium lauryl sulphate.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
  • suspending agents for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats
  • emulsifying agents for example lecithin, sorbitan monooleate, or acacia
  • non-aqueous vehicles which may include edible oils
  • almond oil fractionated coconut oil
  • oily esters such as glycerine, propylene
  • the drug may be made up into a cream, lotion or ointment.
  • Cream or ointment formulations which may be used for the drug are conventional formulations well known in the art, for example as described in standard textbooks of pharmaceutics such as the British Pharmacopoeia.
  • the active ingredient may also be administered parenterally in a sterile medium.
  • the drug can either be suspended or dissolved in the vehicle.
  • adjuvants such as a local anaesthetic, preservative and buffering agents, can be dissolved in the vehicle.
  • the invention includes a method of inhibiting HSP90 activity, comprising bringing into contact, in vitro, an HSP90 enzyme and a compound of formula (A) or (B) as defined and specified above.
  • Resorcinol (4.4g, 40mmol) and 4-methoxyphenylacetic acid (6.6g, 40mmol) in boron trifluoride.etherate (25ml, 0.2mol) was heated, under a nitrogen atmosphere, at 90°C for ⁇ 90mins. to give a pale red solution.
  • the solution was allowed to cool and poured into aqueous sodium acetate (200ml,10%) and the mixture stirred to give a pale yellow precipitate.
  • the solids were removed by filtration and washed with water (200ml). Solids were taken up in ethyl acetate (250ml) and washed with water (200ml). Solution was dried over anhyrous magnesium sulphate and concentrated, to a yellow semi-solid.
  • Acetic anhydride (3ml, 30mmol) was added to a suspension of potassium carbonate (4.0g, 29mmol) and 1-(2,4-dihydroxy-phenyl)-2-(4-methoxy- phenyl)-ethanone (1.95g, 7.5mmol) in DMF (10ml), and the resulting suspension heated at 115°C for ⁇ 90mins. The mixture was allowed to cool and poured into water (200ml), to give an off-white precipitate.
  • Step 3 4-.[4.(4-.
  • Hydroxylamine hydrochloride (0.35g, 5mmol) was added to a suspension of 7-hydroxy-3-(4-methoxy-phenyl)-2-methyl-chromen-4-one (0.14g, O. ⁇ mmol) in pyridine (3ml) and the mixture heated under reflux for ⁇ 4hrs. The solution was allowed to cool and poured into water (50ml) and extracted with diethyl ether (50ml). The extracts were washed with water (3x 50ml) and saturated aqueous sodium chloride solution (30ml). The solution was dried over anhydrous magnesium sulphate and concentrated to give a pale brown gum.
  • Benzyltrimethylammonium tribromide (3.95g, 10mmol) was added portion-wise to an ice cooled suspension of 4-[4-(4-methoxy-phenyl)-3-methyl- isoxazol-5-yl]-benzene-1 ,3-diol (Example 1) (2.95g, 10mmol) in dichloromethane (50ml) and the mixture stirred for ⁇ 60mins, at room temperature. Ethyl acetate (300ml) was added and the mixture washed with water (3x200ml) and saturated aqueous sodium chloride solution (50ml). The solution was dried over anhydrous magnesium sulphate and concentrated to give a pale brown solid.
  • Benzyl bromide (0.36ml, 3mmol) was added suspension of 4-bromo-6- [4-(4-methoxy-phenyl)-3-methyl-isoxazol-5-yl]-benzene-1 ,3-diol (Example 2) (0.55g, 1.5mmol) and cesium carbonate (0.85g, 2.6mmol) in DMF (5ml) and the mixture stirred for ⁇ 18hrs, at room temperature. Water (100ml) was added and the mixture extracted with diethyl ether (2x30ml). The combined extracts were washed with water (4x75ml) and saturated aqueous sodium chloride solution (50ml).
  • Potassium phosphate (0.1g, O. ⁇ mmol) was added to a solution of 5-(2,4-bis- benzyloxy-5-bromo-phenyl)-4-(4-methoxy-phenyl)-3-methyl-isoxazole (0.14g, 0.25mmol) and phenyl boronic acid (0.095g, 0.75mmol) in 1 ,4 dioxan (4ml) under a nitrogen atmosphere. Tetrakis(triphenylphosphine)palladium(0) (cat.) was added and the suspension heated, 80°C for ⁇ 18hrs. The suspension was allowed to cool and ethyl acetate (25ml) added.
  • Ammonium formate (3.2g, 50mmol) was added to a solution of 5-(4,6- bis-benzyloxy-biphenyl-3-yl)-4-(4-methoxy-phenyl)-3-methyl-isoxazole (1.4g, 2.5mmol) in methanol (20ml)/ethyl acetate (10ml) under a nitrogen atmosphere. Palladium on carbon (10%) (cat.) was added and the suspension heated, at 60°C for ⁇ 18hrs. The suspension was allowed to cool and ethyl acetate (150ml) added, and the suspension filtered. The filtrate was washed with water (3x100ml) and saturated aqueous sodium chloride solution (50ml).
  • Step 4 5-[4-(4- ethoxy-phenyl)-3-methyl-isoxazol-5-yl]-biphenyl-2,4-diol
  • the compounds of Examples 1-4 had an HSP90 IC50 in the range A when tested in the Malachite Green ATPase assay described below.
  • the final column gives the result on the same basis for the compound in question, except in the case of Example 12b, where the activity quoted is as measured in the fluorescence polarisation assay described below.
  • Examples 5-16 were prepared using the reaction described for Examples 1-4. Other details of the preparation Examples 6 and 7 are analagous to those of Examples 86 and 87.
  • N-methylpiperazine (0.125ml, 1.1 mmol) was added to a suspension of 4-[4-(4- methoxy-phenyl)-3-methyl-isoxazol-5-yl]-benzene-1 ,3-diol (0.15g, O. ⁇ mmol) and paraformaldehyde (0.040g) in 1 ,4-dioxan (4ml) and the mixture heated under reflux for ⁇ 18hrs., to give a brown yellow solution. The solution was allowed to cool and ethyl acetate (25ml) added. The mixture was washed with water (3x25ml) and saturated aqueous sodium chloride solution (2 ⁇ ml).
  • Stepl n-Butyl lithium (100 ⁇ l) was added to a solution of ⁇ -(2,4-bis-benzyloxy- ⁇ - bromo-phenyl)-4-(4-methoxy-phenyl)-3-methyl-isoxazole (1 ⁇ 4mg, 0.28mmol) in tetrahydrofuran (2. ⁇ ml) under a nitrogen atmosphere at -78°C. Solution stirred at -70°C for 30minutes to give an orange solution. The ion was quenched with methyl chloroformate (100 ⁇ l, 3eq) and allowed to warm to room temperature for 30minut.es. The solution was quenched with saturated aqueous ammonium chloride ( ⁇ ml).
  • Ammonium formate (172mg, 20eq) was added to a solution of 2,4-Bis- benzyloxy- ⁇ -[4-(4-methoxy-phenyl)-3-methyl-isoxazol- ⁇ -yl]-benzoic acid methyl ester (72mg, 0.13mmol) in methanol (2ml)/ethyl acetate (1ml) under a nitrogen atmosphere. 10% Palladium on carbon (cat.) was added and the suspension heated at 60°C overnight. The solution was allowed to cool. Ethyl acetate ( ⁇ ml) added, solution washed with water (2x ⁇ ml) and saturated aqueous sodium chloride solution ( ⁇ ml).
  • the compounds of Examples 14-16 had an HSP90 IC ⁇ O in the ranges 'A', 'B' and 'B', respectively when tested in the Malachite Green ATPase assay described below.
  • Examples 17-20 were prepared quenching with N-formyl piperidine, phenyl thioisocyanate, 2-methoxy phenyl isocyanate and benzaldehyde, respectively.
  • the final deprotection reaction was carried out with boron trichloride as described for example 23 (last reaction on Scheme ⁇ ).
  • Example 21 was a by-product from Stepl , Example 16. Quoted activities are those obtained in the Malachite Green Assay described below.
  • Triethyl amine (10ml, 72.2mmol) was added to a solution of 2,4- dihydroxybenzophenone (1) ( ⁇ .4g,23.3 mmol) in THF ( ⁇ Oml) and the solution cooled to 0°C.
  • Ethyl chloroformate (6.9ml, 72.2mmol) was added slowly and the suspension stirrred for ⁇ 30mins at 0°C, and for ⁇ 3hrs at room temperature.
  • Water 160ml was added and the mixture extracted with diethyl ether (1 ⁇ 0ml). The extracts were washed with water (2x 1 ⁇ 0ml) and saturated aqueous sodium chloride solution (100ml).
  • the solution was dried over anhydrous magnesium sulphate and concentrated to give a pale yellow gum.
  • the gum was taken up in aqueous sodium hydroxide (20ml, 10%), and the solution heated under reflux for ⁇ 60mins.
  • the solution was allowed to cool and acidified with hydochloric acid ( ⁇ ml, 37%).
  • the mixture was extracted with diethyl ether (60ml).
  • the extracts were washed with water (3x 40ml) and saturated aqueous sodium chloride solution (30ml).
  • the solution was dried over anhydrous magnesium sulphate and concentrated to give 4-benzyl- benzene-1 ,3-diol as a dark red gum, (2.1 g).
  • Diisopropylethyl amine (1 ml, ⁇ .7mmol) was added to a suspension of ⁇ -(2,4- Bis-benzyloxy- ⁇ -bromo-phenyl)-4-(4-methoxy-phenyl)-3-methyl-isoxazole (O. ⁇ g, LOmmol) in tert-butyl acrylate (1 ml, 6.8mmol) and 1-butanol (8ml) under a nitrogen atmosphere.
  • Dichlorobis(tri-o-tolylphosphine)palladium (II) (cat.) was added and the suspension heated, 140°C for ⁇ 18hrs., to give a yellow/green solution.
  • the compounds of Examples 22 - 24 had an HSP90 IC ⁇ O in the ranges 'A', 'B' and 'C respectively when tested in the Malachite Green ATPase assay described below.
  • Benzyl bromide (30mL) was added to a mixture of 1-( ⁇ -chloro-2,4-dihydroxy- phenyl)-ethanone (20g, 0.107moles) and potassium carbonate (37g, 2.6 equiv) in acetonitrile (3 ⁇ 0mL). The mixture was heated at reflux for 6 hours then allowed to cool and stirred overnight. The mixture was filtered and the solids were washed with dichloromethane (3 x 100mL).
  • reaction mixture was re-cooled to 0 °C and quenched by the addition of saturated aqueous sodium hydrogen carbonate solution (5 mL). After stirring for ⁇ minutes the dichloromethane was removed in vacuo and the residue was partitioned between ethyl acetate (30 mL) and water (30 mL). The phases were separated and the organic phase was washed with water (30mL), saturated aqueous sodium chloride solution (30 mL) then dried over sodium sulphate.
  • Example 25 had activity 'A' in the Fluorescence Polarisation Assay, as described below.
  • Example 26 was prepared by coupling the Boc protected 4- piperazinophenyl boronate ester as above. This boronate ester was made from 1-(4-bromophenyl)piperazine by boc protection followed by boronate ester formation by Pd-catalysed coupling with bis(tetramethylpinacolato) diboron.
  • Example 27 was made similarly. Example 27a was made by deprotection of ⁇ -(2,4- ⁇ /s-benzyloxy- ⁇ -chlorophenyl)-4-bromo-isoxazole-3- carboxylic acid ethylamide:
  • the diketone (4.0g) was suspended in 80% aq EtOH. Hydroxylamine hydrochloride (3.4g) and sodium acetate (4.0g) was added and the pH adjusted to 8/9 with 2M NaOH. The solution was refiuxed for 24hrs (difficult to monitor by TLC due to very similar R f values). After this time the solution was acidified to pH ⁇ with 1M HCl and poured into water. The white precipitate was filtered, washed with water, and triturated with hexane to give a white solid. Notes; Compound can also be washed with ether if necessary to remove trace impurities but not usually required. NMR indicated this to be the required product.
  • reaction mixtures were combined and partitioned between ethyl acetate (10ml) and water (10ml).
  • the aqueous layer was separated and extracted again with ethyl acetate (10ml).
  • the organics were then combined washed with water (2 x 20ml), brine (20ml), dried over Na 2 SO before being condensed in vaccuo and purified by flash chromatography on silica gel, eluting with 25% ethyl acetate in hexane.
  • Example 28 had activity 'A' in the Fluorescence Polarisation Assay, as described below.
  • Example 29 had activity 'A' in the Fluorescence Polarisation Assay, as described below. In a similar way, example 30 was prepared:
  • reaction mixture was partitioned between more toluene ( ⁇ ml) and water (10ml), the organic layer separated, washed with water (1 x 10ml), dried over MgSO 4 and then evaporated in vacuo to leave a purple/brown residue which was used for suzuki coupling without further purification.
  • Example 31 had activity 'A' in the Fluorescence Polarisation Assay, as described below.
  • Example 39 had activity 'A' in the Fluorescence Polarisation Assay, as described below.
  • Example 40 was similarly prepared:
  • Acetic acid (0.37 ml, 6.44 mmol) was added dropwise to a mixture of 5-(2,4- Bis-benzyloxy- ⁇ -chloro-phenyl)-4-(4-formyl-phenyl)-isoxazole-3-carboxylic acid ethylamide (730 mg, 1.29 mmol), morpholine (0.226 ml, 2.68 mmol), 3A powdered molecular sieves (730 mg) and MeOH (21 ml). This was left to stir overnight under N 2 . The mixture was then evaporated in vacuo and the resultant crude partitioned between CH 2 CI 2 (3 x 40 ml) and sat. NaHCO 3 solution (40 ml).
  • Example 41 had activity 'A' in the Fluorescence Polarisation Assay, as described below.
  • Examples 42-64 were prepared by methods analogous to Example 41 , using the appropriate aldehyde or ketone.
  • N-Bromosuccinimide (207 mg, 1.16 mmol) was added to a suspension of ⁇ - (2,4-Bis-benzyloxy- ⁇ -phenethylphenyl)-isoxazole-3-carboxylic acid ethylamide (564 mg, 1.06 mmol) in acetonitrile (20 mL).
  • Ceric ammonium nitrate (290 mg, 0.53 mmol) was added and the reaction mixture was heated to reflux (affording homogeneous orange solution) and stirred for 30 minutes. The reaction mixture was allowed to cool to ambient temperature and acetonitrile was removed in vacuo.
  • Dichlorobis(triphenylphosphine)palladium (II) (40 mg, 0.067 mmol) was added and reaction mixture was heated under a nitrogen atmosphere at 80 °C for ⁇ hours (reaction mixture becomes dark brown in colour).
  • Another 20 mg (0.029 mmol) of dichlorobis(triphenylphosphine)palladium (II) was added and reaction mixture was heated at 80 °C for 15 hours then allowed to cool to ambient temperature. The majority of solvents were removed in vacuo and the residue was partitioned between ethyl acetate (50 mL) and water (50 mL).
  • reaction mixture was re-cooled to 0 °C and quenched by the addition of saturated aqueous sodium hydrogen carbonate solution (5 mL). After stirring for 5 minutes the dichloromethane was removed in vacuo and the residue was partitioned between ethyl acetate (20 mL) and water (20 mL). The phases were separated and the organic phase was washed with water (20mL), saturated aqueous sodium chloride solution (20 mL) then dried over sodium sulphate.
  • Example 65 had activity 'A' in the Fluorescence Polarisation Assay, as described below.
  • Trimethyloxonium boron trifluoride (Aldrich; 70mg, 0.47mmol) was added to a stirred solution of 5-(2,4-Bis-benzyloxy-5-bromo-phenyl)-4- (4-methoxy-phenyl)-3-methyl-isoxazole (Example 3, Step 1 ) (120mg, 0.22mmol) in dichloromethane (3ml) and stirring was continued for 3h. The resulting mixture was concentrated in vacuo to leave a white semisolid, which was mixed with hydroxylamine hydrochloride (70mg, I .Ommol), potassium carbonate (120mg, 0.87mmol) and methanol (2ml), and heated at reflux for 18h.
  • 1,3-diol as a colourless oil (11mg, 43%).
  • This compound had activity 'A' in the Hsp90 fluorescence polarization assay.
  • Benzyl bromide (10ml, 84mmol) was added to a solution of the acetophenone (13.5g, 65mmol) in DMF (50ml), potassium carbonate (20g, 145mmol) was added and the suspension stirred, at room temperature, for ⁇ 4hrs.
  • the resulting suspension was poured into water (200ml) to give a pale orange precipitate.
  • the solids were removed by filtration and washed with water.
  • the solids were taken up in dichloromethane (150ml) and the solution was washed with water (2x100ml) and saturated aqueous sodium chloride solution (100ml). The solution was dried over anhydrous sodium sulphate and concentrated to a pale red oil.
  • Hydroxylamine hydrochloride (3.6g, 52mmol) was added to a solution of 4- (2,4-Bis-benzyloxy-5-tert-butyl-phenyl)-2-hydroxy-4-oxo-but-2-enoic acid ethyl ester (9.0g, 18.5mmol) in ethanol (75ml) and the suspension heated under reflux for ⁇ 4hrs. The resulting solution was allowed to cool and poured into water (200ml) to give an off-white precipitate. The solids were removed by filtration and taken up in dichloromethane (150ml). The solution was washed with water (150ml) and saturated aqueous sodium chloride solution (50ml).
  • N-iodosuccinimide (9.0g, 40mmol) was added to a suspension of 5-(2,4-Bis- benzyloxy-5-tert-butyl-phenyl)-isoxazole-3-carboxylic acid ethylamide (9.9g, 20.4mmol) in acetonitrile (60ml).
  • Ammonium cerium nitrate (0.25g, 0.46mmol) was added and the suspension stirred for ⁇ 18hrs. The resulting suspension was concentrated and the residue taken up in dichloromethane(125ml).
  • Aqueous potassium phosphate (25ml, 1.2M) solution was added to a solution of 5-(2,4-bis-benzyloxy-5-tert-butyl-phenyl)-4-iodo-isoxazole-3-carboxylic acid ethylamide (6.1g, 10mmol) and 4-formylphenyl boronic acid (2.35g, 15.7mmol) in 1 ,4-Dioxan (75ml), under a nitrogen atmosphere.
  • Dichloro- bis(tri-o-tolyl phosphine)palladium(ll) cat.
  • the mixture was allowed to cool, and the aqueous layer separated and extracted with ethyl acetate (100ml).
  • the combined organics were concentrated to give a pale brown gum.
  • the crude product was purified by column chromatography, silica (600ml), eluting with ethyl acetate/ hexane (1 :3), to give 5-(2,4-Bis-benzyloxy- 5-tert-butyl-phenyl)-4-(4-formyl-phenyl)-isoxazole-3-carboxylic acid ethylamide as a pale yellow foam (5.18g, 88%).
  • This compound had activity 'A' in the Hsp90 fluorescence polarization assay.
  • examples 77a-f were prepared.
  • Methyltriphenylphosphonium bromide (1.1 eq) was suspended in an. THF and cooled to 0°C under nitrogen. 1.6M "Butyllithium in hexanes (1.1 eq) was added drop wise, and stirred for 30 minutes. 1-(2,4-Bis-benzyloxy-phenyl)- ethanone (1eq) was dissolved in an. THF and added drop wise to the suspension. When addition was completed, the ice bath was removed and the reaction mixture was stirred at room temperature under nitrogen overnight. Methanol was added to the reaction mixture and the resulting solution was evaporated in vacuo. Hexane was added to the resulting oil and heated to reflux for 30 minutes, then filtered through Celite.
  • This compound had activity 'A' in the Hsp90 fluorescence polarization assay.
  • examples 78a-u were prepared.
  • Phosphoric acid 4-chloro-5-(diethoxy-phosphoryloxy)-2-[3- ethylcarbamoyl-4-(4-methoxy-phenyl)-isoxazol-5-yl]-phenyl ester diethyl ester
  • Step l 1-(2 s 4-Dihydroxy-phenyl)-2-methyl-propan-1-one
  • Resorcinol (1eq) was taken up in BF 3 .OEt 2 (6eq) and isobutyric acid (1 eq) added. The solution was heated for 1.5 hours at 90°C than allowed to cool to room temperature. The solution was added drop wise to 10%NaOAc (aq) and allowed to stand for 4 hours, before being extracted in to EtOAc. The organic phases were combined and washed with sat. NaHCO 3 (aq), then dried over magnesium sulfate, filtered and concentrated in vacuo to give 1-(2,4- dihydroxy-phenyl)-2-methyl-propan-1-one as a red oil which was usedwithout additional purification
  • This compound had activity 'A' in the Hsp90 fluorescence polarization assay.
  • example 80 was prepared. Purification of the sample by preparative LC/MS gave the compound as a white solid
  • Step l 3 «(4-Bromo-phenyl)-6-chloro-7-hydroxy-4-oxo-4H-chromene-8- carbaldehyde
  • Step l 1-(5-Ethyl-2,4-dihydroxy-phenyl)-2-(4-fluoro-phenyl)-ethanone
  • the intrinsic ATPase activity of HSP90 may be measured using yeast HSP90 as a model system.
  • the assay based on the use of malachite green for the measurement of inorganic phosphate, was used to test the HSP90 inhibitory activity of some of the compounds of the Examples herein.
  • Greiner 384-well Greiner 781101
  • Costar 384-well flat-bottomed polystyrene multiwell plates VWR
  • E. coli expressed yeast HSP90 protein Stored at -20°C. ( ⁇ ) E. coli expressed yeast HSP90 protein, purified >95% (see, e.g.,
  • the polyvinyl alcohol dissolves in boiling water with difficulty and stirring for 2-3 h is required.
  • the time interval between addition of the malachite green reagent and the sodium citrate should be kept as short as possible in order to reduce the non-enzymatic hydrolysis of ATP. Once the sodium citrate is added, the colour is stable for up to 4 h at room temperature.
  • Compounds can be added to the assay plates using a Biomek FX Robot (Beckman Coulter).
  • a Multidrop 334 dispenser (Thermo Labsystems, Basingstoke, UK) can be conveniently used to add reagents to the plate.
  • Control wells are at either side of the 96 well plates, where 40 ⁇ l of medium is added.
  • the first row will be the 100% control with no drug, but with stain). Leave for 15 mins. 12)Wash off unbound SRB stain with four washes of 1 % acetic acid. 13)Dry plates in incubator. 14)Solubilise SRB using 100 ⁇ l of 10mM Tris base and put plates on plate shaker for 5 mins. 15) Determine absorbance at 540nm using a plate reader. Calculate mean absorbance for quadruplicate wells and express as a percentage of value for control, untreated wells. 16)Plot % absorbance values versus log drug concentration and determine
  • the compound of Example 2 gave an IC50 in the 'A' range ( ⁇ 50uM) for the SRB growth arrest assay.
  • Fluorescence polarization ⁇ also known as fluorescence anisotropy ⁇ measures the rotation of a fluorescing species in solution, where the larger molecule the more polarized the fluorescence emission.
  • the emitted light is also polarized.
  • the molecular size is proportional to the polarization of the fluorescence emission.
  • Test compound is added to the assay plate, left to equilibrate and the anisotropy measured again. Any change in anisotropy is due to competitive binding of compound to HSP90, thereby releasing probe.
  • Chemicals are of the highest purity commercially available and all aqueous solutions are made up in AR water.
  • BSA bovine serum albumen
  • E. coli expressed human full-length HSP90 protein purified >95% (see, e.g., Panaretou et al., 199 ⁇ ) and stored in 50 ⁇ L aliquots at - ⁇ 0°C .
  • the Z' factor is calculated from zero controls and positive wells. It typically gives a value of 0.7 - 0.9.
  • Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW and Pearl LH. 1997 “Identification and structural characterization of the ATP/ADP-binding site in the HSP90 molecular chaperone", CeJI, Vol. 90, pp. 65-75.
  • Rous sarcoma virus Rous sarcoma virus", Mol. Cell. Biol., Vol. 6, pp. 219 ⁇ -2206. Waxman, Lloyd H. Inhibiting hepatitis C virus processing and replication.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)

Abstract

Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: (A), (B) wherein R1, is a group of formula (IA): -Ar1-(Alk1)p-(Z)r-(Alk2)S-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1and Alk2 are optionally substituted divalent Cl-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is -0-, -S-, -(C=O)-, -(C=S)-, -SO2-, -C(=O)O-, -C(=O)NRA-, -C(=S)NRA-, - SO2NRA-, -NRAC(=O)-, -NRASO2- or -NRA- wherein RA is hydrogen or Cl-C6 alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R2 is (i) a group of formula (IA) above or (ii) a carboxamide radical; or (iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula -(Alk1)p-(Z)r-(Alk2)s-Q wherein Q, Alk1, Alk2, Z, p, r and s are as defined above in relation to group (IA); and R3 is hydrogen, optionally substituted cycloalkyl, cycloalkenyl, C1-C6 alkyl, C1-C6 alkenyl, or C1-C6 alkynyl; or a carboxyl, carboxamide, or carboxyl ester group.

Description

Isoxazole Compounds
This invention relates to substituted isoxazoles having HSP90 inhibitory activity, to the use of such compounds in medicine, in relation to diseases which are responsive to inhibition of HSP90 activity such as cancers, and to pharmaceutical compositions containing such compounds.
Background to the invention
Molecular chaperones maintain the appropriate folding and conformation of proteins and are crucial in regulating the balance between protein synthesis and degradation. They have been shown to be important in regulating many important cellular functions, such as cell proliferation and apoptosis (Jolly and Morimoto, 2000; Smith et al., 1998; Smith, 2001).
Heat Shock Proteins (HSPs) Exposure of cells to a number of environmental stresses, including heat shock, alcohols, heavy metals and oxidative stress, results in the cellular accumulation of a number of chaperones, commonly known as heat shock proteins (HSPs). Induction of HSPs protects the cell against the initial stress insult, enhances recovery and leads to maintenance of a stress tolerant state. It has also become clear, however, that certain HSPs may also play a major molecular chaperone role under normal, stress-free conditions by regulating the correct folding, degradation, localization and function of a growing list of important cellular proteins.
A number of multigene families of HSPs exist, with individual gene products varying in cellular expression, function and localization. They are classified according to molecular weight, e.g., HSP70, HSP90, and HSP27. Several diseases in humans can be acquired as a result of protein misfolding (reviewed in Tytell et al., 2001 ; Smith et al., 1998). Hence the development of therapies which disrupt the molecular chaperone machinery may prove to be beneficial. In some conditions (e.g., Alzheimer's disease, prion diseases and Huntington's disease), misfolded proteins can cause protein aggregation resulting in neurodegenerative disorders. Also, misfolded proteins may result in loss of wild type protein function, leading to deregulated molecular and physiological functions in the cell.
HSPs have also been implicated in cancer. For example, there is evidence of differential expression of HSPs which may relate to the stage of tumour progression (Martin et al., 2000; Conroy et al., 1996; Kawanishi et al., 1999; Jameel et al., 1992; Hoang et al., 2000; Lebeau et al., 1991). As a result of the involvement of HSP90 in various critical oncogenic pathways and the discovery that certain natural products with anticancer activity are targeting this molecular chaperone, the fascinating new concept has been developed that inhibiting HSP function may be useful in the treatment of cancer. The first molecular chaperone inhibitor is currently undergoing clinical trials.
HSP90 HSP90 constitutes about 1-2% of total cellular protein, and is usually present in the cell as a dimer in association with one of a number of other proteins (see, e.g., Pratt, 1997). It is essential for cell viability and it exhibits dual chaperone functions (Young et al., 2001 ). It plays a key role in the cellular stress response by interacting with many proteins after their native conformation has been altered by various environmental stresses, such as heat shock, ensuring adequate protein folding and preventing non-specific aggregation (Smith et al., 1998). In addition, recent results suggest that HSP90 may also play a role in buffering against the effects of mutation, presumably by correcting the inappropriate folding of mutant proteins (Rutherford and Lindquist, 1998). However, HSP90 also has an important regulatory role. Under normal physiological conditions, together with its endoplasmic reticulum homologue GRP94, HSP90 plays a housekeeping role in the cell, maintaining the conformational stability and maturation of several key client proteins. These can be subdivided into three groups: (a) steroid hormone receptors, (b) Ser/Thr or tyrosine kinases (e.g., ERBB2, RAF-1, CDK4, and LCK), and (c) a collection of apparently unrelated proteins, e.g., mutant p53 and the catalytic subunit of telomerase hTERT. All of these proteins play key regulatory roles in many physiological and biochemical processes in the cell. New HSP90 client proteins are continuously being identified.
The highly conserved HSP90 family in humans consists of four genes, namely the cytosolic HSP90α and HSP90β isoforms (Hickey et al., 1989), GRP94 in the endoplasmic reticulum (Argon et al., 1999) and HSP75/TRAP1 in the mitochondrial matrix (Felts et al., 2000). It is thought that all the family members have a similar mode of action, but bind to different client proteins depending on their localization within the cell. For example, ERBB2 is known to be a specific client protein of GRP94 (Argon et al., 1999) and type 1 tumour necrosis factor receptor (TNFR1) and RB have both been shown to be clients of TRAP1 (Song et al., 1995; Chen et al., 1996).
HSP90 participates in a series of complex interactions with a range of client and regulatory proteins (Smith, 2001 ). Although the precise molecular details remain to be elucidated, biochemical and X-ray crystallographic studies (Prodromou et al., 1997; Stebbins et al., 1997) carried out over the last few years have provided increasingly detailed insights into the chaperone function of HSP90.
Following earlier controversy on this issue, it is now clear that HSP90 is an ATP-dependent molecular chaperone (Prodromou et al, 1997), with dimerization of the nucleotide binding domains being essential for ATP hydrolysis, which is in turn essential for chaperone function (Prodromou et al, 2000a). Binding of ATP results in the formation of a toroidal dimer structure in which the N terminal domains are brought into closer contact with each other resulting in a conformational switch known as the 'clamp mechanism' (Prodromou and Pearl, 2000b).
Known HSP90 Inhibitors The first class of HSP90 inhibitors to be discovered was the benzoquinone ansamycin class, which includes the compounds herbimycin A and geldanamycin. They were shown to reverse the malignant phenotype of fibroblasts transformed by the v-Src oncogene (Uehara et al., 1985), and subsequently to exhibit potent antitumour activity in both in vitro (Schulte et al., 1998) and in vivo animal models (Supko et al., 1995).
Immunoprecipitation and affinity matrix studies have shown that the major mechanism of action of geidanamycin involves binding to HSP90 (Whitesell et al., 1994; Schulte and Neckers, 1998). Moreover, X-ray crystallographic studies have shown that geidanamycin competes at the ATP binding site and inhibits the intrinsic ATPase activity of HSP90 (Prodromou et al., 1997; Panaretou et al., 1998). This in turn prevents the formation of mature multimeric HSP90 complexes capable of chaperoning client proteins. As a result, the client proteins are targeted for degradation via the ubiquitin proteasome pathway. 17-Allylamino, 17-demethoxygeldanamycin (17AAG) retains the property of HSP90 inhibition resulting in client protein depletion and antitumour activity in cell culture and xenograft models (Schulte et al, 1998; Kelland et al, 1999), but has significantly less hepatotoxicity than geidanamycin (Page et al, 1997). 17AAG is currently being evaluated in Phase I clinical trials.
Radicicol is a macrocyclic antibiotic shown to reverse the malignant phenotype of v-Src and v-Ha-Ras transformed fibroblasts (Kwon et al, 1992; Zhao et al, 1995). It was shown to degrade a number of signalling proteins as a consequence of HSP90 inhibition (Schulte et al., 1998). X-ray crystallographic data confirmed that radicicol also binds to the N terminal domain of HSP90 and inhibits the intrinsic ATPase activity (Roe et al., 1998). Radicicol lacks antitumour activity in vivo due to the unstable chemical nature of the compound.
Coumarin antibiotics are known to bind to bacterial DNA gyrase at an ATP binding site homologous to that of the HSP90. The coumarin, novobiocin, was shown to bind to the carboxy terminus of HSP90, i.e., at a different site to that occupied by the benzoquinone ansamycins and radicicol which bind at the N-terminus (Marcu et al., 2000b). However, this still resulted in inhibition of HSP90 function and degradation of a number of HSP90-chaperoned signalling proteins (Marcu et al., 2000a). Geldanamcyin cannot bind HSP90 subsequent to novobiocin; this suggests that some interaction between the N and C terminal domains must exist and is consistent with the view that both sites are important for HSP90 chaperone properties.
A purine-based HSP90 inhibitor, PU3, has been shown to result in the degradation of signalling molecules, including ERBB2, and to cause cell cycle arrest and differentiation in breast cancer cells (Chiosis et al., 2001 ).
HSP90 as a Therapeutic Target Due to its involvement in regulating a number of signalling pathways that are crucially important in driving the phenotype of a tumour, and the discovery that certain bioactive natural products exert their effects via HSP90 activity, the molecular chaperone HSP90 is currently being assessed as a new target for anticancer drug development (Neckers et al., 1999).
The predominant mechanism of action of geidanamycin, 17AAG, and radicicol involves binding to HSP90 at the ATP binding site located in the N-terminal domain of the protein, leading to inhibition of the intrinsic ATPase activity of HSP90 (see, e.g., Prodromou et al., 1997; Stebbins et al., 1997; Panaretou et al., 1998).
Inhibition of HSP90 ATPase activity prevents recruitment of co-chaperones and encourages the formation of a type of HSP90 heterocomplex from which these client proteins are targeted for degradation via the ubiquitin proteasome pathway (see, e.g., Neckers et al., 1999; Kelland et al., 1999).
Treatment with HSP90 inhibitors leads to selective degradation of important proteins involved in cell proliferation, cell cycle regulation and apoptosis, processes which are fundamentally important in cancer.
Inhibition of HSP90 function has been shown to cause selective degradation of important signalling proteins involved in cell proliferation, cell cycle regulation and apoptosis, processes which are fundamentally important and which are commonly deregulated in cancer (see, e.g., Hostein et al., 2001). An attractive rationale for developing drugs against this target for use in the clinic is that by simultaneously depleting proteins associated with the transformed phenotype, one may obtain a strong antitumour effect and achieve a therapeutic advantage against cancer versus normal cells. These events downstream of HSP90 inhibition are believed to be responsible for the antitumour activity of HSP90 inhibitors in cell culture and animal models (see, e.g., Schulte et al., 1998; Kelland et al., 1999).
Brief description of the invention
The present invention relates to the use of a class of substituted isoxazole compounds as HSP90 inhibitors, for example for inhibition of cancer cell proliferation. The invention also includes novel isoxazole compounds per se, and pharmaceutical compositions containing them
Detailed description of the invention
According to the present invention there is provided the use of a compound of formula (A) or (B) or a salt, N-oxide, hydrate or solvate thereof, or a prodrug thereof, in the preparation of a composition for inhibition of HSP90 activity:
Figure imgf000008_0001
(A) (B) wherein
Ri is a group of formula (IA):
-Ar1-(Alk1)p-(Z)r-(Alk2)s-Q (IA) wherein in any compatible combination
Ar1 is an optionally substituted aryl or heteroaryl radical,
Alk1 and Alk2 are optionally substituted divalent C C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1 , Z is -O-, -S-, -(C=O)-, -(C=S)-, -SO2-, -C(=O)O-, -C(=O)NRA- ,
-C(=S)NRA-, -SO2NRA-, -NRAC(=O)-, -NRASO2- or -NRA- wherein RA is hydrogen or C Cβ alkyl, and
Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical;
R2 is (i) a group of formula (IA) as defined in relation to R ;
(ii) a carboxamide radical; or
(iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula -(Alk1)p-(Z)r-(Alk2)s-Q wherein Q, Alk1, Alk2, Z, p, r and s are as defined above in relation to group (IA); and
R3 is hydrogen, optionally substituted cycloalkyl, cycloalkenyl, Ci-Cβ alkyl, Cι-C6 alkenyl, or Cι-C6 alkynyl; or a carboxyl, carboxamide, or carboxyl ester group.
In general, the class of compounds defined above in relation to formula (I) is believed to be novel, and the invention includes all novel members of that class and their salts, hydrates and solvates, and prodrugs thereof.
As used herein: the term "carboxyl group" refers to a group of formula -COOH;
the term "carboxyl ester group" refers to a group of formula -COOR, wherein R is a radical actually or notionally derived from the hydroxyl compound ROH; and
the term " carboxamide group" refers to a group of formula -CONRaRb, wherein -NRaRb is a primary or secondary (including cyclic) amino group actually or notionally derived from ammonia or the amine HNRaRb.
As used herein, the term "(Ca-Cb)alkyl" wherein a and b are integers refers to a straight or branched chain alkyl radical having from a to b carbon atoms. Thus when a is 1 and b is 6, for example, the term includes methyl, ethyl, n- propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl and n-hexyl.
As used herein the term "divalent (Ca-Cb)alkylene radical" wherein a and b are integers refers to a saturated hydrocarbon chain having from a to b carbon atoms and two unsatisfied valences..
As used herein, the term "(Ca-Cb)alkenyl" wherein a and b are integers refers to a straight or branched chain alkenyl radical having from a to b carbon atoms and containing at least one double bond of E or Z configuration, including for example, ethenyl and allyl.
As used herein the term "divalent (Ca-Cb)alkenylene radical" wherein a and b are integers refers to a hydrocarbon chain having from a to b carbon atoms, at least one double bond, and two unsatisfied valences.
As used herein, the term "(Ca-Cb)alkynyl" wherein a and b are integers refers to a straight or branched chain alkenyl radical having from a to b carbon atoms and containing at least one triple bond, including for example, ethynyl and prop-2-ynyl.
As used herein, the term "divalent (Ca-Cb)alkynylene radical" wherein a and b are integers refers to a straight or branched chain alkynyl radical having from a to b carbon atoms and containing at least one triple bond, and two unsatisfied valencies.
As used herein the term "cycloalkyl" refers to a saturated carbocyclic radical having from 3-8 carbon atoms and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. As used herein the term "cycloalkenyl" refers to a carbocyclic radical having from 3-8 carbon atoms containing at least one double bond, and includes, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl.
As used herein the term "aryl" refers to a mono-, bi- or tri-cyclic carbocyclic aromatic radical. Illustrative of such radicals are phenyl, biphenyl and napthyl.
As used herein the term "carbocyclic" refers to a cyclic radical whose ring atoms are all carbon, and includes monocyclic aryl, cycloalkyl and cycloalkenyl radicals.
As used herein the term "heteroaryl" refers to a mono-, bi- or tri-cyclic aromatic radical containing one or more heteroatoms selected from S, N and O. Illustrative of such radicals are thienyl, benzthienyl, furyl, benzfuryl, pyrrolyl, imidazolyl, benzimidazolyl, thiazolyl, benzthiazolyl, isothiazolyl, benzisothiazolyl, pyrazolyl, oxazolyl, benzoxazolyl, isoxazolyl, benzisoxazolyl, isothiazolyl, triazolyl, benztriazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl and indazolyl.
As used herein the unqualified term "heterocyclyl" or "heterocyclic" includes "heteroaryl" as defined above, and in particular means a mono-, bi- or tricyclic non-aromatic radical containing one or more heteroatoms selected from S, N and O, and to groups consisting of a monocyclic non-aromatic radical containing one or more such heteroatoms which is covalently linked to another such radical or to a monocyclic carbocyclic radical. Illustrative of such radicals are pyrrolyl, furanyl, thienyl, piperidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, pyrazolyl, pyridinyl, pyrrolidinyl, pyrimidinyl, morpholinyl, piperazinyl, indolyl, morpholinyl, benzfuranyl, pyranyl, isoxazolyl, benzimidazolyl, methylenedioxyphenyl, ethylenedioxyphenyl, maleimido and succinimido groups.
Unless otherwise specified in the context in which it occurs, the term "substituted" as applied to any moiety herein means substituted with up to four compatible substituents, each of which independently may be, for example, (Cι-C6)alkyl, (CrC6)alkoxy, hydroxy, hydroxy(Cι-C6)alkyl, mercapto, mercapto(Cι-C6)alkyl, (C -Cβjalkylthio, halo (including fluoro, bromo and chloro), trifluoromethyl, trifluoromethoxy, nitro, nitrile (-CN), oxo, phenyl, - COOH, -COORA, -CORA, -SO2RA, -CONH2l -SO2NH2, -CONHRA, -SO2NHRA, -CONRARB, -SO2NRARB, -NH2, -NHRA, -NRARB, -OCONH2, -OCONHRA , -OCONRARB, -NHCORA, -NHCOORA, -NRBCOORA, -NHSO2ORA, -NRBSO2OH, -NRBSO2ORA,-NHCONH2) -NRACONH2, -NHCONHR6 -NRACONHRB, -NHCONRARB, or -NRACONRARB wherein RA and RB are independently a (Cι-C6)alkyl group. An "optional substituent" may be one of the foregoing substituent groups. Of the above substituents, (Cι-C6)alkyl, halo, trifluoromethyl, trifluoromethoxy, trifluoromethylsulfonyl, and phenyl are those most commonly regarded as lipophilic. Other substituents listed which contain alkyl groups may be lipophilic depending on the particular alkyl groups present.
As used herein the term "salt" includes base addition, acid addition and quaternary salts. Compounds of the invention which are acidic can form salts, including pharmaceutically or veterinarily acceptable salts, with bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. N-methyl-D-glucamine, choline tris(hydroxymethyl)amino- methane, L-arginine, L-lysine, N-ethyl piperidine, dibenzylamine and the like. Those compounds (I) which are basic can form salts, including pharmaceutically or veterinarily acceptable salts with inorganic acids, e.g. with hydrohalic acids such as hydrochloric or hydrobromic acids, sulphuric acid, nitric acid or phosphoric acid and the like, and with organic acids e.g. with acetic, tartaric, succinic, fumaric, maleic, malic, salicylic, citric, methanesulphonic, p-toluenesulphonic, be4nzoic, benzenesunfonic, glutamic, lactic, and mandelic acids and the like.
The term "lipophilic" as used herein in relation to a substituent means that it has a positive substituent hydrophobicity constant (π). (A positive value for π indicates that the substituent is more lipophilic than hydrogen, whereas a negative value indicates it is less lipophilic, i.e. more hydrophilic, than hydrogen).
Some compounds of the invention contain one or more actual or potential chiral centres because of the presence of asymmetric carbon atoms. The presence of several asymmetric carbon atoms gives rise to a number of diastereoisomers with R or S stereochemistry at each chiral centre. The invention includes all such diastereoisomers and mixtures thereof.
An aspect of the invention includes compounds of formula (A) or (B) above and a salts, N-oxides, hydrates or solvates thereof and prodrugs thereof, except the following three compounds (X), (Y) and (Z) which are commercially available:
Figure imgf000013_0001
(X) (Y) (Z)
Subject to those exclusions, the invention particularly includes those wherein the substituents Ri , R2 and R3 are as discussed and specified in the following sections headed "The radical R ", "The radical R2", and "The radical R3", Another aspect includes the use of such compounds for the treatment of diseases responsive to inhibition of HSP90 activity.
Figure imgf000013_0002
In general, it is currently preferred that the radical Ar1 present in the Ri group is optionally substituted phenyl, preferably with one of the optional substituents being a hydroxy group in position 2 relative to the point of attachment of the phenyl ring to isoxazole ring. In other words, the group Ri preferably has formula (IB)
Figure imgf000014_0001
wherein Alk1, Alk2, p, r, s, Z and Q are as defined above in relation to Ri, and R represents one or more optional substituents. In such structures, it is further preferred that the ring carbon atom adjacent the hydroxyl group be unsubstituted. In the further discussion of Ri which follows, this preference applies in addition to any other possibilities mentioned.
In the simplest structures with which the invention is concerned, each of p, r and s may be 0, and Q may be hydrogen, so that Ri is optionally substituted aryl or heteroaryl. In such cases, R may be, for example, optionally substituted phenyl, preferably 2-hydroxyphenyl which may be further substituted, for example by one or more of hydroxy, methyl, ethyl, methoxy, ethoxy , chloro, or bromo. Currently preferred are compounds wherein Ri is 2,4-dihydroxyphenyl, substituted in the 5-position by a small lipophilic substituent,, for example having a molecular volume equal to or less than that of tert-butyl, such as methyl, ethyl, isopropyl, isobutyl, tert-butyl, chloro, or bromo, especially ethyl, isopropyl, or chloro. In such 5-substituted, 2,4- diyhdroxy phenyl compounds of the invention, the hydroxyl groups may be protected by groups which are cleaved in the body to release the hydroxyl groups. Known prodrug-type groups of this kind which are cleaved to hydroxyls include alkylcarbonyloxy groups such as methylcarbonyloxy, and alkylaminocarbonyloxy groups such as dialkylamino- or isopropylamino- carbonyloxy.
In other simple structures with which the invention is concerned, p, r and s may again each be 0, and Q may be an optionally substituted carbocyclic or heterocyclic ring, for example a phenyl or pyridyl ring. In such cases, Q is a direct substituent in the optionally substituted Ar1 ring
In more complex structures with which the invention is concerned, one or more of p, r and s may be 1 , and Q may be hydrogen or an optionally substituted carbocyclic or heterocyclic ring. For example, p and/or s may be 1 and r may be 0, so that Q is linked to Ar1 by an alkylene or alkenylene radical, for example a C C3 alkylene radical, which is optionally substituted. In other cases each of p, r, and s may be 1, in which cases, Q is linked to Ar1 by an alkylene or alkenylene radical which is interrupted by the hetero atom- containing Z radical. In still other cases, p and s may be 0 and r may be 1 , in which case Q is linked to Ar1 via the hetero atom-containing Z radical.
Specific examples of Ri groups of the above types are present in the compounds of the Examples herein.
The radical R?
When R2 is of type (i), i.e. a group of formula (IA), examples include phenyl, 2-, 3-, or 4-pyridyl, 2- or 3-furanyl, 2- or 3-thienyl, and thiazolyl wherein optional substituents include any of those listed above in the definition of "substituted", for example methoxy , ethoxy, methylenedioxy, ethylenedioxy, fluoro, chloro, bromo, and trifluoromethyl. For example R2 may be phenyl substituted in the 4 position by C C6 alkoxy such as methoxy or ethoxy, or by fluoro, chloro, bromo, piperazinyl, N-methylpiperazinyl, or piperidinyl.
Presently preferred R2 substituents include those having the partial structure:
Figure imgf000015_0001
wherein the substituted amino group -NR10R11 is a solubilising group. Many such solubilising groups are known in medicinal chemistry. Examples include morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, ethylamino, isopropylamino, diethylamino, cyclohexylamino, cyclopentylamino, methoxyethylamino, piperidin-4-yl, N-acetylpiperazinyl, methylsulfonylamino, thiomorpholinyl, thiomorpholinyldioxide, 4-hydroxyethylpiperidinyl, and 4-hydroxypiperidinyl.
Our copending international patent application no. PCT/GB2003/005275 discloses HSP90 inhibiting pyrazole compounds analogous to the isoxazoles with which this invention is concerned, and which are believed to bind to the HSP90 target in an analogous fashion. Those pyrazole compounds have a carboxamide group in the position corresponding to R2 of the present isoxazoles. Hence, when R2 in the present isoxazoles is a carboxamide radical of type (ii) above, examples include those present in the pyrazole compounds of PCT/GB2003/005275, for example carboxamides of formula - CONRB(Alk)nRA wherein
Alk is a divalent alkylene, alkenylene or alkynylene radical, for example a -CH2-, -CH2CH2-, -CH2CH2CH2-, -CH2CH=CH-, or-CH2CCCH2- radical, and the Alk radical may be optionally substituted,
n is O or 1 ,
RB is hydrogen or a C C6 alkyl or C2-C6 alkenyl group, for example methyl, ethyl, n- or iso-propyl, or allyl,
RA is hydroxy or optionally substituted carbocyclic, for example hydroxy and/or chloro-substituted phenyl and 3,4 methylenedioxyphenyl; or heterocyclyl, for example pyridyl, furyl, thienyl, N-piperazinyl, or N- morpholinyl any of which heterocyclic rings may be substituted,
or RA and RB taken together with the nitrogen to which they are attached form an N-heterocyclic ring which may optionally contain one or more additional hetero atoms selected from O, S and N, and which may optionally be substituted on one or more ring C or N atoms, examples of such N-heterocyclic rings including morpholino, piperidinyl, piperazinyl and N-phenylpiperazinyl.
The radical Rg
R3 may be, for example, hydrogen, methyl, ethyl, n- or iso-propyl, trifluoromethyl, hydroxyethyl, methylsulfonaminomethyl, or a carboxamide group -CONRB(Alk)nRA as discussed above for R2. A carboxamide group is presently preferred, especially ethylaminocarbonyl and isopropylaminocarbonyl.
A particular sub-set of the compounds with which this invention is concerned consists of those of formula (ID), and the formula B regioisomers thereof, and their salts, solvates and hydrates, and prodrugs thereof:
Figure imgf000017_0001
(ID)
wherein each R independently represents an optional substituent and R3 represents a carboxamide group.
A preferred sub-set of the compounds with which this invention is concerned consists of those of formula (IE), and the formula (B) regioisomers thereof, and their salts, solvates and hydrates, and prodrugs thereof:
Figure imgf000017_0002
(IE) wherein R3 represents a carboxamide group (such as ethylaminocarbonyl CH3CH2NHC(=O)-, or isopropylaminocarbonyl (CH3)2CHNHC(=O)-); R9 represents -CH2NR10R11 or-NR10R11 wherein the substituted amino group -NR10R11 is a solubilising group, (such as morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, ethylamino, isopropylamino, diethylamino, cyclohexylamino, cyclopentylamino, methoxyethylamino, piperidin-4-yl, N-acetylpiperazinyl, N- methylpiperazinyl, methylsulfonylamino, thiomorpholinyl, thiomorpholinyl- dioxide, 4-hydroxyethylpiperidinyl, and 4-hydroxypiperidinyl); and Re represents an optional substituent, especially a small lipophilic group (such as ethyl, isopropyl, bromo, or chloro).
Specific compounds with which the invention is concerned include those of the Examples, particularly the following, and their salts, N-oxides, hydrates and solvates, and prodrugs thereof:
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-piperidin-1-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
4-(4-Diethylaminomethyl-phenyl)-5-(2,4-dihydroxy-5-isopropyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-[4-(4-methyl-piperazin-1- ylmethyl)-phenyl]-isoxazole-3-carboxylic acid ethylamide
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-ethylaminomethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-[4-(isopropylamino-methyl)- phenyl]-isoxazole-3-carboxylic acid ethylamide
4-(4-Cyclohexylaminomethyl-phenyl)-5-(2,4-dihydroxy-5-isopropyl- phenyl)-isoxazole-3-carboxylic acid ethylamide
4-[4-(tert-Butylamino-methyl)-phenyl]-5-(2,4-dihydroxy-5-isopropyl- phenyl)-isoxazole-3-carboxylic acid ethylamide
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-{4-[(2-methoxy-ethylamino)- methyl]-phenyl}-isoxazole-3-carboxylic acid ethylamide
5-(2,4-Dihydroxy-5-isopropyl-ρhenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxylic acid isopropylamide
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-[4-(4-methyl-piperazin-1- ylmethyl)-phenyl]-isoxazole-3-carboxylic acid isopropylamide
5-(5-tert-Butyl-2,4-dihydroxy-phenyl)-4-[4-(4-methyl-piρerazin-1- ylmethyl)-phenyl]-isoxazole-3-carboxylic acid ethylamide
5-(5-tert-Butyl-2,4-dihydroxy-phenyl)-4-(4-piperidin-1-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(2,4-Dihydroxy-5-isobutyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(2,4-Dihydroxy-5-isobutyl-phenyl)-4-(4-piperidin-1-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide 5-(5-tert-Butyl-2,4-dihydroxy-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(5-tert-Butyl-2,4-dihydroxy-phenyl)-4-(4-diethylaminomethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
3-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-5-carboxylic acid ethylamide
4-(4-Diethylaminomethyl-phenyl)-5-(4,6-dihydroxy-2'-methyl-biphenyl-3- yl)-isoxazole-3-carboxylic acid ethylamide
4-(4-Diethylaminomethyl-phenyl)-5-(4'-fluoro-4,6-dihydroxy-biphenyl-3- yl)-isoxazole-3-carboxylic acid ethylamide
4-(4-Diethylaminomethyl-phenyl)-5-(4,6-dihydroxy-biphenyl-3-yl)- isoxazole-3-carboxylic acid ethylamide
5-(2'-Fluoro-4,6-dihydroxy-biphenyl-3-yl)-4-(4-pyrrolidin-1-ylmethyl- phenyl)-isoxazole-3-carboxylic acid ethylamide
5-(4,6-Dihydroxy-biphenyl-3-yl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(2,4-Dihydroxy-5-phenethyl-phenyl)-4-(4-morpholin-4-ylmethyl- phenyl)-isoxazole-3-carboxylic acid ethylamide
5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-piperidin-1-ylmethyl-phenyl)- isoxazole-3-carboxylic acid isopropylamide 4-(4-Diethylaminomethyl-phenyl)-5-(5-ethyl-2,4-dihydroxy-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(5-Ethyl-2,4-dihydroxy-phenyl)-4-[4-(4-methyl-piperazin-1-ylmethyl)- phenyl]-isoxazole-3-carboxylic acid ethylamide
5-(5-Ethyl-2,4-dihydroxy-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-diethylaminomethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(5-Chloro-2,4-dihydroxy-phenyl)-4-[4-(4-methyl-piperazin-1-ylmethyl)- phenyl]-isoxazole-3-carboxylic acid ethylamide
5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
Compounds with which the invention is concerned may be prepared by literature methods, such as those of the preparative Examples herein, and methods analogous thereto.
For example, some compounds of formula (IA) may be prepared by reaction of hydroxylamine and a compound of formula (III)
Figure imgf000021_0001
wherein ring A corresponds to the group Ri of compounds (IA) and R2 and R3 are as defined in relation to formula (I). Compounds prepared in this way may then be chemically modified to introduce desired substituents, to produce other compounds of formula (A) For example where Ri is a phenyl ring, optionally already carrying substituents, the introduction of a bromo substituent will often enable introduction of other substituents at the bromo site by sp2 coupling.
In another route to some compounds of formula (A), the isoxazole ring is formed by the reaction of a comound (IV) with hydroxylamine
R1ι R1 3
O Y OH (i )
wherein R'ι and R'3 are members of the substutuent classes Ri and R3 defined above, to produce the isoxazole (V)
Figure imgf000022_0001
followed by introduction of the additional substituent R2 (for example by bromination or iodination of the ring carbon in (V) and sp2 coupling, and/or modification of the resultant R\ R1 3 and R2 substituents of the isoxazole.
Furthermore, some isoxazole regioisomers (B) may be prepared from the isoxazoles (A) by reaction with trimethyloxonium boron trifluoride, and again compounds prepared in this way may then be chemically modified to introduce desired substituents, to produce other compounds of formula (IA).
It will be understood that during the above syntheses, it may be desirable to protect any reactive groups such as hydroxyls, and to deprotect later. Further synthetic details are described in the examples herein.
The compounds of the invention are inhibitors of HSP90 and are thus useful in the treatment of diseases which are responsive to inhibition of HSP90 activity such as cancers; viral diseases such as Hepatitis C (HCV) (Waxman, 2002); Immunosupression such as in transplantation (Bijlmakers, 2000 and Yorgin, 2000); Anti-inflammatory diseases (Bucci, 2000) such as Rheumatoid arthritis, Asthma, MS, Type I Diabetes, Lupus, Psoriasis and Inflammatory Bowel Disease; Cystic fibrosis (Fuller, 2000); Angiogenesis-related diseases (Hur, 2002 and Kurebayashi, 2001 ): diabetic retinopathy, haemangiomas, psoriasis, endometriosis and tumour angiogenesis. Also an Hsp90 inhibitor of the invention may protect normal cells against chemotherapy-induced toxicity and be useful in diseases where failure to undergo apoptosis is an underlying factor. Such an Hsp90 inhibitor may also be useful in diseases where the induction of a cell stress or heat shock protein response could be beneficial, for example, protection from hypoxia-ischemic injury due to elevation of Hsp70 in the heart (Hutter, 1996 and Trost, 1998) and brain (Plumier, 1997 and Rajder, 2000). An Hsp90 inhibitor could also be useful in diseases where protein misfolding or aggregation is a major causal factor , for example, scrapie/CJD, Huntingdon's and Alzheimer's (Sittler, 2001 ; Trazelt, 1995 and Winklhofer, 2001 ).
Accordingly, the invention also provides:
(i) a method of treatment of diseases or conditions responsive to inhibition of HSP90 activity in mammals, particularly humans, which method comprises administering to the mammal an amount of a compound of formula (A) or (B) as defined above, or a salt, hydrate or solvate thereof, effective to inhibit said HSP90 activity.; and
(ii) a compound of formula (A) or (B) as defined above, or a salt hydrate or solvate thereof, for use in human or veterinary medicine, particularly in the treatment of diseases or conditions responsive to inhibition of HSP90 activity;
(iii) a pharmaceutical composition comprising a compound of formula (A) or (B) as defined and specified above, together with a pharmaceutically acceptable carrier. In particular, the invention includes a solution or suspension of such compound in a sterile, physiologically acceptable carrier, for example aqueous saline.
It will be understood that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the causative mechanism and severity of the particular disease undergoing therapy. In general, a suitable dose for orally administrable formulations will usually be in the range of 0.1 to 3000 mg once, twice or three times per day, or the equivalent daily amount administered by infusion or other routes. However, optimum dose levels and frequency of dosing will be determined by clinical trials as is conventional in the art.
The compounds with which the invention is concerned may be prepared for administration by any route consistent with their pharmacokinetic properties. The orally administrable compositions may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical, or sterile parenteral solutions or suspensions. Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, fragacanth, or polyvinyl-pyrrolidone; fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricant, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants for example potato starch, or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
For topical application to the skin, the drug may be made up into a cream, lotion or ointment. Cream or ointment formulations which may be used for the drug are conventional formulations well known in the art, for example as described in standard textbooks of pharmaceutics such as the British Pharmacopoeia.
The active ingredient may also be administered parenterally in a sterile medium. Depending on the vehicle and concentration used, the drug can either be suspended or dissolved in the vehicle. Advantageously, adjuvants, such as a local anaesthetic, preservative and buffering agents, can be dissolved in the vehicle.
Compounds of the invention are also useful in in vitro assays dependent on inhibition of HSP90 activity, for example in screening for alternative classes of HSP90 inhibitors wherein the test compound competes with or displaces a compound of this invention. Accordingly, in yet another aspect, the invention includes a method of inhibiting HSP90 activity, comprising bringing into contact, in vitro, an HSP90 enzyme and a compound of formula (A) or (B) as defined and specified above.
The following examples illustrate the preparation and activities of specific compounds of the invention. Examples 1-4
Scheme 1 : preparation of bromo intermediate and subsequent arylation
Figure imgf000026_0001
Example 1 4-[4-(4-Methoxy-phenyl)-3-methyl-isoxazol-5-yl]-benzene-1,3-diol
Figure imgf000026_0002
Step l 1-(2,4-Dihydroxy-phenyl)-2-(4-methoxy-phenyl)-ethanone
Figure imgf000026_0003
Resorcinol (4.4g, 40mmol) and 4-methoxyphenylacetic acid (6.6g, 40mmol) in boron trifluoride.etherate (25ml, 0.2mol) was heated, under a nitrogen atmosphere, at 90°C for ~90mins. to give a pale red solution. The solution was allowed to cool and poured into aqueous sodium acetate (200ml,10%) and the mixture stirred to give a pale yellow precipitate. The solids were removed by filtration and washed with water (200ml). Solids were taken up in ethyl acetate (250ml) and washed with water (200ml). Solution was dried over anhyrous magnesium sulphate and concentrated, to a yellow semi-solid. Trituration with diethyl ether (100ml) gave the 1-(2,4-dihydroxy-phenyl)-2-(4- methoxy-phenyl)-ethanone as a pale orange solid, dried in vacuo, (2.2g) LC retention time 2.39 minutes [M+H]+ 259.2 (Run time 3.75mins)
N.M.R (DMSO-d6) 7.95(d J 8.9Hz ArH) 7.2(d J 8.7Hz 2ArH) 6.9(d J 8.7Hz 2ArW) 6.4(d J 9.9 ArH) 6.25(s ArH) 4.2(s 2CH2) 3.75(s 3OCH3)
Step 2 7-Hydroxy-3-(4-methoxy-phenyl)-2-methyl-chromen-4-one
Figure imgf000027_0001
Acetic anhydride (3ml, 30mmol) was added to a suspension of potassium carbonate (4.0g, 29mmol) and 1-(2,4-dihydroxy-phenyl)-2-(4-methoxy- phenyl)-ethanone (1.95g, 7.5mmol) in DMF (10ml), and the resulting suspension heated at 115°C for ~90mins. The mixture was allowed to cool and poured into water (200ml), to give an off-white precipitate. The solids were removed by filtration and washed with water (100ml) and diethyl ether (2x40ml), to give 7-hydroxy-3-(4-methoxy-phenyl)-2-methyl-chromen-4-one as an off-white powder, dried in vacuo, (1.65g)
LC retention time 2.26 minutes [M+H]+ 283.2 (Run time 3.75mins)
N.M.R (DMSO-de) 7.8(d J 8.7Hz ArW) 7.2(d J 8.8Hz 2ArH) 7.0(d J 8.8Hz 2ArH) 6.9(d J 8.7 ArW) 6.8(s ArH) 3.8(s 3OCW3) 2.2(s 3CW3)
Step 3 4-.[4.(4-.|\/lethoxy-phenyl)-3-methyl-isoxazoI-5-yl]-benzene-1,3-diol
Figure imgf000027_0002
Hydroxylamine hydrochloride (0.35g, 5mmol) was added to a suspension of 7-hydroxy-3-(4-methoxy-phenyl)-2-methyl-chromen-4-one (0.14g, O.δmmol) in pyridine (3ml) and the mixture heated under reflux for ~4hrs. The solution was allowed to cool and poured into water (50ml) and extracted with diethyl ether (50ml). The extracts were washed with water (3x 50ml) and saturated aqueous sodium chloride solution (30ml). The solution was dried over anhydrous magnesium sulphate and concentrated to give a pale brown gum.
Crude product was purified by column chromatography, on silica, eluting with ethyl acetate/ hexane (1 :2), to give a colourless gum. Trituration with hexane gave 4-[4-(4-methoxy-phenyl)-3-methyl-isoxazol-5-yl]-benzene-1 ,3-diol as a white powder, dried in vacuo, (0.087g)
LC retention time 2.20 minutes [M+H]+ 298.2 (Run time 3.75mins)
N.M.R (DMSO-d6) 7.1 (d J 8.8Hz 2ArH) 6.85(d J 8.6Hz ArH) 6.8(d J 8.8Hz 2ArH) 6.25(s ArH) 6.15(d J 8.6Hz ArH) 3.65(s 3OCH3) 2.15(s 3CH3)
Example 2
4-Bromo-6-[4-(4-methoxy-phenyl)-3-methyl-isoxazol-5-yl]-benzene-1 ,3- diol
Figure imgf000028_0001
Benzyltrimethylammonium tribromide (3.95g, 10mmol) was added portion-wise to an ice cooled suspension of 4-[4-(4-methoxy-phenyl)-3-methyl- isoxazol-5-yl]-benzene-1 ,3-diol (Example 1) (2.95g, 10mmol) in dichloromethane (50ml) and the mixture stirred for ~60mins, at room temperature. Ethyl acetate (300ml) was added and the mixture washed with water (3x200ml) and saturated aqueous sodium chloride solution (50ml). The solution was dried over anhydrous magnesium sulphate and concentrated to give a pale brown solid. Crude product was purified by column chromatography, on silica, eluting with ethyl acetate/ hexane (1 :2), to give 4- bromo-6-[4-(4-methoxy-phenyl)-3-methyl-isoxazol-5-yl]-benzene-1 ,3-diol as a white solid, dried in vacuo, (3.42g) LC retention time 2.38 minutes [M+H]+ 378.2 (Run time 3.75mins) N.M.R (Acetone-d6) 7.35(s ArH) 7.2(d J 8.8Hz 2ArH) 6.9(d J 8.8Hz 2ArH) 6.65(s ArH) 3.8(s 3OCH3) 2.25(s 3CH3)
Example 3 5-[4-(4-Methoxy-phenyl)-3-methyl-isoxazol-5-yl]-biphenyl-2,4-diol
Figure imgf000029_0001
Step l
5-(2,4-BJs-benzyloxy-5-bromo-phenyl)-4-(4-methoxy-phenyl)-3-methyl- isoxazole
Figure imgf000029_0002
Benzyl bromide (0.36ml, 3mmol) was added suspension of 4-bromo-6- [4-(4-methoxy-phenyl)-3-methyl-isoxazol-5-yl]-benzene-1 ,3-diol (Example 2) (0.55g, 1.5mmol) and cesium carbonate (0.85g, 2.6mmol) in DMF (5ml) and the mixture stirred for ~18hrs, at room temperature. Water (100ml) was added and the mixture extracted with diethyl ether (2x30ml). The combined extracts were washed with water (4x75ml) and saturated aqueous sodium chloride solution (50ml). The solution was dried over anhydrous magnesium sulphate and concentrated to give a pale brown gum. Trituration with hexane gave 5- (2,4-bis-benzyloxy-5-bromo-phenyl)-4-(4-methoxy-phenyl)-3-methyl-isoxazole as an off-white solid, dried in vacuo, (0.5g).
LC retention time 3.08 minutes [M+H]+ 558.4 (Run time 3.75mins)
N.M.R (Chloroform-d) 7.55(s ArH) 7.35-7.25(m 5ArH) 7.2(m 3ArH) 6.95(d J 8.8Hz 2ArH) 6.85(m 2ArH) 6.7(d J 8.8Hz 2ArH) 6.35(s ArH) 4.95(s 2CH2) 4.6(s 2CH2) 3.75(s 3OCH3) 2.25(s 3CH3) Step 2
5-(4,6-Bis-benzyloxy-biphenyl-3-yl)-4-(4-methoxy-phenyl)-3-methyl- isoxazole
Figure imgf000030_0001
Potassium phosphate (0.1g, O.δmmol) was added to a solution of 5-(2,4-bis- benzyloxy-5-bromo-phenyl)-4-(4-methoxy-phenyl)-3-methyl-isoxazole (0.14g, 0.25mmol) and phenyl boronic acid (0.095g, 0.75mmol) in 1 ,4 dioxan (4ml) under a nitrogen atmosphere. Tetrakis(triphenylphosphine)palladium(0) (cat.) was added and the suspension heated, 80°C for ~18hrs. The suspension was allowed to cool and ethyl acetate (25ml) added. The mixture was washed with water (3x25ml) and saturated aqueous sodium chloride solution (25ml). The solution was dried over anhydrous magnesium sulphate and concentrated to give a pale brown gum. Trituration with hexane gave 5-(4,6-bis-benzyloxy- biphenyl-3-yl)-4-(4-methoxy-phenyl)-3-methyl-isoxazole as an off-white solid, dried in vacuo.
LC retention time 3.08 minutes [M+H]+ 554.4 (Run time 3.75mins)
N.M.R (Chloroform-d) 7.4(m 2ArH) 7.35(s ArH) 7.3-7.1(m 11 ArH) 6.95(d J 8.8Hz 2ArH) 6.9(m 2ArH) 6.7(d J 8.8Hz 2ArH) 6.45(s ArH) 4.9(s 2CH2) 4.7(s 2CH2) 3.75(s 3OCH3) 2.25(s 3CH3)
Step 3 7-Hydroxy-3-(4-methoxy-phenyl)-2-methyl-6-phenyl-chromen-4-one
Figure imgf000030_0002
Ammonium formate (3.2g, 50mmol) was added to a solution of 5-(4,6- bis-benzyloxy-biphenyl-3-yl)-4-(4-methoxy-phenyl)-3-methyl-isoxazole (1.4g, 2.5mmol) in methanol (20ml)/ethyl acetate (10ml) under a nitrogen atmosphere. Palladium on carbon (10%) (cat.) was added and the suspension heated, at 60°C for ~18hrs. The suspension was allowed to cool and ethyl acetate (150ml) added, and the suspension filtered. The filtrate was washed with water (3x100ml) and saturated aqueous sodium chloride solution (50ml). The solution was dried over anhydrous magnesium sulphate and concentrated to give a pale brown gum. Trituration with methanol gave 7- hydroxy-3-(4-methoxy-phenyl)-2-methyl-6-phenyl-chromen-4-oneas an off- white solid, dried in vacuo.
LC retention time 2.58 minutes [M+H]+ 359.2 (Run time 3.75mins)
N.M.R (DMSO-dβ) 7.9(s ArH) 7.5-7.3(m 5ArH) 7.25(d J 8.8Hz 2ArH) 7.1 (s ArH) 7.05(d J 8.8Hz 2ArH) 3.85(s 3OCH3) 2.2(s 3CH3)
Step 4 5-[4-(4- ethoxy-phenyl)-3-methyl-isoxazol-5-yl]-biphenyl-2,4-diol
Figure imgf000031_0001
Hydroxylamine hydrochloride (75mg, 1.08mmol) was added to a suspension of 7-hydroxy-3-(4-methoxy-phenyl)-2-methyl-6-phenyl-chromen-4-one (105mg, 0.29mmol) in pyridine (2ml) and the mixture heated under reflux for ~6hrs., to give a pale yellow solution. The solution was allowed to cool and water (20ml) added. The mixture was extracted with diethyl ether (2x10ml). The combined extracts were washed with water (2x20ml) and saturated aqueous sodium chloride solution (10ml). The solution was dried over anhydrous magnesium sulphate and concentrated. The crude products were purified by column chromatography, silica, eluting with ethyl acetate/hexane (1 :1), to give the title compound as an off-white powder (80mg)
LC retention time 2.56 minutes [M+H]+ 374.3 (Run time 3.75mins)
N.M.R (Acetone-d6) 7.5-7.3(m 5ArH) 7.2(d J 8.8Hz 2ArH) 7.0(d J 8.8Hz 2ArH) 6.9(d J 8.6Hz ArH) 6.35(s ArH) 6.1 (d J 8.7Hz ArH) 3.85(s 3OCH3) 2.25(s 3CH3) Example 4
4-Chloro-6-[4-(4-methoxy-phenyl)-3-methyl-isoxazol-5-yl]-benzene-1 ,3- diol
Figure imgf000032_0001
Hydroxylamine hydrochloride (0.7g, 10mmol) was added to a suspension of 6- chloro-7-hydroxy-3-(4-methoxy-phenyl)-2-methyl-chromen-4-one [prepared analogously to Example 1 , Step 2] (0.32g, 1.Ommol) in pyridine (4ml) and the mixture heated under reflux for ~6hrs., to give a pale yellow solution. The solution was allowed to cool and water (20ml) added. The mixture was extracted with diethyl ether (2x10ml). The combined extracts were washed with water (2x20ml) and saturated aqueous sodium chloride solution (10ml). The solution was dried over anhydrous magnesium sulphate and concentrated. The crude products were purified by column chromatography, silica, eluting with ethyl acetate/hexane (1 :1), to give 4-chloro-6-[4-(4- methoxy-phenyl)-3-methyl-isoxazol-5-yl]-benzene-1 ,3-diol as an off-white powder (0.103g)
LC retention time 2.37 minutes [M+H]+ 332.2 (Run time 3.75mins)
N.M.R (Acetone-de) 7.2(d J 8.8Hz 2ArH) 7.15(s ArH) 6.9(d J 8.8Hz 2ArH) 6.6(s ArH) 3.85(s 3OCH3) 2.25(s 3CH3)
The compounds of Examples 1-4 had an HSP90 IC50 in the range A when tested in the Malachite Green ATPase assay described below. In the following tables, the final column gives the result on the same basis for the compound in question, except in the case of Example 12b, where the activity quoted is as measured in the fluorescence polarisation assay described below.
Examples 5-16 were prepared using the reaction described for Examples 1-4. Other details of the preparation Examples 6 and 7 are analagous to those of Examples 86 and 87.
Figure imgf000033_0001
Figure imgf000034_0001
*Also available commercially from Interbioscreen §available commercially from Enamine ** prepared from protected bromo resorcinol intermediate with copper (I) cyanide in dimethylformamide at 150°C
*** Fluorescence Polarisation Assay: 'A' = <10uM; 'B' = >10uM
Example 14
4-[4-(4-Methoxy-phenyl)-3-methyl-isoxazol-5-yl]-6-phenethyl-benzene- 1 ,3-diol
Figure imgf000035_0001
was prepared from styryl boronic acid coupling of the bromo isoxazole compound of Example 2 Step 1 , as described above, followed by reduction and treatment with hydroxylamine, analogously to Example 3.
LC retention time 2.56 minutes [M+H]+ 402 (Run time 3.75mins)
Example 15
4-[4-(4-Methoxy-phenyl)-3-methyl-isoxazol-5-yl]-2,6-bis-(4-methyl- piperazin-1 -ylmethyl)-benzene-1 ,3-diol
Figure imgf000035_0002
Scheme 2: Mannich reaction
Figure imgf000036_0001
N-methylpiperazine (0.125ml, 1.1 mmol) was added to a suspension of 4-[4-(4- methoxy-phenyl)-3-methyl-isoxazol-5-yl]-benzene-1 ,3-diol (0.15g, O.δmmol) and paraformaldehyde (0.040g) in 1 ,4-dioxan (4ml) and the mixture heated under reflux for ~18hrs., to give a brown yellow solution. The solution was allowed to cool and ethyl acetate (25ml) added. The mixture was washed with water (3x25ml) and saturated aqueous sodium chloride solution (2δml). The solution was dried over anhydrous magnesium sulphate and concentrated to a pale brown gum. Trituration with hexane, gave 4-[4-(4-methoxy-phenyl)-3- methyl-isoxazol-δ-yl]-2,6-bis-(4-methyl-piperazin-1-ylmethyl)-benzene-1 ,3-diol (0.121g) as a pale brown powder.
LC retention time 1.61 minutes [M+H]+ 622.6 (Run time 3.7δmins)
N.M.R (Acetone-de) 7.2(d J 8.8Hz 2ArH) 6.9δ(s ArH) 6.8(d J 8.8Hz 2ArH) 3.8δ(s 3OCH3) 3.7δ(s 2CH2) 3.6δ(s 2CH2) 2.9-2,0(br s 16 CH2) 2.3(s 3CH3) 2.2δ(s 3CH3) 2.2(s 3CH3)
Example 16
2,4-Dihydroxy-5-[4-(4-methoxy-phenyl)-3-methyl-isoxazol-5-yl]-benzoic acid methyl ester
Figure imgf000036_0002
Scheme 3: formation of ester
Figure imgf000037_0001
Stepl n-Butyl lithium (100μl) was added to a solution of δ-(2,4-bis-benzyloxy-δ- bromo-phenyl)-4-(4-methoxy-phenyl)-3-methyl-isoxazole (1 δ4mg, 0.28mmol) in tetrahydrofuran (2.δml) under a nitrogen atmosphere at -78°C. Solution stirred at -70°C for 30minutes to give an orange solution. The ion was quenched with methyl chloroformate (100μl, 3eq) and allowed to warm to room temperature for 30minut.es. The solution was quenched with saturated aqueous ammonium chloride (δml). The mixture was extracted with ethyl acetate (3 x δml). The combined extracts were washed with water (2xδml) and saturated aqueous sodium chloride solution (δml). The solution was dried over anhydrous magnesium sulphate and concentrated. The crude products were purified by column chromatography, silica, eluting with ethyl acetate in hexane (gradient 20% to 60% ethyl acetate) to give 2,4-Bis-benzyloxy-δ-[4-(4- methoxy-phenyl)-3-methyl-isoxazol-δ-yl]-benzoic acid methyl ester (72mg). LC retention time 4.9δ minutes [M+H]+ 636.4 (Run time 7.δmins) N.M.R (DMSO-de) 7.8(s ArH) 7.δδ(d J 7.1 Hz 2ArH) 7.4(t J 6.2Hz 2ArH) 7.3δ(d J 6.1 Hz ArH) 7.3(m 3ArH) 7.1 (m 4ArH) 7.0(s ArH) 6.9(d 8.8Hz 2ArH) δ.3(s 2CH2) 5.1 (s 2CH2) 3.78(s OCH3) 3.76(s OCH3) 2.28(s CH3)
Step 2
Ammonium formate (172mg, 20eq) was added to a solution of 2,4-Bis- benzyloxy-δ-[4-(4-methoxy-phenyl)-3-methyl-isoxazol-δ-yl]-benzoic acid methyl ester (72mg, 0.13mmol) in methanol (2ml)/ethyl acetate (1ml) under a nitrogen atmosphere. 10% Palladium on carbon (cat.) was added and the suspension heated at 60°C overnight. The solution was allowed to cool. Ethyl acetate (δml) added, solution washed with water (2xδml) and saturated aqueous sodium chloride solution (δml). The solution was dried over anhydrous magnesium sulphate and concentrated. The crude products were purified by column chromatography, silica, eluting with ethyl acetate in hexane (gradient 2δ% to 4δ% ethyl acetate) to give 2,4-dihydroxy-δ-[4-(4-methoxy- phenyl)-3-methyl-isoxazol-δ-yl]-benzoic acid methyl ester (7.0mg). LC retention time 2.49 minutes [M+H]+ 3δ6.3 (Run time 3.7δmins) N.M.R (CDCI3) δ = 10.8δ(s ArOH) 7.δ2(s ArOH) 7.12(d J8Hz 2ArH) 6.98(s ArH) 6.91 (d J8Hz 2ArH) 6.4δ(s ArH) 3.78(s 3 OCH3) 3.71 (s 3 OCH3) 2.21 (s 3 CH3).
The compounds of Examples 14-16 had an HSP90 ICδO in the ranges 'A', 'B' and 'B', respectively when tested in the Malachite Green ATPase assay described below.
Similarly, Examples 17-20 were prepared quenching with N-formyl piperidine, phenyl thioisocyanate, 2-methoxy phenyl isocyanate and benzaldehyde, respectively. The final deprotection reaction was carried out with boron trichloride as described for example 23 (last reaction on Scheme δ). Example 21 was a by-product from Stepl , Example 16. Quoted activities are those obtained in the Malachite Green Assay described below.
Figure imgf000038_0001
Figure imgf000039_0001
Example 22
4-Benzyl-6-[4-(4-methoxy-phenyl)-3-methyl-isoxazol-5-yl]-benzene-1 ,3- diol
Figure imgf000039_0002
Scheme 4: Synthesis of benzyl resorcinol
Figure imgf000039_0003
Carbonic acid 2-benzoyl-5-ethoxycarbonyloxy-phenyl ester ethyl ester
Figure imgf000040_0001
Triethyl amine (10ml, 72.2mmol) was added to a solution of 2,4- dihydroxybenzophenone (1) (δ.4g,23.3 mmol) in THF (δOml) and the solution cooled to 0°C. Ethyl chloroformate (6.9ml, 72.2mmol) was added slowly and the suspension stirrred for ~30mins at 0°C, and for ~3hrs at room temperature. Water (160ml) was added and the mixture extracted with diethyl ether (1δ0ml). The extracts were washed with water (2x 1δ0ml) and saturated aqueous sodium chloride solution (100ml). The solution was dried over anhydrous magnesium sulphate and concentrated to give 4-benzyl-benzene- 1 ,3-diol as a pale green gum, solidified on standing, (8.2g). LC retention time 2.73 minutes [M+H]+ 3δ9.2 (Run time 3.7δmins) δ (Chloroform-d) 7.7(m 2ArH) 7.δ(m 2ArH) 7.3δ(m 2ArH) 7.1 δ(m 2ArH) 4.2δ(q J 7.1Hz 2CH2) 4.0δ(q J 7.1 Hz 2 CH2) 1.3δ(t J 7.1Hz 3CH3) 1.15(t J 7.1Hz 3 CH3)
4-benzyl-benzene-1 ,3-diol
Figure imgf000040_0002
A solution of sodium borohydride (1.8δg, 49mmol) in water (30ml) was added to an ice cooled solution of carbonic acid 2-benzoyl-δ-ethoxycarbonyloxy- phenyl ester ethyl ester (3.6g, 10mmol) in THF (30ml). The mixture was stirred for ~60mins. at 0°C, and for ~60hrs. at room temperature, to give a pale red suspension. Water (1δ0ml) was added and the mixture extracted with diethyl ether (1δ0ml). The extracts were washed with water (2x 100ml) and saturated aqueous sodium chloride solution (δOml). The solution was dried over anhydrous magnesium sulphate and concentrated to give a pale yellow gum. The gum was taken up in aqueous sodium hydroxide (20ml, 10%), and the solution heated under reflux for ~60mins. The solution was allowed to cool and acidified with hydochloric acid (δml, 37%). The mixture was extracted with diethyl ether (60ml). The extracts were washed with water (3x 40ml) and saturated aqueous sodium chloride solution (30ml). The solution was dried over anhydrous magnesium sulphate and concentrated to give 4-benzyl- benzene-1 ,3-diol as a dark red gum, (2.1 g).
LC retention time 2.28 minutes [M+H]+ no ion (Run time 3.7δmins) δ (Chloroform-d) 7.2(m 3ArH) 7.1 (m 2ArH) 6.8δ(d J 8.1 Hz ArH) 6.3(d J 8.1 Hz ArH) 6.2(s ArH) 3.8δ(s 2CH2)
The 4-benzyl-benzene-1 ,3-diol was used as the starting material in a Scheme 1 synthesis to provide Example 23.
Example 23
3-{2,4-Dihydroxy-5-[4-(4-methoxy-phenyl)-3-methyl-isoxazol-5-yl]- phenyl}-acrylic acid
Figure imgf000041_0001
Scheme δ: Heck reaction and boron trichloride deprotection
Figure imgf000041_0002
Step l
3-{2,4-Bis-benzyloxy-5-[4-(4-methoxy-phenyl)-3-methyl-ϊsoxazol-5-yl]- phenyl}-acrylic acid tert-butyl ester
Figure imgf000042_0001
Diisopropylethyl amine (1 ml, δ.7mmol) was added to a suspension of δ-(2,4- Bis-benzyloxy-δ-bromo-phenyl)-4-(4-methoxy-phenyl)-3-methyl-isoxazole (O.δβg, LOmmol) in tert-butyl acrylate (1 ml, 6.8mmol) and 1-butanol (8ml) under a nitrogen atmosphere. Dichlorobis(tri-o-tolylphosphine)palladium (II) (cat.) was added and the suspension heated, 140°C for ~18hrs., to give a yellow/green solution. The solution was allowed to cool and concentrated to a yellow/ green gum. The crude product was purified by column chromatography, silica, eluting with ethyl acetate/ hexane (1 :9), to give 3-{2,4- Bis-benzyloxy-δ-[4-(4-methoxy-phenyl)-3-methyl-isoxazol-δ-yl]-phenyl}-acrylic acid tert-butyl ester as a yellow/green gum (31 δ mg). Starting material (170 mg) was recovered.
LC retention time 3.23 minutes [M+H]+ 604.6 (Run time 3.7δmins)
N.M.R (Chloroform-d) 7.8δ(d J 16.1 Hz CH) 7.6(s ArH) 7.4-7.2δ(m 8ArH) 7.05(d J 8.8Hz 2ArH) 6.9(m 2ArH) 6.8(d J 8.8Hz 2ArH) 6.5(s ArH) 6.3δ (d J 16.1 Hz CH) δ.0δ(s 2CH2) 4.7δ(s 2CH2) 3.7δ(s 3OCH3) 2.2δ(s 3CH3) 1.δ(s 9CCH3)
Step 2
3-{2,4-Dihydroxy-5-[4-(4-methoxy-phenyl)-3-methyl-isoxazol-5-yl]- phenyl}-acrylic acid
Figure imgf000042_0002
Boron trichloride solution (2ml, 1.0M in dichloromethane) was added slowly to a solution of 3-{2,4-Bis-benzyloxy-δ-[4-(4-methoxy-phenyl)-3-methyl-isoxazol- δ-yl]-phenyl}-acrylic acid tert-butyl ester (δOmg, 0.09mmol) in dichloromethane (1ml), at -78 °C (dry ice/ acetone) under a nitrogen atmosphere. The resulting solution was stirred for ~1 hr at -78 °C, and for ~ 90mins. at room temperature. The solution was cooled to -78°C and water (2ml) added and the mixture was stirred for ~30mins at room temperature. Ethyl acetate (30ml) was added and the solution washed with water (2xδml) and saturated aqueous sodium chloride solution (10ml). The solution was dried over anhydrous magnesium sulphate and concentrated to a pale yellow gum. Trituration with hexane gave a yellow solid, solids were removed by filtration and washed with hexane.dried in vacuo, to give 3-{2,4-dihydroxy-δ-[4-(4-methoxy-phenyl)-3-methyl-isoxazol- δ-yl]-phenyl}-acrylic acid (10mg) as yellow powder. LC retention time 2.08 minutes [M+H]+ 368.3 (Run time 3.7δmins)
N.M.R (Acetone-d6) 7.8δ(d J 16.1 Hz CH) 7.δ(s ArH) 7.2δ(d J 8.8Hz 2ArH) 6.9δ(d J 8.8Hz 2ArH) 6.6(s ArH) 6.3δ (d J 16.1 Hz CH) 3.8(s 3OCH3) 2.2δ(s 3CH3)
Similarly, 4-[4-(4-methoxy-phenyl)-3-methyl-isoxazol-5-yl]-6-styryl- benzene-1 ,3-diol (Example 24) was prepared by boron trichloride deprotection of δ-(2,4-Bis-benzyloxy-δ-styryl-phenyl)-4-(4-methoxy-phenyl)-3- methyl-isoxazole (prepared from styryl boronic acid coupling of bromo isoxazole intermediate, Example 3))
LC retention time 2.08 minutes [M+H]+ 368.3 (Run time 3.7δmins)
The compounds of Examples 22 - 24 had an HSP90 ICδO in the ranges 'A', 'B' and 'C respectively when tested in the Malachite Green ATPase assay described below.
Scheme 6: Synthesis of δ-carboxamido isoxazoles
Figure imgf000044_0001
Example 2δ
5-(5-chloro-2,4-dihydroxyphenyl)-4-(4-methoxy-phenyl)-isoxazole-3- carboxylic acid ethylamide
Figure imgf000044_0002
Step l 1-(5-Chloro-2,4-dihydroxy-phenyl)-ethanone
Figure imgf000044_0003
Acetic acid (17.δmL) was added dropwise to a suspension of 4- chlororesorcinol (42. δg, 0.293mmol) in boron trifluoride etherate (200mL) under a nitrogen atmosphere. The reaction mixture was heated at 90°C for 3.δ hours and then allowed to cool to room temperature. A solid had formed after around 1 hour of cooling. The mixture was poured into 700mL of a 10% w/v aqueous sodium acetate solution. This mixture was stirred vigorously for 2.δ hours. A light brown solid had formed which was filtered, washed with water and air-dried overnight to afford 1-(δ-chloro-2,4-dihydroxy-phenyl)- ethanone (31.6g, 68%). LCMS: [M-H]+ 185. Step 2 1-(2,4-Bis-benzyloxy-5-chloro-phenyl)-ethanone
Figure imgf000045_0001
Benzyl bromide (30mL) was added to a mixture of 1-(δ-chloro-2,4-dihydroxy- phenyl)-ethanone (20g, 0.107moles) and potassium carbonate (37g, 2.6 equiv) in acetonitrile (3δ0mL). The mixture was heated at reflux for 6 hours then allowed to cool and stirred overnight. The mixture was filtered and the solids were washed with dichloromethane (3 x 100mL). The combined organic extracts were evaporated in vacuo to leave a pale yellow solid which was triturated with a mixture of hexane (3δ0mL) / ethyl acetate (1δmL) and filtered to give an off-white solid, 1-(2,4-bis-benzyloxy-δ-chloro-phenyl)-ethanone (3δ.4g, 90%). 1 H NMR (400MHz) consistent with structure.
Step 3
4-(2,4-Jb/s-benzyloxy-5-chlorophenyl)-2-hydroxy-4-oxo-but-2-enoic acid ethyl ester
Figure imgf000045_0002
Sodium metal (1.36 g, 0.068 mol) was added in small pieces over a period of 20 minutes to stirred anhydrous ethanol under a nitrogen atmosphere. The reaction mixture was then stirred for a further 10 minutes until all the sodium had reacted to give a homogeneous solution. 1 -(2,4-6/s-benzyloxy-5-chloro- phenyl)-ethanone (10.0g, 0.027 mol) was added in portions over 2-3 minutes and the resulting suspension was stirred for 5 minutes prior to addition of diethyl oxalate (6 ml, 0.043 mol) which afforded a thicker, yellow precipitate. The reaction mixture was heated to reflux (giving homogeneous brown solution) for 4 hours, then allowed to cool to room temperature and acetic acid (6 ml) was added. The resulting which solid forms was triturated, filtered, washed with ethanol and dried to give a yellow solid (12.0 g, 96%). 1H NMR (400 MHz, CDCI3) δ 1.2 (t, 3H), 4.19 (q, 2H), δ.Oδ (s, 2H), 5.10 (s, 2H), 6.50 (s, 1 H), 7.22-7.41 (m, 10H), 7.97 (s, 1 H).
Step 4
5-(2,4-S/s-benzyIoxy-5-chlorophenyl)-isoxazole-3-carboxylic acid ethyl ester
Figure imgf000046_0001
Hydroxylamine hydrochloride (0.89 g; 12.8 mmol) was added to a suspension of 4-(2,4-b/s-benzyloxy-δ-chlorophenyl)-2-hydroxy-4-oxo-but-2-enoic acid ethyl ester (6.00 g; 10.7 mmol) in absolute ethanol (100 ml). The reaction mixture was heated at reflux for four hours then allowed to cool to ambient temperature (during this time the mixture remains heterogeneous but becomes lighter yellow in colour). The mixture was filtered and the filtered solid was washed with water (2 x 20 ml), ethanol (2 x 20 ml) and dried in vacuo at 46 °C. This affords δ-(2,4-b/s-benzyloxy-δ-chlorophenyl)-isoxazole-3- carboxylic acid ethyl ester as a fluffy yellow solid, 4.49 g (91 %) LCMS: [M+H]+ 466, 464 (37CI; 35CI). ). 1H NMR (400 MHz, CDCI3) δ 1.42 (t, 3H), 4.42 (q, 2H), δ.13 (s, 2H), 5.14 (s, 2H), 6.62 (s, 1H), 7.01 (s, 1H), 7.35-7.43 (m, 10H), 8.00 (s, 1 H).
Step 5
5-(2,4-S/s-benzyloxy-5-chlorophenyl)-isoxazole-3-carboxylic acid ethylamide
Figure imgf000047_0001
A solution of ethylamine in methanol solution (2.0M; 40 mL; 80 mmol) was added to a stirred suspension of 5-(2,4-bis-benzyloxy-δ-chlorophenyl)- isoxazole-3-carboxylic acid ethyl ester (4.40 g; 9.61 mmol) in absolute ethanol (60 ml). The reaction mixture was heated to 80 °C (oil-bath temperature) for five hours. The reaction mixture was allowed to cool to ambient temperature and left to stand overnight. A colourless solid product formed and the reaction mixture was further cooled in an ice-water bath, filtered and washed with cold ethanol (2 x 20 ml). The colourless product was dried in vacuo to afford δ- (2,4-b/s-benzyloxy-5-chlorophenyl)-isoxazole-3-carboxylic acid ethylamide 3.42 g (78%) LCMS: [M+H]+ 465, 463 (37CI; 35CI). 1H NMR (400 MHz, CDCI3) δ 1.25 (t, 3H), 3.48 (m, 2H), 5.10 (s, 2H), 5.2 (s, 2H), 6.59 (s, 1 H), 6.83 (bit, 1 H), 7.08 (s, 1 H), 7.30-7.41 (m, 10H), 7.97 (s, 1 H).
Step 6
5-(2,4-β/s-benzyloxy-5-chlorophenyl)-4-bromo-isoxazole-3-carboxylic acid ethylamide
Figure imgf000047_0002
A solution of bromine in acetic acid (0.6M; 7.2mL; 4.32 mmol) was added to a stirred suspension of 5-(2,4-β/s-benzyloxy-5-chlorophenyl)-4-bromo- isoxazole-3-carboxylic acid ethylamide (2.00 g; 4.32 mmol) and sodium acetate (0.708 g, 8.64 mmol) in acetic acid (30 ml) at ambient temperature. The mixture was heated to 80 °C and becomes homogeneous within 5-10 minutes, to afford a dark red solution. After heating for 2.5 hours the solution was yellow in colour. TLC analysis showed starting material and product present. A further 2.0 ml (1.2 mmol) of the bromine in acetic acid solution was added over the next two hours. The reaction mixture was allowed to cool to ambient temperature and acetic acid was removed in vacuo to afford a solid residue, which was partitioned between ether (200 ml) and water (200ml). The phases were separated and the organic phase was washed with water (3 x 100ml), saturated aqueous sodium bicarbonate solution (2 x100 ml) and saturated sodium chloride solution (1 x 200 ml). The organic phase was dried over sodium sulphate, filtered and the filtrate solvents were removed in vacuo to afford a yellow oil which was purified by flash chromatography on silica gel, eluting with 1-20% ethyl acetate in hexane. This affords product as colourless solid, 1.2 g (62%) LCMS: [M+Hf 643, 641 (81Br; 79Br). 1H NMR (400 MHz, CDCIs) δ 1.26 (t, 1 H), 3.50 (m, 2H), 5.01 (s, 2H), 5.12 (s, 2H), 6.62 (s, 1 H), 6.74 (br t, 1 H), 2.28-7.41 (m, 10H), 7.53 (s, 1 H).
Step 7
5-(2,4-β/s-benzyloxy-5-chlorophenyl)-4-(4-methoxy-phenyl)-isoxazole-3- carboxylic acid ethylamide
Figure imgf000048_0001
To a mixture of 4-methoxyphenylboronic acid (0.178 g, 1.17 mmol) and 5-(2,4- β/s-benzyloxy-δ-chlorophenyl)-4-bromo-isoxazole-3-carboxylic acid ethylamide (0.607 g, 0.94 mmol) was added sodium hydrogen carbonate (237 mg, 2.82 mmol) followed by DMF (δ mL) and water (1.0 mL). The mixture was degassed by evacuation and flushing with nitrogen (three times), followed by bubbling nitrogen gas through mixture for five minutes. Dichloroø/s(triphenylphosphine)palladium (II) (66 mg, 0.094 mmol) was added and reaction mixture was heated under a nitrogen atmosphere at 90 °C for two hours (reaction mixture becomes dark brown in colour). Another 10 mg of dichlorob/s(triphenylphosphine)palladium (II) was added and reaction mixture was heated at 90 °C for 1δ hours then allowed to cool to ambient temperature. The majority of solvents were removed in vacuo and the residue was partitioned between ethyl acetate (60 mL) and water (60 mL). This mixture was filtered through a pad of celite to remove palladium residues and then the phases were separated and the organic phase was washed with water (2 x 30mL), saturated aqueous sodium chloride solution (60 mL) then dried over sodium sulphate. The mixture was filtered and the filtrate solvents were removed in vacuo to afford a yellow oil (698 mg). The crude reaction product was purified by adsorption onto silica gel then flash chromatography on silica gel (20 g 1ST) eluting with a solvent gradient of 1 to 20 % ethyl acetate in hexane. This affords 5-(2,4-β/s-benzyioxy-δ-chlorophenyl)-4-(4- methoxy-phenyl)-isoxazole-3-carboxylic acid ethylamide as a colourless solid (0.223 g, 40%). LCMS: [M+H]+ 571 , 569 (37CI; 35CI). 1H NMR (400 MHz, CDCI3) δ 1.21 (t, 3H), 3.44 (m, 2H), 3.79 (s, 3H), 4.73 (s, 2H), 6.45 (s, 1 H), 6.65 (t, 1 H), 6.80 (d, 2H), 7.14 to 7.44 (m, 8H), 6.95 (m 2H).
Step 8
5-(5-chloro-2,4-dihydroxyphenyl)-4-(4-methoxy-phenyl)-isoxazole-3- carboxylic acid ethylamide
Figure imgf000049_0001
To an ice-bath cooled solution of 5-(2,4-β/s-benzyloxy-5-chlorophenyl)-4-(4- methoxy-phenyl)-isoxazole-3-carboxylic acid ethylamide (0.213 mg, 0.374 mmol) in dichloromethane (δ mL) under a nitrogen atmosphere was added a 1.0M solution of Boron trichloride in dichloromethane (1.12 mL; 1.12 mmol). The reaction mixture was stirred at 0 °C for 1 δ minutes then at ambient temperature for 36 minutes. The reaction mixture was re-cooled to 0 °C and quenched by the addition of saturated aqueous sodium hydrogen carbonate solution (5 mL). After stirring for δ minutes the dichloromethane was removed in vacuo and the residue was partitioned between ethyl acetate (30 mL) and water (30 mL). The phases were separated and the organic phase was washed with water (30mL), saturated aqueous sodium chloride solution (30 mL) then dried over sodium sulphate. The mixture was filtered and the filtrate solvents were removed in vacuo to afford a foam-like colourless solid which was purified by adsorption onto silica gel then flash chromatography on silica gel (10 g 1ST) eluting with 60 % ethyl acetate in hexane. This affords δ-(δ- chloro-2,4-dihydroxyphenyl)-4-(4-methoxy-phenyl)-isoxazole-3-carboxylic acid ethylamide as a colourless solid (0.097 g; 67%). LCMS: [M+H]+ 391 , 389 (37CI; 35CI). 1H NMR (400 MHz, d6-DMSO) D 1.08 (t, 3H), 3.22 (m, 2H), 3.73 (s, 3H), 6.69 (s 1H), 6.87 (d, 1 H), 7.13-7.17 (m, 3H). 8.88 (br t, 1 H), 10.09 (s, 1H), 10.62 (s, 1 H).
Example 25 had activity 'A' in the Fluorescence Polarisation Assay, as described below.
Similarly, Example 26 was prepared by coupling the Boc protected 4- piperazinophenyl boronate ester as above. This boronate ester was made from 1-(4-bromophenyl)piperazine by boc protection followed by boronate ester formation by Pd-catalysed coupling with bis(tetramethylpinacolato) diboron. Example 27 was made similarly. Example 27a was made by deprotection of δ-(2,4-β/s-benzyloxy-δ-chlorophenyl)-4-bromo-isoxazole-3- carboxylic acid ethylamide:
Figure imgf000050_0001
Figure imgf000051_0001
* Fluorescence Polarisation Assay
Scheme 7: Preparation of 5-(2,4-bis-benzyloxy-δ-chloro-phenyl)-4-iodo-3- methyl-isoxazole intermediate
Figure imgf000051_0002
Example 28
4-Chloro-6-[3-methyl-4-(3-morpholin-4-ylmethyl-phenyl)-isoxazol-5-yl]- benzene-1 ,3-diol
Figure imgf000051_0003
Step l 1-(2,4-Bis-benzyloxy-5-chloro-phenyl)-3-hydroxy-but-2-en-1-one:
To a solution of ketone (1δg) in EtOAc (200ml) was added sodium metal (3.0g) in small pieces. The suspension was stirred at room temperature for 1 δmins, then heated to reflux overnight. The reaction was quenched with acetic acid, and the yellow precipitate filtered. This was triturated in hexanes to give bright yellow crystals. NMR indicated this was the required product - mostly in enol form - small trace of keto form.
Step 2 5-(2,4-Bis-benzyloxy-5-chloro-phenyl)-3-methyl-isoxazole:
The diketone (4.0g) was suspended in 80% aq EtOH. Hydroxylamine hydrochloride (3.4g) and sodium acetate (4.0g) was added and the pH adjusted to 8/9 with 2M NaOH. The solution was refiuxed for 24hrs (difficult to monitor by TLC due to very similar Rf values). After this time the solution was acidified to pHδ with 1M HCl and poured into water. The white precipitate was filtered, washed with water, and triturated with hexane to give a white solid. Notes; Compound can also be washed with ether if necessary to remove trace impurities but not usually required. NMR indicated this to be the required product.
Step 3 5-(2,4-Bis-benzyloxy-5-chloro-phenyl)-4-iodo-3-methyl-isoxazole:
Isoxazole (2g) was placed in a mixture of acetic acid (24ml) and water (30ml). lodinemonochloride (2g excess) was added and the solution heated at 80°C for 2-3hrs. After cooling to room temperature 10% Na2SO3 (Sodium sulphite) in water was added (60ml). A viscous orange solid/oil was separated from the mixture and was washed with water. It was then dissolved in acetone and filtered. Removal of the acetone under vacuum gave a sticky orange oil which solidified to a orange solid overnight. NMR and LCMS indicated this was the required product. Step 4
3-[5-(2,4-Bis-benzyloxy-5-chloro-phenyl)-3-methyl-isoxazol-4-yl]- benzaldehyde
Figure imgf000053_0001
δ-(2,4-Bis-benzyloxy-5-chloro-phenyl)-4-iodo-3-methyl-isoxazole (200mg, 0.38mmol), and 3-formylbenzene boronic acid (8δmg, 1.5 equiv.) were dissolved in DMF (12ml) before 1 M Sodium hydrogen carbonate solution (1.1ml, 3.0 equiv) and Pd(Ph3P)2CI2(21mg, 0.08 equiv.) were added with stirring. The reaction mixture was transferred to three microwave tubes which were sealed and the mixtures within degassed before being irradiated by an initial power of 200W to a temperature of 150°C for 15 minutes in a CEM microwave apparatus. Upon cooling the reaction mixtures were combined and partitioned between ethyl acetate (10ml) and water (10ml). The aqueous layer was separated and extracted again with ethyl acetate (10ml). The organics were then combined washed with water (2 x 20ml), brine (20ml), dried over Na2SO before being condensed in vaccuo and purified by flash chromatography on silica gel, eluting with 25% ethyl acetate in hexane.
LCMS tR = 9.06, MS m/z 510.4 [M+H]+
Step 5
4-{3-[5-(2,4-Bis-benzyloxy-5-chloro-phenyl)-3-methyl-isoxazol-4-yl]- benzyl}-morpholine
Figure imgf000053_0002
3-[δ-(2,4-Bis-benzyloxy-δ-chloro-phenyl)-3-methyl-isoxazol-4-yl]- benzaldehyde (2δmg, O.Oδmmol) and morpholine (0.3ml) were mixed with DCE (0.5ml) in an microwave tube. Sodium triacetoxyborohydride (15mg, 1.4 equiv) was added, the tube sealed, and nitrogen atmosphere introduced. After 1 hr more sodium triacetoxyborohydride (15mg) was added and the reaction left stirring overnight. TLC analysis showed that the reaction had not gone to completion so a drop of acetic acid was added and the reaction again left stirring overnight after which the reaction was quenched with 1 M NaHCO3 solution (7ml) and extracted into EtOAc (δml). This was dried over MgSO and the solvent removed in vaccuo to provide 13mg of the crude product as an off white powder which was taken over to the deprotection step.
Step 6
4-Chloro-6-[3-methyl-4-(3-morpholin-4-ylmethyl-phenyl)-isoxazol-5-yl]- benzene-1 ,3-diol
Figure imgf000054_0001
4-{3-[5-(2,4-Bis-benzyloxy-δ-chloro-phenyl)-3-methyl-isoxazol-4-yl]-benzyl}- morpholine was deprotected as previously shown and the crude purified by preparative TLC eluting with 10% Ethanol in dichloromethane to provide 0.6mg (7% yield) of the product as a white powder.
LCMS tR = 5.46, MS m/z 399.3 [M-H]"
Example 28 had activity 'A' in the Fluorescence Polarisation Assay, as described below.
Example 29
1-{3-[5-(2,4-Bis-benzyloxy-5-chloro-phenyl)-3-methyl-isoxazol-4-yl]- benzyl}-piperidine-4-carboxylic acid amide
Figure imgf000055_0001
Prepared in using a similar procedure to 4-chloro-6-[3-methyl-4-(3-morpholin- 4-ylmethyl-phenyl)-isoxazol-5-yl]-benzene-1 ,3-diol except that isonipecotamide replaced the morpholine and the sodium triacetoxyborohydride (3 equiv.) and acetic acid (1 drop) were added initially. The reaction was complete after 18hrs and the crude obtained after work up was taken over to the deprotection step.
1-{3-[5-(5-Chloro-2,4-dihydroxy-phenyl)-3-methyl-isoxazol-4-yl]-benzyl}- piperidine-4-carboxylic acid amide
Figure imgf000055_0002
1-{3-[δ-(2,4-Bis-benzyloxy-δ-chloro-phenyl)-3-methyl-isoxazol-4-yl]-benzyl}- piperidine-4-carboxylic acid amide was deprotected as previously shown and the crude purified by preparative TLC eluting with 10% Ethanol in dichloromethane to provide 0.7mg (3% yield) of the product as a white powder.
LCMS tR = δ.36, MS m/z 442.3 [M+H]+
Example 29 had activity 'A' in the Fluorescence Polarisation Assay, as described below. In a similar way, example 30 was prepared:
Figure imgf000056_0004
Flu
Figure imgf000056_0001
Example 31
Scheme 8:
Figure imgf000056_0002
Step l
5-(2,4-Bis-benzyloxy-5-chloro-phenyl)-4-iodo-isoxazole-3-carboxylic acid ethylamide
Figure imgf000056_0003
δ-(2,4-Bis-benzyloxy-δ-chloro-phenyl)-isoxazole-3-carboxylic acid ethylamide (0.90g, 1.94mmol), N-lodosuccinimide (0.44g, 1 equiv.) and Ammonium cerium (IV) nitrate (0.63g, O.δ equiv) were suspended in Acetonitrile (5δml) before heating to reflux (oil bath 10OoC) where upon the mixture became homogeneous. After 18hrs the solution was cooled and the solvent removed in vaccuo to give a thick orange oil. This was partitioned between DCM (25ml) and water (10ml), the organic layer was kept and washed with brine (2 x 25ml) before drying over Na2SO4. The DCM was removed in vaccuo to provide 0.88g (77% yield) of the product as a orange/tan coloured powder. LCMS tR = 8.76, MS m/z 689.1 [M+H]+
Step 2 1-(3-Bromo-phenyl)-4-methyl-piperazine
Figure imgf000057_0001
1 ,3-Dibromobenzene (0.90ml, 7.49 mmol), Λ/-methylpiperazine (0.28ml, 2.60mmol) and anhydrous toluene (7ml) were added by syringe to a dry, argon filled flask. The solution was thoroughly mixed before BINAP (47mg) and Pd2dba3 (23mg) were delivered and the flask refilled with Argon and DBU (0.93g, 2.5 equiv.) added via syringe. The reaction mixture was warmed to 60°C before freshly ground sodium tertbutoxide was added in one portion to start the reaction. The reaction was left stirring at 60°C overnight and the TLC analysis appeared to show that some piperazine was still present so the reaction was heated to 100°C and stirred for another 24hrs after which it was partitioned between EtOAc (20ml) and water (20ml). The aqueous layer was extracted again with EtOAc and the combined organics were washed with 1.6M HCl solution (2 x 10ml). The acidic solution containing the product was then basified first with a similar volume of 1 M NaOH solution to acid solution and then carefully solid sodium bicarbonate was added to make the pH=8.5 before extraction back into EtOAc (2 x 1 δml), which was washed with brine, dried over MgSO4 and evaporated to dryness to provide O.δOg (78% yield) of the pure product as a yellow oil.
LCMS tR = 4.5δ, MS m/z 255.4/257.3 [M+H]+
Step 3
1-Methyl-4-[3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]- piperazine
Figure imgf000058_0001
To a solution of PdCI2 (dppf).DCM (10mg, 0.012 mmol) in anhydrous toluene (4ml) in an argon filled sealed microwave tube was added the 1-(3-Bromo- phenyl)-4-methyl-piperazine (100mg, 0.39mmol), Et3N (0.11 ml, 2 equiv.), and 4,4,5, 5-tetramethyl-1 ,3,2-dioxaborolane (0.09ml, 1.5 equiv). The microwave tube was evacuated and backfilled with Argon before being irradiated in a CEM Microwave reactor at 100°C for 1hr using an initial power of 200W. The reaction mixture was partitioned between more toluene (δml) and water (10ml), the organic layer separated, washed with water (1 x 10ml), dried over MgSO4 and then evaporated in vacuo to leave a purple/brown residue which was used for suzuki coupling without further purification.
LCMS tR = 0.97, MS m/z 303.5 [M+H]+
Step 4
5-(2,4-Bis-benzyloxy-5-chloro-phenyl)-4-[3-(4-methyl-piperazin-1-yl)- phenyl]-isoxazole-3-carboxylic acid ethylamide
Figure imgf000058_0002
5-(2,4-Bis-benzyloxy-5-chloro-phenyl)-4-bromo-isoxazole-3-carboxylic acid ethylamide (38mg, 0.07mmol) and 1-Methyl-4-[3-(4,4,δ,δ-tetramethyl- [1 ,3,2]dioxaborolan-2-yl)-phenyl]-piperazine (31 mg, 2 equiv.) were coupled together using the suzuki method previously described to provide 37mg (83% yield) of the crude as a brown oil which was taken on to the deprotection step.
Step δ
5-(5-Chloro-2,4-dihydroxy-phenyl)-4-[3-(4-methyl-piperazin-1-yl)-phenyl]- isoxazole-3-carboxylic acid ethylamide
Figure imgf000059_0001
δ-(2,4-Bis-benzyloxy-δ-chloro-phenyl)-4-[3-(4-methyl-piperazin-1-yl)-phenyl]- isoxazole-3-carboxylic acid ethylamide was deprotected as previously shown. The precipitate formed during the reaction was separated, partitioned between EtOAc and water. The aqueous layer was kept, basified using solid sodium hydrogen carbonate and the product extracted using EtOAc (2 x 10ml). The combined organics were washed with brine (10ml) dried over MgSO4 and evaporated in vaccuo to provide δ.2mg (20% yield) of product as a tan coloured powder.
LCMS tR = 5.68, MS m/z 457.3 [M+H]+ δH (d4-MeOH), 7.17 (1H, m, Ar-H), 7.09 (1H, s, Ar-H), 6.94 (1H, m, Ar-H), 6.80 (1 H, m, Ar-H), 6.49 (1 H, s, Ar-H), 3.13 (4H, t, NCH2CH2N-CH3), 2.69 (2H, q, CONHCH2CH3), 2.61 (4H, t, NCH2CH2N-CH3), 2.37 (3H, s, NCH2CH2N-CH3), 1.19 (3H, t, CONHCH2CH3).
Example 31 had activity 'A' in the Fluorescence Polarisation Assay, as described below.
Examples 32 - 38 in the Table below were prepared similarly, but with the following variations:
1. For Example 36, the dioxaborolan intermediate was prepared as follows: Scheme
Figure imgf000060_0001
Step l 1-(4-Bromo-phenyl)-4-methyl-piperazine
Figure imgf000060_0002
1-(4-Bromo-phenyl)-piperazine (1g, 4.1 mmol) and potassium carbonate (1.8g, 3eq) in DMF (1δml) treated with methyl iodide (2δ0μl, 1.1 equivalents), solution stirred at room temperature overnight. Reaction quenched with deionised water (10ml), extracted with ethyl acetate. Organic phase washed with sodium hydrogen carbonate to remove any dimethylated impurity, dried and solvent removed to give 1-(4-Bromo-phenyl)-4-methyl-piperazine in 73% yield. LC retention time 2.21 minutes [M+H]+ 266 (Run time 3.7δmins).
Step 2
1-Methyl-4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]- piperazine
Figure imgf000060_0003
1-(4-Bromo-phenyl)-4-methyl-piperazine (750mg, 3mmol) in DMSO (1 δml) with bis(pinacolato)diboran (1.1g, 1.5 equivalents) and potassium acetate (900mg, 3 equivalents). Suspension degassed before treatment with PdCI2(dppf) (cat.), stirred at 80C. Additional bis(pinacolato)diboran (1eq) added after 3hours, stirred for a further 2hours. Suspension partitioned between ethyl acetate and water. Purification by column chromatography 0- 8% methanol gradient in dichloromethane to give 1-Methyl-4-[4-(4,4,5,δ- tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-phenyl]-piperazine in 62% yield. LC retention time 1.83 minutes [M+H]+ 303 (Run time 3.75mins).
2. For examples 37 and 38, a boronic acid intermediate was used instead of a diaoxaborolan, the former being prepared as follows:
4-[(2-Methylsulfonyl)-ethylaminomethyl]-phenyl boronic acid (intermediate for Example 37)
Figure imgf000061_0001
4-Aminomethyl phenyl boronic acid hydrochloride (660mg, 3mmol) in ethanol (δml) was treated with methyl vinyl sulfone (260μl, 1 equivalent) and triethyl amine (1.2ml, 3 equivalents). The solution was stirred at 100oC for 2hrs. Ethanol removed under vacuum, partitioned in water and butanol to give 4-[(2- methylsulfonyl)-ethylaminomethyl]-phenyl boronic acid in 94% yield. LC retention time 0.39 minutes [M+H]+ 258 (Run time 3.75mins).
4-[N-methy S,S-dioxo-thiomorpholino]-phenyl boronic acid (Intermediate for Example 38)
Figure imgf000062_0001
4-Aminomethyl phenyl boronic acid hydrochloride (4δ6mg, 2.4mmol) in ethanol (δml) treated with vinyl sulfone (244μl, 1 equivalent) and triethylamine (2equivalents), solution stirred at 100C for 3hrs. Ethanol removed under vacuum, partitioned in water and butanol to give the product in 8δ% yield.
LC retention time 1.65 minutes [M+H]+ 270 (Run time 8mins).
Figure imgf000062_0002
Figure imgf000063_0001
Example 39
Scheme 9:
Figure imgf000064_0001
Step l
5-(2,4-Bis-benzyloxy-5-chIoro-phenyl)-4-(3-chloro-phenyl)-isoxazole-3- carboxylic acid ethylamide
Figure imgf000064_0002
δ-(2,4-Bis-benzyloxy-δ-chloro-phenyl)-4-bromo-isoxazole-3-carboxylic acid ethylamide (60mg, 0.11 mmol), and 3-chlorobenzene boronic acid (23mg, 1.3 equiv.) were coupled together using the suzuki method previously described to provide 3δmg (δδ% yield) of the crude as a brown powder which was taken on to the next step.
Step 2
[5-(2,4-Bis-benzyloxy-5-chloro-phenyl)-4-(3-chloro-phenyl)-isoxazol-3- ylmethyl]-ethyl-amine
Figure imgf000064_0003
To a solution of δ-(2,4-Bis-benzyloxy-δ-chloro-phenyl)-4-(3-chloro-phenyl)- isoxazole-3-carboxylic acid ethylamide (36mg, O.Oβmmol) in anhydrous THF under argon was added 1M Borane-THF complex (1ml) and the solution refiuxed overnight. After cooling the solution was poured on to a Isolute® SPE Flash SCX-2 δg column which was quickly eluted with methanol (2 x 20ml). The desired product was then recovered by eluting with a mixture of 10% ammonia in methanol (2 x 10ml) which was evaporated in vaccuo to provide 23mg (66% yield) of a light yellow powder. LCMS (LCT) tR = 8.18, MS m/z δδδ.8 [M+H]+
Example 39 had activity 'A' in the Fluorescence Polarisation Assay, as described below.
Example 40 was similarly prepared:
Figure imgf000065_0002
Fluorescence Polarisation Assay
Example 41
Scheme 10:
Figure imgf000065_0001
Step l
5-(2,4-Bis-benzyloxy-5-chloro-phenyl)-4-(4-formyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
Figure imgf000066_0001
δ-(2,4-Bis-benzyloxy-δ-chloro-phenyl)-4-iodo-isoxazole-3-carboxylic acid ethylamide (prepared as for Example 31 ) (2 g, 3.4 mmol), 4-formylboronic acid (0.612 g, 4.08 mmol), NaHCO3 (10.2 ml, 1 M aq. solution, 10.2 mmol), PdCI2(PPh3 )2 (119 mg, 0.17 mmol) and DMF (60 ml) were combined. The mixture was then degassed by bubbling N2 through it for δ minutes before being heated at 80°C for 1 hour. The mixture was then evaporated in vacuo and partitioned between EtOAc (3 x 60 ml) and water (60 ml). The combined, dried (Na2SO ) organics were evaporated in vacuo to give a crude oil. This was dissolved in EtOAc and passed through a plug of SiO2, washing through with EtOAc. The filtrate was evaporated in vacuo and the resulting oil triturated with Et2O to afford δ-(2,4-Bis-benzyloxy-δ-chloro-phenyl)-4-(4- formyl-phenyl)-isoxazole-3-carboxylic acid ethylamide (1.677 g, 82%) as a pale coloured solid, LC/MS: RT = 2.908 min. 667.3 (MH+).
Step 2
5-(2,4-Bis-benzyloxy-5-chloro-phenyl)-4-(4-morpholin-4-ylmethyl- phenyl)-isoxazole-3-carboxylic acid ethylamide
Figure imgf000066_0002
Acetic acid (0.37 ml, 6.44 mmol) was added dropwise to a mixture of 5-(2,4- Bis-benzyloxy-δ-chloro-phenyl)-4-(4-formyl-phenyl)-isoxazole-3-carboxylic acid ethylamide (730 mg, 1.29 mmol), morpholine (0.226 ml, 2.68 mmol), 3A powdered molecular sieves (730 mg) and MeOH (21 ml). This was left to stir overnight under N2. The mixture was then evaporated in vacuo and the resultant crude partitioned between CH2CI2 (3 x 40 ml) and sat. NaHCO3 solution (40 ml). The combined, dried (Na SO4) organics were evaporated in vacuo to give crude δ-(2,4-Bis-benzyloxy-δ-chloro-phenyl)-4-(4-morpholin-4- ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide (810 mg) as a yellow solid, LC/MS: RT = 2.365 min. 638.4 (MH+).
Step 3
5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-morpholin-4-yImethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
Figure imgf000067_0001
BCI3 (1 M sol. in CH2CI2) 3.87 ml, 3.87 mmol) was added dropwise to a solution of the crude 5-(2,4-Bis-benzyloxy-δ-chloro-phenyl)-4-(4-morpholin-4- ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide (810 mg, ~ 1.29 mmol) in CH2CI2 (30 ml) at 0°C. The reaction was then allowed to reach RT. Saturated aqueous NaHCO3 (40 ml) was then added slowly and the resultant mixture concentrated in vacuo. This was then partitioned between EtOAc (3 x 60 ml) and water (60 ml). The combined, dried (Na2SO4) organics were evaporated in vacuo. Flash chromatography eluting with CH2CI2 - 10%MeOH / 1% NH3 / CH2CI2 afforded δ-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-morpholin- 4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide (380 mg, 64% over 2 steps) as a yellow foam, LC/MS: RT = 1.751 min. 458.2 (MH+).
Example 41 had activity 'A' in the Fluorescence Polarisation Assay, as described below. In the following Table, Examples 42-64 were prepared by methods analogous to Example 41 , using the appropriate aldehyde or ketone.
Figure imgf000068_0001
Figure imgf000069_0001
Figure imgf000070_0001
Figure imgf000071_0001
Figure imgf000072_0001
*Fluorescence Polarisation Assay
**prepared from ethyl resorcinol starting material Additional compounds 41a-s were prepared by methods analogous to Example 41:
Figure imgf000073_0001
Figure imgf000074_0001
•
Figure imgf000075_0001
• ** prepared from ethyl resorcinol starting material prepared by reduction of the aldehyde intermediate * prepared by alkyation of the intermediate phenol ** prepared from the naphthyl aldehyde
Example 65
Reaction scheme:
Figure imgf000076_0001
Figure imgf000076_0002
Step l 1-(2,4-Bis-benzyloxy-phenyl)-ethanone
Figure imgf000077_0001
3δg of 2,4-dihydroxyacetophenone (0.230 mol, 1eq) were dissolved in 600ml acetonitrile. 79.δg of potassium carbonate (0.676 mol, 2.δeq) and 86.6g benzyl bromide (0.606 mol, 2.2eq) were added. The mixture was refiuxed for 64 hours, cooled down and acetonitrile removed under reduced pressure. The residue was separated between water and ethyl acetate. The residue was mainly mono-benzylated resorcinol.
The crude product (43g) was then dissolved in 2δ0ml DMF. Potassium carbonate (29g, 0.210 mol, 1.2eq) and 2δml benzyl bromide (0.210 mol, 1.2 eq) were added and the mixture was stirred over night. The solvent was removed under reduced pressure and the residue was separated between ethyl acetate and water. After removal of the solvent, the residue was triturated with hexane to remove excess benzyl bromide. LC-MS [M+H]+ = 333 Yield: 51.2g (67%)
Step 2 1-(2,4-Bis-benzyloxy-5-bromo-phenyl)-ethanone
Figure imgf000077_0002
51.2g of 1-(2,4-Bis-benzyloxy-phenyl)-ethanone (0.154 mol, 1 eq) were dissolved in 250ml DMF. 27.42g N-bromosuccinimide (0.154 mol, 1 eq) in 100ml DMF were added dropwise. The mixture was stirred at room temperature over night. The reaction mixture was poured onto 700ml of water and the precipitate filtered off. The filter cake was rinsed with water and the colourless solid was recrystallised from 370ml acetonitrile.
LC-MS [M+H]+ = 411 & 413
Yield: 68.1 δg (92%)
Step 3
4-(2,4-Bis-benzyloxy-5-bromo-phenyl)-2.4-dioxo-butyric acid ethyl ester
Figure imgf000078_0001
9.75g sodium (0.424 mol, 3eq) were dissolved in 500ml absolute ethanol (1.5 hours). 58g of 1-(2,4-Bis-benzyloxy-5-bromo-phenyl)- ethanone (0.141 mol, 1eq) and 30.98g diethyl oxalate (0.212 mol, 1.5eq) were added and the mixture was refiuxed for 2 hours. After cooling down, the mixture was poured onto 220ml of 2N aqueous HCl and the product was extracted into 700ml dichloromethane. The solvent was removed under reduced pressure and the yellow residue was triturated with 150ml diethyl ether. Yield: 69.24g (96%)
1H NMR (400 MHz, CDCI3) δ 1.27 (t, 3H), 4.27 (q, 2H), δ.13 (d, 2H), 6.64 (s, 1H), 7.37 (m. 10H). 8.17 (s, 1H). Step 4
5-(2,4-Bis-benzyloxy-5-bromo-phenyl)-isoxazole-3-carboxylic acid ethyl ester
Figure imgf000079_0001
69.3g of 4-(2,4-Bis-benzyloxy-5-bromo-phenyl)-2,4-dioxo-butyric acid ethyl ester (0.135 mol, 1eq) were dissolved in 750ml ethanol. 14.11g hydroxylamine hydrochloride (0.203 mol, 1.5eq) were added. The mixture was refiuxed for 2.5 hours and cooled down. It was then poured onto 1000ml water, the precipitate was filtered off. The filter cake was washed with 500ml of water followed by 75ml diethyl ether and dried. Yield: 67.62g (99%)
1H NMR (400 MHz, CDCI3) δ 1.39 (t, 3H), 4.41 (q, 2H), 5.11 (d, 2H), 5.1 δ (d, 2H), 6.58 (s, 1 H), 6.99 (s, 1 H), 7.35 (m, 10H), 8.16 (s, 1 H).
Step 5
5-(2,4-Bis-benzyloxy-5-bromo-phenyl)-isoxazole-3-carboxylic acid ethylamide
Figure imgf000079_0002
5-(2, 4 - bis-benzyloxy-5-bromo-phenyl)-isoxazole-3-carboxylic acid ethyl ester was suspended in ethanol and ethylamine (2M in methanol, 3eq), the resulting yellow suspension was heated to reflux (80oC) under nitrogen, at which point the reagents went into solution. This was heated for 14 hours, then left to cool to ambient temperature. A white precipitate formed, which was filtered off and washed with further ethanol before being dried in vacuo.
LC-MS retention time 2.868 minutes [M+H]+ = 607 & 609 (run time 3.76 minutes)
Step 6
5-(2,4-Bis-benzyloxy-5-styrylphenyl)-isoxazole-3-carboxylic acid ethylamide
Figure imgf000080_0001
To a mixture of trans-2-phenylvinylboronic acid (0.472 g, 3.2 mmol) and δ- (2,4-Bis-benzyloxy-δ-bromophenyl)-isoxazole-3-carboxylic acid ethylamide (1.079 g, 2.13 mmol) was added sodium hydrogen carbonate (636 mg, 6.39 mmol) followed by DMF (25 mL) and water (5 mL). The mixture was degassed by evacuation and flushing with nitrogen (three times), followed by bubbling nitrogen gas through mixture for five minutes.
Dichlorobis(triphenylphosphine)palladium (II) (149 mg, 0.21 mmol) was added and reaction mixture was heated under a nitrogen atmosphere at 80 °C for seven hours (reaction mixture becomes dark brown in colour after 10 minutes). The reaction mixture was allowed to cool to ambient temperature and the majority of solvents were removed in vacuo. The resulting residue was partitioned between ethyl acetate (100 mL) and water (100 mL) and this mixture was filtered through a pad of celite to remove Palladium residues. The phases were separated and the organic phase was washed with water (2 x δOmL), saturated aqueous sodium chloride solution (100 mL) then dried over sodium sulphate. The mixture was filtered and the filtrate solvents were removed in vacuo to afford a brown solid (800 mg). The celite filter cake was washed with dichloromethane then dried over sodium sulphate. The mixture was filtered and the filtrate solvents were removed in vacuo to afford a brown solid (641 mg). The combined product batches were purified by trituration with ethyl acetate-hexane mixture. This affords δ-(2,4-Bis-benzyloxy-δ- styrylphenyl)-isoxazole-3-carboxylic acid ethylamide as a light brown solid (808 mg, 71 %). LCMS: [M+H]+ 631. 1 H NMR (400 MHz, CDCI3) δ 1.12 (t, 3H), 3.37 (m, 2H), 4.96 (s, 2H), δ.07 (s, 2H), 6.46 (s, 1 H), 6.70 (brt, 1 H). 7.11 (s, 1 H), 7.17 (d, 1 H), 7.23 (d, 1H), 7.32-7.44 (m, 15H), 8.09 (s, 1 H).
Step 7
5-(2,4-Bis-benzyloxy-5-phenethylphenyl)-isoxazole-3-carboxylic acid ethylamide
Figure imgf000081_0001
Palladium on charcoal catalyst (10%; δOmg) was added to a degassed solution of δ-(2,4-Bis-benzyloxy-δ-styrylphenyl)-isoxazole-3-carboxylic acid ethylamide (690 mg, 1.30 mmol) in 1 ,4-dioxane (60 mL) under a nitrogen atmosphere. The reaction mixture was hydrogenated for a total of 4.76 hrs with further Pd on charcoal catalyst (60 mg) added at 0.76 and 2.6 hrs. The reaction mixture was filtered through a pad of celite, which was washed with 1,4-dioxane (20 mL) and dichloromethane (20 mL). The combined filtrate solvents were removed in vacuo to afford a cream-coloured solid, which was purified by flash chromatography on silica gel (20 g, 1ST) eluting with 10 to 60 % ethyl acetate in hexane. This affords δ-(2,4-Bis-benzyloxy-δ- phenethylphenyl)-isoxazole-3-carboxylic acid ethylamide as a pale yellow solid (609 mg, 88%). LCMS: [M+H]+ 533. 1 H NMR (400 MHz, CDCI3) .51.26 (t, 3H), 2.86-2.96 (m, 4H), 3.49 (m, 2H), 5.03 (s, 2H), 5.18 (s, 2H), 6.56 (s, 1H), 6.81 (t, 1 H), 7.07 (s, 1 H), 7.15-7.20 (m, 3H), 7.23-7.28 (m, 2H), 7.31-7.42 (m, 10H), 7.73 (s,1 H). Step 8
5-(2,4-bis-benzyloxy-5-phenethylphenyl)-4-bromo-isoxazole-3-carboxylic acid ethylamide
Figure imgf000082_0001
N-Bromosuccinimide (207 mg, 1.16 mmol) was added to a suspension of δ- (2,4-Bis-benzyloxy-δ-phenethylphenyl)-isoxazole-3-carboxylic acid ethylamide (564 mg, 1.06 mmol) in acetonitrile (20 mL). Ceric ammonium nitrate (290 mg, 0.53 mmol) was added and the reaction mixture was heated to reflux (affording homogeneous orange solution) and stirred for 30 minutes. The reaction mixture was allowed to cool to ambient temperature and acetonitrile was removed in vacuo. The residue was partitioned between ethyl acetate (50 mL) and water (60 mL) and the phases were separated. The organic phase was washed with saturated aqueous sodium chloride solution (60 mL) and dried over sodium sulphate. The mixture was filtered and the filtrate solvents were removed in vacuo to afford a yellow oil which was purified by flash chromatography on silica gel (20g, 1ST) eluting with 10-30% ethyl acetate in hexane. This affords δ-(2,4-Bis-benzyloxy-5-phenethylphenyl)-4-bromo- isoxazole-3-carboxylic acid ethylamide as yellow oil (326 mg, 63%). LCMS: [M+H]+ 613, 611. Step 9
5-(2,4-bis-benzyloxy-5-phenethyl-phenyI)-4-(4-morpholin-4-ylmethyl- phenyl)-isoxazole-3-carboxylic acid ethylamide
Figure imgf000083_0001
To a mixture of 4-morpholin-4-ylmethyl-phenyl pinnacol borane (0.216 g, 0.71 mmol) and δ-(2,4-Bis-benzyloxy-δ-phenethylphenyl)-4-bromo-isoxazole-3- carboxylic acid ethylamide (0.347 g, 0.67 mmol) was added sodium hydrogen carbonate (142 mg, 1.69 mmol) followed by DMF (10 mL) and water (2.0 mL). The mixture was degassed by evacuation and flushing with nitrogen (three times), followed by bubbling nitrogen gas through mixture for five minutes. Dichlorobis(triphenylphosphine)palladium (II) (40 mg, 0.067 mmol) was added and reaction mixture was heated under a nitrogen atmosphere at 80 °C for δ hours (reaction mixture becomes dark brown in colour). Another 20 mg (0.029 mmol) of dichlorobis(triphenylphosphine)palladium (II) was added and reaction mixture was heated at 80 °C for 15 hours then allowed to cool to ambient temperature. The majority of solvents were removed in vacuo and the residue was partitioned between ethyl acetate (50 mL) and water (50 mL). This mixture was filtered through a pad of celite to remove Palladium residues and then the phases were separated and the organic phase was washed with water (2 x 50mL), saturated aqueous sodium chloride solution (60 mL) then dried over sodium sulphate. The mixture was filtered and the filtrate solvents were removed in vacuo to afford a brown oil. The crude reaction product was purified by flash chromatography on silica gel (20 g, 1ST) eluting with a solvent gradient of 30 to 70 % ethyl acetate in hexane. This affords 5-(2,4-bis- benzyloxy-δ-phenethyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole- 3-carboxylic acid ethylamide as yellow oil (0.110 g, 27%). LCMS: [M+H]+ 708. Step 10
5-(2,4 -dihydroxy-5-phenethyl-phenyl)-4-(4-morpholin-4-ylmethyl- phenyl)-isoxazole-3-carboxylic acid ethylamide hydrochloride
Figure imgf000084_0001
To an ice-bath cooled solution of 5-(2,4-bis-benzyloxy-δ-phenethyl-phenyl)-4- (4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide (0.109 g, 0.15 mmol) in dichloromethane (4 mL) under a nitrogen atmosphere was added a 1.0M solution of Boron trichloride in dichloromethane (0.45 mL; 0.45 mmol). The reaction mixture was stirred at 0 °C for 20 minutes then at ambient temperature for 3.5 hours. The reaction mixture was re-cooled to 0 °C and quenched by the addition of saturated aqueous sodium hydrogen carbonate solution (5 mL). After stirring for 5 minutes the dichloromethane was removed in vacuo and the residue was partitioned between ethyl acetate (20 mL) and water (20 mL). The phases were separated and the organic phase was washed with water (20mL), saturated aqueous sodium chloride solution (20 mL) then dried over sodium sulphate. The mixture was filtered and the filtrate solvents were removed in vacuo to afford a light-brown oil which was purified by adsorption onto silica gel then flash chromatography on silica gel (10 g 1ST) eluting with 0 to 5% methanol in ethyl acetate. This affords a colourless oil which was triturated with 1.0M HCl in diethyl ether solution (5 mL) to afford 5-(2,4 -dihydroxy-5-phenethyl-phenyl)-4-(4- morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide hydrochloride (0.019 g; 24%). LCMS: [M+H]+ 528. 1 H NMR (400 MHz, d6- DMSO) D 1.08 (t, 3H), 2.60 (m, 4H), 2.90-3.30 (m, 6H), 3.67 (m, 2H), 3.87 (m, 2H), 4.30 (s, 2H), 6.46 (s, 1H), 6.84 (s, 1 H), 7.05-7.49 (m, 5H), 7.40-7.68 (m, 4H), 8.90 (brs, 1H), 9.67 (s, 1H), 9.89 (s, 1H), 10.75 (brs, 1 H). Example 65 had activity 'A' in the Fluorescence Polarisation Assay, as described below.
The examples in the following Table were prepared by methods analogous to Example 64, and had the activities shown in the Fluorescence Polarisation Assay, as described below.
Figure imgf000085_0001
Figure imgf000086_0001
Figure imgf000087_0001
The additional examples 75a-v in the following table were also prepared by methods analogues to example 65.
Figure imgf000087_0002
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0001
Figure imgf000091_0003
Example 76
Reaction Scheme
Figure imgf000091_0001
Step l
3-(2,4-Bis-benzyloxy-5-bromo-phenyl)-4-(4-methoxy-phenyl)-5-methyl- isoxazole
Figure imgf000091_0002
Trimethyloxonium boron trifluoride (Aldrich; 70mg, 0.47mmol) was added to a stirred solution of 5-(2,4-Bis-benzyloxy-5-bromo-phenyl)-4- (4-methoxy-phenyl)-3-methyl-isoxazole (Example 3, Step 1 ) (120mg, 0.22mmol) in dichloromethane (3ml) and stirring was continued for 3h. The resulting mixture was concentrated in vacuo to leave a white semisolid, which was mixed with hydroxylamine hydrochloride (70mg, I .Ommol), potassium carbonate (120mg, 0.87mmol) and methanol (2ml), and heated at reflux for 18h. The reaction mixture was partitioned between water (20ml) and ethyl acetate (2x10ml) and the combined organic phases were dried over anhydrous magnesium sulphate and evaporated in vacuo to leave an colourless oil. The crude product was purified by column chromatography, silica (10g), eluting with hexane, followed by diethyl ether/hexane (1 :1 ), to give 3-(2,4-Bis- benzyloxy-5-bromo-phenyl)-4-(4-methoxy-phenyl)-5-methyl-isoxazole as a white solid (44mg, 37%)
LC retention time 5.55 minutes [M+H]+ 556.0 and 558.0 (Run time δ.OOmins)
N.M.R (Chloroform-d) 7.64 (s ArH) 7.356.76 (m 14 ArH) 6.34 (sArH) 4.90 (s 2CH2) 4.60 (s 2CH2) 3.79 (s 3CH3 ) 2.46 (s 3CH3 )
Step 2
4-Bromo-6-[4-(4-methoxy-phenyl)-5-methyl-isoxazol-3-yl]-benzene- 1 ,3-diol
Figure imgf000092_0001
Boron trichloride solution (1M in dichloromethane, 1ml, 1mmol) was added to a solution of 3-(2,4-Bis-benzyloxy-5-bromo-phenyl)-4-(4- methoxy-phenyl)-5-methyl-isoxazole (38mg, 0.068mmol) in dichloromethane (1ml), and stirring was continued for 1h. The reaction mixture was partitioned between water (20ml) and dichloromethane
(2x20ml) and the combined organic phases were dried over anhydrous magnesium sulphate and concentrated in vacuo to leave a brown oil.
The crude product was purified by column chromatography, silica (10g), eluting with hexane, followed by hexane/diethyl ether (3:1 then 1 :1 ), to give 4-Bromo-6-[4-(4-methoxy-phenyl)-5-methyl-isoxazol-3-yl]-benzene-
1,3-diol as a colourless oil (11mg, 43%).
LC retention time 2.52 minutes [M+H]+ 376.1 and 378.1 (Run time
3.75mins)
N.M.R (DMSO-d6) 10.40 (s OH) 9.69 (s OH) 7.22 (ArH) 7.10-6.89(m
4ArH) 6.5 (s ArH) 3.7(s OCH3) 2.46(s CH3)
This compound had activity 'A' in the Hsp90 fluorescence polarization assay.
Example 76A
The following compound is commercially available (Interbioscreen) and had activity "B) in the fluorescence polarization assay:
Figure imgf000093_0001
The following compounds were made according to Example 76:
Figure imgf000094_0002
Example 77
Preparation of 5-(5-tert-Butyl-2,4-dihydroxy-phenyl)-4-(4-morphoIin-4- ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide
Figure imgf000094_0001
Reaction Scheme:
Figure imgf000095_0001
Step l 1-(5-tert-Butyl-2,4-dihydroxy-phenyl)-ethanone
Figure imgf000095_0002
Sulphuric acid (4ml, 75mmol) was added to a suspension of 2,4- dihyroxyacetophenone (22.8g, 150mmol) in a mixture of 2-methyl-2-propanol (35g, 470mmol) and trifluoroacetic acid (80ml), under a nitrogen atmosphere. The resulting suspension was heated, oil bath temperature 75°C, for ~3hrs. to give a pale red solution. The resulting solution was allowed to cool and poured into ice/water (350ml), to give a pale pink precipitate. The solids were removed by filtration and washed with water (600ml) and hexane (200ml) to give a pale pink powder. Dried in vacuo (40°C), to give 1-(5-tert-butyl-2,4- dihydroxy-phenyl)-ethanone as a pale orange powder (28.8g, 92%). LC retention time 2.74 minutes [M+Hf 209.1 (Run time 3.75mins)
N.M.R (Chloroform-d) 7.35(s ArH) 6.05(s ArH) 7.35(m 2ArH) 2.35(s 3CH3) 1.15(s 9 CH3) Step 2 1-(2,4-Bis-benzyloxy-5-tert-butyl-phenyl)-ethanone
Figure imgf000096_0001
Benzyl bromide (10ml, 84mmol) was added to a solution of the acetophenone (13.5g, 65mmol) in DMF (50ml), potassium carbonate (20g, 145mmol) was added and the suspension stirred, at room temperature, for ~4hrs. The resulting suspension was poured into water (200ml) to give a pale orange precipitate. The solids were removed by filtration and washed with water. The solids were taken up in dichloromethane (150ml) and the solution was washed with water (2x100ml) and saturated aqueous sodium chloride solution (100ml). The solution was dried over anhydrous sodium sulphate and concentrated to a pale red oil.
The oil was taken up in 2-methyl-2-propanol (100ml) and potassium tert-butoxide (7.5g, 67mmol) added, to give a pale yellow precipitate, benzyl bromide (8ml, 67mmol) was added and the mixture heated under reflux for ~1 hr. The resulting suspension was allowed to cool and poured into water (250ml), to give a pale orange precipitate. The solids were removed by filtration and washed with water. The solids were taken up in ethyl acetate (150ml) and washed with water (2x200ml) and saturated aqueous sodium chloride solution (100ml). The solution was dried over anhydrous sodium sulphate and concentrated to a orange semi-solid, trituration with methanol gave a pale pink solid. Solids were removed by filtration and dried in vacuo (40°C), to give 1-(2,4-bis-benzyloxy-5-tert-butyl-phenyl)-ethanone as a pale pink powder (9.1g, 36%).
LC retention time 3.03 minutes [M+H]+ 389.3 (Run time 3.75mins)
N.M.R (Chloroform-d) 7.65(s ArH) 7.25-7.15(m 10ArH) 6.35(s ArH) 4.95(s 2CH2) 4.9(s 2 CH2) 2.4(s 3CH3) 1.2(s 9 CH3)
Step 3
4-(2,4-Bis-benzyloxy-5-tert-butyl-phenyl)-2-hydroxy-4-oxo-but-2-enoic acid ethyl ester
Figure imgf000097_0001
Sodium ethoxide (2.8g, 41 mmol) was added to a suspension of the 1-(2,4-bis- benzyloxy-5-tert-butyl-phenyl)-ethanone (7.8g, 20mmol) in ethanol (40ml). Diethyl oxalate (4ml, 29.5mmol) was added and the resulting suspension heated under reflux for ~2hrs. to give a pale red solution. The solution was allowed to cool and poured into water (200ml), the mixture was acidified with hydrochloric acid (50ml, 1 M) and extracted with dichloromethane (150ml). The extracts were washed with water (2x200ml) and saturated aqueous sodium chloride solution (100ml). The solution was dried over anhydrous sodium sulphate and concentrated to a yellow gum. Trituration with hexane gave a yellow solid. Solids were removed by filtration and washed with hexane and dried in vacuo (40°C), to give 4-(2,4-Bis-benzyloxy-5-tert-butyl-phenyl)-2- hydroxy-4-oxo-but-2-enoic acid ethyl ester as a yellow powder (9.1g, 93%).
N.M.R (Chloroform-d) 8.0(s ArH) 7.5-7.35(m 11 ArH) 6.6(s ArH) 5.2(s 2CH2) 5.15(s 2 CH2) 4.3(q J 7.1 Hz 2 CH2) 1.4(s 9 CH3) 1.25(t J 7.1 Hz 3CH3)
Step 4
5-(2,4-Bis-benzyloxy-5-tert-butyI-phenyl)-isoxazole-3-carboxylic acid ethyl ester
Figure imgf000097_0002
Hydroxylamine hydrochloride (3.6g, 52mmol) was added to a solution of 4- (2,4-Bis-benzyloxy-5-tert-butyl-phenyl)-2-hydroxy-4-oxo-but-2-enoic acid ethyl ester (9.0g, 18.5mmol) in ethanol (75ml) and the suspension heated under reflux for ~4hrs. The resulting solution was allowed to cool and poured into water (200ml) to give an off-white precipitate. The solids were removed by filtration and taken up in dichloromethane (150ml). The solution was washed with water (150ml) and saturated aqueous sodium chloride solution (50ml). The solution was dried over anhydrous sodium sulphate and concentrated to an off-white solid. Solids were washed with hexane and dried in vacuo (40°C), to give 5-(2,4-bis-benzyloxy-5-tert-butyl-phenyl)-isoxazole-3-carboxylic acid ethyl ester as a pale brown powder (8.0g, 89%).
LC retention time 3.13 minutes [M+H]+ 486.5 (Run time 3.75mins)
N.M.R (Chloroform-d) 7.85(s ArH) 7.4-7.25(m 10ArH) 6.9(s ArH) 6.5 (s ArH) 5.1(s 2CH2) 5.0(s 2 CH2) 4.35(q J 7.1 Hz 2 CH2) 1.4(s 9 CH3) 1.35(t J 7.1 Hz 3CH3)
Step 5
5-(2,4-Bis-benzyloxy-5-tert-butyl-phenyl)-isoxazole-3-carboxylic acid ethylamide
Figure imgf000098_0001
5-(2,4-Bis-benzyloxy-5-tert-butyl-phenyl)-isoxazole-3-carboxylic acid ethyl ester (10.0g, 20.6mmol) was added to a solution of ethylamine in methanol (60ml, 2.0M) and the suspension heated, oil bath temperature 75°C, for ~2hrs. The resulting solution was allowed to cool and concentrated to a pale brown oil, dichloromethane (150ml) was added and the solution washed with water (100ml) and saturated aqueous sodium chloride solution (75ml). The solution was dried over anhydrous sodium sulphate and concentrated to a brown oil, solidified on standing (9.9g, -quant).
LC retention time 3.02 minutes [M+H]+ 485.3 (Run time 3.75mins)
N.M.R (Chloroform-d) 7.8(s ArH) 7.4-7.2(m 10ArH) 7.0(s ArH) 6.75(br t J 5.4Hz NH) 6.5 (s ArH) 5.1 (s 2CH2) 5.0(s 2 CH2) 3.4(dq J 5.4Hz, 7.1 Hz 2 CH2) 1.35(s 9 CH3) 1.15(t J 7.1 Hz 3CH3) Step 6
5-(2,4-Bis-benzyloxy-5-tert-butyl-phenyl)-4-iodo-isoxazole-3-carboxylic acid ethylamide
Figure imgf000099_0001
N-iodosuccinimide (9.0g, 40mmol) was added to a suspension of 5-(2,4-Bis- benzyloxy-5-tert-butyl-phenyl)-isoxazole-3-carboxylic acid ethylamide (9.9g, 20.4mmol) in acetonitrile (60ml). Ammonium cerium nitrate (0.25g, 0.46mmol) was added and the suspension stirred for ~18hrs. The resulting suspension was concentrated and the residue taken up in dichloromethane(125ml). The resulting solution was washed aqueous sodium metabisulphite solution (2x100ml, 5%), water (100ml) and saturated aqueous sodium chloride solution (100ml). The solution was dried over anhydrous sodium sulphate and concentrated to a pale red gum. Trituration with ethanol (25ml) gave an off- white solid, solids were removed by filtration and washed with ethanol. Dried in vacuo (40°C), to give 5-(2,4-Bis-benzyloxy-5-tert-butyl-phenyl)-4-iodo- isoxazole-3-carboxylic acid ethylamide as an off-white powder (7.75g, 62%). LC retention time 3.07 minutes [M+H]+ 611.2 (Run time 3.75mins)
N.M.R (Chloroform-d) 7.45-7.25(m 11 ArH) 6.8(br t J 5.4Hz NH) 6.6(s ArH) 5.05(s 4CH2) 3.5(dq J 5.4Hz, 7.1 Hz 2 CH2) 1.35(s 9 CH3) 1.2(t J 7.1 Hz 3CH3) Step 7
5-(2,4-Bis-benzyloxy-5-tert-butyl-phenyl)-4-(4-formyl-phenyl)-isoxazole-3- carboxylic acid ethylamide
Figure imgf000100_0001
Aqueous potassium phosphate (25ml, 1.2M) solution was added to a solution of 5-(2,4-bis-benzyloxy-5-tert-butyl-phenyl)-4-iodo-isoxazole-3-carboxylic acid ethylamide (6.1g, 10mmol) and 4-formylphenyl boronic acid (2.35g, 15.7mmol) in 1 ,4-Dioxan (75ml), under a nitrogen atmosphere. Dichloro- bis(tri-o-tolyl phosphine)palladium(ll) (cat.) was added and the mixture heated, oil bath temperature 100°C for ~1hr. The mixture was allowed to cool, and the aqueous layer separated and extracted with ethyl acetate (100ml). The combined organics were concentrated to give a pale brown gum.
The crude product was purified by column chromatography, silica (600ml), eluting with ethyl acetate/ hexane (1 :3), to give 5-(2,4-Bis-benzyloxy- 5-tert-butyl-phenyl)-4-(4-formyl-phenyl)-isoxazole-3-carboxylic acid ethylamide as a pale yellow foam (5.18g, 88%).
LC retention time 3.01 minutes [M+Hf 589.4 (Run time 3.75mins)
N.M.R (Chloroform-d) 9.75(s CHO) 7.5(d J 6.9Hz 2 ArH) 7.2(d J 6.9Hz 2 ArH) 7.15-7.0(m 8ArH) 6.8(m 2 ArH) 6.65 (br t J 5.4Hz NH) 6.2(s ArH) 4.8(s 2CH2) 4.5(s 2 CH2) 3.2(dq J 5.4Hz, 7.1Hz 2 CH2) 1.1(s 9 CH3) 1.05(t J 7.Hz 3CH3) Step 8
5-(2,4-Bis-benzyloxy-5-tert-butyl-phenyl)-4-(4-morpholin-4-ylmethyl- phenyl)-isoxazole-3-carboxylic acid ethylamide
Figure imgf000101_0001
Sodium cyanoborohydride (65mg, 1.03mmol) was added to a solution of 5- (2,4-Bis-benzyloxy-5-tert-butyl-phenyl)-4-(4-formyl-phenyl)-isoxazole-3- carboxylic acid ethylamide (125mg,0.21mmol), morpholine (50μl, 0.57mmol) and acetic acid (cat.) in methanol (4ml) and the solution stirred for ~72hrs. Dichloromethane (50ml) was added and the solution washed with water (2x50ml) and saturated aqueous sodium chloride solution (50ml). The solution was dried over anhydrous sodium sulphate and concentrated to a colourless gum.
The crude product was purified by column chromatography, silica (20g), eluting with ethyl acetate/ hexane (1 :1), to give 5-(2,4-Bis-benzyloxy-5-tert- butyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide as a colourless oil (35mg, 25%).
LC retention time 2.56 minutes [M+H]+ 660.8 (Run time 3.75mins)
N.M.R (Chloroform-d) 7.35-7.05(m 15ArH) 6.7 (br t J 5.4Hz NH) 6.4(s ArH) 4.9(s 2CH2) 4.75(s 2 CH2) 3.6(t J 4.5Hz 4 CH2) 3.(s 2 CH2) 3.35(dq J 5.4Hz, 7.1 Hz 2 CH2) 2.35(br s 4 CH2) 1.15(t J 7.1 Hz 3CH3) 1.1(s 9 CH3) Step 9
5-(5-tert-Butyl-2,4-dihydroxy-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
Figure imgf000102_0001
Boron trichloride (1 ml, 1.0M in dichloromethane) solution was added to a solution of 5-(2,4-Bis-benzyloxy-5-tert-butyl-phenyl)-4-(4-morpholin-4- ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide (35mg, O.Oδmmol) in dichloromethane (1ml) at -20°C (ice/methanol), under a nitrogen atmosphere. The resulting solution was stirred at 0°C (ice/water) for ~90mins. Methanol (2ml) was added and the solution concentrated to a brown gum.
The crude product was purified by preparative HPLC, to give 5-(5-tert- Butyl-2,4-dihydroxy-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3- carboxylic acid ethylamide as a white powder (formate salt) (21 mg, 75%). LC retention time 1.97 minutes [M+H]+ 480.5 (Run time 3.75mins)
N.M.R (DMSO-d6) 8.8 (t J 5.6Hz NH) 7.25(d J 7.2Hz 2ArH) 7.15(d J 7.2Hz 2ArH) 6.7(s ArH) 6.45(s ArH) 3.45(br s 4 CH2) 3.2(dq J 5.6Hz, 7.2Hz 2 CH2) 2.3(br s 4 CH2) 1.1 (s 9 CH3) 1.05(t J 7.2Hz 3CH3)
This compound had activity 'A' in the Hsp90 fluorescence polarization assay.
In a similar manner to the preparation of the compound of example 77, examples 77a-f were prepared.
Figure imgf000103_0001
Figure imgf000104_0002
Example 78
Preparation of 5-(2,4-Dihydroxy-5-isobutyl-phenyl)-4-(4-morpholin-4-ylmethyl- phenyl)-isoxazole-3-carboxylic acid ethylamide
Figure imgf000104_0001
Reaction Scheme
Figure imgf000105_0001
Step l 1-(2,4-Bis-benzyloxy-phenyl)-ethanone
Figure imgf000105_0002
Potassium carbonate (2.5eq) was added to a solution of 2',4'- dihydroxyacetophenone (1eq) in acetonitrile (400mL), and the suspension stirred at room temperature. Benzyl bromide (2.5eq) was added drop wise over 10 minutes and the mixture heated at reflux for 18 hours. The mixture was cooled and evaporated in vacuo to give slurry. The slurry was partitioned between water and ethyl acetate, and the layers were separated. The aqueous layer was further extracted with dichloromethane and the organic extracts were combined, dried (MgS0 ) and evaporated in vacuo. The product was triturated with hexane, filtered and washed with cold hexane and dried in vacuo at 45 °C to give 1-(2,4-Bis-benzyloxy-phenyl)-ethanone as a white powder.
LC retention time 2.704min [M+H]+ 333.3
Step 2 2,4-Bis-benzyloxy-1-isopropenyl-benzene
Figure imgf000106_0001
Methyltriphenylphosphonium bromide (1.1 eq) was suspended in an. THF and cooled to 0°C under nitrogen. 1.6M "Butyllithium in hexanes (1.1 eq) was added drop wise, and stirred for 30 minutes. 1-(2,4-Bis-benzyloxy-phenyl)- ethanone (1eq) was dissolved in an. THF and added drop wise to the suspension. When addition was completed, the ice bath was removed and the reaction mixture was stirred at room temperature under nitrogen overnight. Methanol was added to the reaction mixture and the resulting solution was evaporated in vacuo. Hexane was added to the resulting oil and heated to reflux for 30 minutes, then filtered through Celite. The liquor was evaporated in vacuo to give an oil which was purified by column chromatography, eluting with 30% EtOAc in hexane, to give 2,4-Bis-benzyloxy-1-isopropenyl-benzene. Rf retention time 0.722, 3:1 Hexane: EtOAc.
Step 3 4-lsopropyl-benzene-1 ,3-diol
Figure imgf000106_0002
2,4-Bis-benzyloxy-1-isopropenyl-benzene was taken up in solution in ethanol and added to 10% palladium on carbon, which had been pre-wetted with water. Hydrogen was introduced to the flask and the mixture was allowed to shake for 16 hours. The catalyst was filtered from the reaction mixture, by a suitable method, and the liquor was concentrated in vacuo, to give 4- isopropyl-benzene-1,3-diol as a white crystalline solid. LC retention time 2.088min [M+H]+ 153.1
Step 4 1-(2,4-Dihydroxy-5-isopropyl-phenyl)-ethanone
Figure imgf000107_0001
4-lsopropyl-benzene-1 ,3-diol (1eq) was taken up in BF3.OEt2 (6eq) and acetic acid was added (2eq). The solution was heated for 16 hours at 90°C than allowed to cool to room temperature. The solution was added drop wise to 10%NaOAc (aq) and allowed to stand for 4 hours, before being extracted in to EtOAc. The organic phases were combined and washed with sat. NaHCO3 (aq), then dried over MgSO4, filtered and concentrated in vacuo. The residual oil was purified by column chromatography, eluting with dichloromethane, to give 1 -(2,4-Dihydroxy-5-isopropyl-phenyl)-ethanone as a white solid. LC retention time 2.633min [M+H]+ 195.1
Step 5 1-(2,4-Bis-benzyloxy-5-isopropyl-phenyl)-ethanone
Figure imgf000107_0002
1-(2,4-Dihydroxy-5-isopropyl-phenyl)-ethanone (1eq) was dissolved in DMF and potassium carbonate (2.2eq) then benzyl bromide (2.2eq) were added. The suspension was heated, with stirring to 150°C, under nitrogen, for 16hrs. The solution was cooled to room temperature and the mixture was poured into 1 MHCI (aq) then extracted in to ethyl acetate. The organic phases were combined and washed again with 1 MHCI (aq) then five times with brine solution. The organic phase was dried over MgSO4, filtered and concentrated in vacuo, to give a solid, which was purified by diethyl ether: hexane (1 :1 ) trituration to give 1-(2,4-Bis-benzyloxy-5-isopropyl-phenyl)-ethanone. LC retention time 3.575min [M+H]+ 375.2
Step 6
4-(2,4-Bis-benzyloxy-5-isopropyl-phenyl)-2-hydroxy-4-oxo-but-2-enoic acid ethyl ester
Figure imgf000108_0001
Sodium (2.8eq) was added to ethanol under nitrogen at room temperature and stirred for 25 minutes to generate sodium ethoxide. 1 -(2,4-Bis-benzyloxy-5- isopropyl-phenyl)-ethanone (1eq) was dissolved in further ethanol and added to the sodium ethoxide solution. Diethyl oxalate (1.64eq) was added and the reaction mixture heated to reflux for 4 hours. The mixture was allowed to cool to room temperature and enough 1 MHCI (aq) was added to acidify the reaction mixture, which was then concentrated in vacuo. The resulting gum was partitioned between dichloromethane and brine, and the organic phase was dried over MgSO4, filtered and evaporated in vacuo to give 4-(2,4-Bis- benzyloxy-5-isopropyl-phenyl)-2-hydroxy-4-oxo-but-2-enoic acid ethyl ester as a yellow gum. LC retention time 3.057min [M+H]+ 475 Step 7
5-(2,4-Bis-benzyloxy-5-isopropyl-phenyl)-isoxazole-3-carboxylic acid ethyl ester
Figure imgf000109_0001
4-(2,4-Bis-benzyloxy-5-isopropyl-phenyl)-2-hydroxy-4-oxo-but-2-enoic acid ethyl ester (1eq) was dissolved in ethanol with stirring. Hydroxylamine hydrochloride (1.2eq) was added and the solution was heated to reflux for 4 hours under a nitrogen atmosphere. The reaction mixture was cooled to room temperature and concentrated in vacuo. The residue was partitioned between brine and dichloromethane. The organic phase was dried over MgSO4, filtered and concentrated in vacuo to give 5-(2,4-Bis-benzyloxy-5-isopropyl-phenyl)- isoxazole-3-carboxylic acid ethyl ester as a solid. LC retention time 3.059min [M+H]+ 472
Step 8
5-(2,4-Bis-benzyIoxy-5-isopropyl-phenyl)-isoxazole-3-carboxylic acid ethylamide
Figure imgf000109_0002
5-(2,4-Bis-benzyloxy-5-isopropyl-phenyl)-isoxazole-3-carboxylic acid ethyl ester was dissolved in excess 2M ethylamine in methanol and heated in the
Smith Synthesiser microwave at 120°C for 600 seconds. The solution was concentrated in vacuo to give a solid which was purified by hexane trituration, to give 5-(2,4-Bis-benzyloxy-5-isopropyl-phenyl)-isoxazole-3-carboxylic acid ethylamide.
LC retention time 2.979min [M+H]+ 471.3 Step 9
5-(2,4-Bis-benzyloxy-5-isopropyl-phenyl)-4-iodo-isoxazole-3-carboxylic acid ethylamide
Figure imgf000110_0001
5-(2,4-Bis-benzyloxy-5-isopropyl-phenyl)-isoxazole-3-carboxylic acid ethylamide (1eq) was dissolved in an. acetonitrile and N-iodosuccinimide (2.0eq), followed by eerie ammonium nitrate (0.05eq) were added, and the solution was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo and the resulting gum was partitioned between ethyl acetate and brine. The organic phase was dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by column chromatography, eluting with 9:1 hexane: ethyl acetate, to give 5-(2,4-Bis-benzyloxy-5- isopropyl-phenyl)-4-iodo-isoxazole-3-carboxylic acid ethylamide as an oil. LC retention time 2.97δmin [M+H]+ 597.2
Step 10
5-(2,4-Bis-benzyloxy-5-isopropyl-phenyl)-4-iodo-isoxazole-3-carboxylic acid ethylamide
Figure imgf000110_0002
5-(2,4-Bis-benzyloxy-5-isopropyl-phenyl)-4-iodo-isoxazole-3-carboxylic acid ethylamide (1eq) was dissolved in an. DMF. 1 MNa2CO3 (aq) was added, followed by 4-formylphenylboronic acid (2eq) and then catalytic PdCI2 (PPh3)2. Nitrogen was bubbled through the solution for ten minutes at ambient temperature, after which time, the temperature was elevated to 80°C under a nitrogen atmosphere, for 15 minutes. The reaction mixture was allowed to cool to room temperature and the reaction mixture was diluted with ethyl acetate. This solution was washed with brine, then dried over MgSO4, filtered and concentrated in vacuo to give an oil. Purified by column chromatography, eluting with 10%EtOAc in hexane, to give 5-(2,4-Bis- benzyloxy-δ-isopropyl-phenyl)-4-iodo-isoxazole-3-carboxylic acid ethylamide as a white solid. LC retention time 2.981 min [M+H]+ 575.3
Step 11
5-(2,4-Bis-benzyloxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
Figure imgf000111_0001
5-(2,4-Bis-benzyloxy-5-isopropyl-phenyl)-4-iodo-isoxazole-3-carboxylic acid ethylamide (1eq) was dissolved in methanol and powdered 3A sieves were added. Morpholine (2eq) was added, followed by sodium cyanoborohydride (2eq). Acetic acid (5eq) was added drop wise and the suspension was stirred under nitrogen at ambient temperature for 16hours. The reaction mixture was diluted with DCM and washed with sat. NaHCO3(aq). The organic phase was dried over MgSO4, filtered and concentrated in vacuo. The resulting gum was purified by flash chromatography, eluting with 1%MeOH in DCM to give δ- (2,4-Bis-benzyloxy-δ-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide as a colourless oil. LC retention time 4.42min [M+H]+ 646.2 method B Step 12
5-(2,4-Dihydroxy-δ-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
Figure imgf000112_0001
5-(2,4-Bis-benzyloxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide (1eq) was dissolved in an. DCM and under a nitrogen atmosphere, was cooled to 0°C. 1 MBCI3 in DCM was added drop wise and the solution was stirred under these conditions for 30 minutes. Methanol (2ml) was added and the reaction mixture was concentrated in vacuo. Purification of the sample by preparative LC/MS gave δ-(2,4- dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3- carboxylic acid ethylamide as a white solid. LC retention time 1.991 min [M+H]+ 466.3
This compound had activity 'A' in the Hsp90 fluorescence polarization assay.
In a similar manner to the preparation of the compound of example 78, examples 78a-u were prepared.
Figure imgf000113_0001
Figure imgf000114_0001
Figure imgf000115_0001
Figure imgf000116_0001
Figure imgf000117_0001
Figure imgf000118_0001
Figure imgf000119_0001
Example 78v
Phosphoric acid 4-chloro-5-(diethoxy-phosphoryloxy)-2-[3- ethylcarbamoyl-4-(4-methoxy-phenyl)-isoxazol-5-yl]-phenyl ester diethyl ester
Figure imgf000120_0001
To a solid mixture of 5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-methoxy- phenyl)-isoxazole-3-carboxylic acid ethylamide (11 mg, 2.1 x 10~2 mmol) and MgO (25 mg) in a small vial, 10 drops of diethyl chlorophosphate was added. The resulting mixture was heated and stirred at 70 °C for an hour, the progress of the reaction was monitored by TLC. When cooled, MeOH (1 ml) and DCM (1 ml) were added. After filtration, the solvents were evaporated and yellow oil was obtained. The di-phosphoryl ester was separated by preparative TLC, yielding 4 mg. Rf = 0.35; 1H NMR δ = 7.95 (1 H, s, broad); 7.74 (1 H, s); 7.55 (1 H, s); 7.32 (2H, d, J = 9.0 Hz); 6.90 (2H, d, J = 9.0 Hz); 4.30 (8H, q); 3.80 (3H, s); 3.40 (2H, q); 1.35 (12H, t) and 1.25 (3H, t). LCMS: (M+1 )+ = 661.1 (RT = 7.60 min.)
Example 79
Preparation of δ-(2,4-Dihydroxy-δ-isobutyl-phenyl)-4-(4-morpholin-4-ylmethyl- phenyl)-isoxazole-3-carboxylic acid ethylamide
Figure imgf000120_0002
Reaction Scheme
Figure imgf000121_0001
Step l 1-(2s4-Dihydroxy-phenyl)-2-methyl-propan-1-one
Figure imgf000121_0002
Resorcinol (1eq) was taken up in BF3.OEt2 (6eq) and isobutyric acid (1 eq) added. The solution was heated for 1.5 hours at 90°C than allowed to cool to room temperature. The solution was added drop wise to 10%NaOAc (aq) and allowed to stand for 4 hours, before being extracted in to EtOAc. The organic phases were combined and washed with sat. NaHCO3 (aq), then dried over magnesium sulfate, filtered and concentrated in vacuo to give 1-(2,4- dihydroxy-phenyl)-2-methyl-propan-1-one as a red oil which was usedwithout additional purification
LC retention time 2.279 min [M+H]+ 181.1
Step 2 4-lsobutyl-benzene-1 ,3-diol
Figure imgf000122_0001
Ethyl chloroformate (3 eq) was added slowly to a cooled (0 °C) solution of 1- (2,4-dihydroxy-phenyl)-2-methyl-propan-1-one (1 eq) and triethylamine (3 eq) in THF. The mixture was warmed to ambient temperature and stirred for three hours before being filtered and the solids washed with cold THF. The combined filtrates were cooled to 0 °C and sodium borohydride (4 eq) in a volume of water equal to the THF filtrates added slowly. The mixture was warmed to ambient temperature, stirred for three hours and diluted with water. The mixture was twice extracted with diethyl ether, the combined extracts concentrated to dryness and re-suspended in 10% aqueous sodium hydroxide solution (4 eq). After refluxing for 90 minutes, the mixture was cooled, acidified with δM aq HCl and twice extracted with diethyl ether. The organic extracts were dired over magnesium sulphate, filtered and concentrated to dryness to give 4-isobutyl-benzene-1 ,3-diol as a cloudy oil, which was used without further purification.
NMR consistent with structure.
Example 3: 1-(2,4-Dihydroxy-5-isobutyl-phenyl)-ethanone
Figure imgf000122_0002
4-lsobutyl-benzene-1 ,3-diol (1eq) was taken up in BF3.OEt2 (6eq) and acetic acid (2 eq) was added. The solution was heated for 16 hours at 90°C than allowed to cool to room temperature. The solution was added drop wise to 10%NaOAc (aq) and allowed to stand for 4 hours, before being extracted twice with diethyl ether. The organic phases were combined and washed with sat. NaHCO3 (aq), then dried over magnesium sulfate, filtered and concentrated in vacuo to give 1-(2,4-dihydroxy-δ-isobutyl-phenyl)-ethanone, which was used without additional purification.
NMR consistent with structure.
Step 4 1-(2,4-Bis-benzyloxy-5-isobutyl-phenyl)-ethanone
Figure imgf000123_0001
1-(2,4-Dihydroxy-δ-isobutyl-phenyl)-ethanone (1 eq) was dissolved in DMF and potassium carbonate (4.4 eq) then benzyl bromide (4.4 eq) was added. The suspension was heated, with stirring to 1δ0°C, under nitrogen, for 16hrs. The solution was cooled to room temperature, filtered and concentrated to dryness. This solid was purified column chromatography (silica, hexanes:ethyl aceate 4:1 ) then re-crystallised from ethyl acetate:hexanes to give 1-(2,4-Bis- benzyloxy-δ-isobutyl-phenyl)-ethanone as colourless crystals.
LC retention time 3.030 min [M+H]+ 389.3
Step δ
4-(2,4-Bis-benzyloxy-5-isobutyl-phenyl)-2,4-dioxo-butyric acid ethyl ester
Figure imgf000123_0002
Sodium (3 eq) was added to ethanol under nitrogen at room temperature and stirred until complete dissolution occured. 1-(2,4-Bis-benzyloxy-δ-isobutyl- phenyl)-ethanone (1 eq) was added, followed by diethyl oxalate (1.5 eq) and the reaction mixture heated to reflux for 4 hours. The mixture was allowed to cool to room temperature and acidified with 2M HCl (aq) to give a yellow precipitate of 4-(2,4-Bis-benzyloxy-5-isobutyl-phenyl)-2,4-dioxo-butyric acid ethyl ester, which was obtained by filtration.
LC retention time 3.264 min [M+H]+ 489.3
Step 6
5-(2,4-Bis-benzyloxy-5-isobutyl-phenyl)-isoxazole-3-carboxylic acid ethyl ester
Figure imgf000124_0001
4-(2,4-Bis-benzyloxy-δ-isobutyl-phenyl)-2,4-dioxo-butyric acid ethyl ester (1 eq) was dissolved in ethanol with stirring. Hydroxylamine hydrochloride (1.2 eq) was added and the solution was heated to reflux for 2 hours. The reaction mixture was cooled to room temperature, to give a precipitate. This precipitate was obtained by filtration to give 5-(2,4-Bis-benzyloxy-5-isobutyl- phenyl)-isoxazole-3-carboxylic acid ethyl ester as a white solid.
LC retention time 3.261 min [M+H]+ 486.3
Step 7
5-(2,4-Bis-benzyloxy-5-isobutyl-phenyl)-isoxazole-3-carboxylic acid ethylamide
Figure imgf000125_0001
δ-(2,4-Bis-benzyloxy-δ-isobutyl-phenyl)-isoxazole-3-carboxylic acid ethyl ester was dissolved in 2M ethylamine in methanol (10 eq) and heated in the Smith Synthesiser microwave at 120°C for 600 seconds. The solution was concentrated in vacuo to give 5-(2,4-bis-benzyloxy-5-isobutyl-phenyl)- isoxazole-3-carboxylic acid ethylamide as a white solid which was used without additional purification.
LC retention time 3.112 min [M+H]+ 485.3
Step 8
5-(2,4-Bis-benzyloxy-5-isobutyl-phenyl)-4-iodo-isoxazole-3-carboxylic acid ethylamide
Figure imgf000125_0002
δ-(2,4-Bis-benzyloxy-δ-isobutyl-phenyl)-isoxazole-3-carboxylic acid ethylamide (1 eq) and N-iodosuccinimide (2.0 eq), were dissolved in acetonitrile, eerie ammonium nitrate (0.1 eq) added and the solution was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo and the resulting gum was partitioned between ethyl acetate and brine. The organic phase was dried over magnesium sulfate, filtered and concentrated in vacuo. The residue was purified by column chromatography, eluting with 4:1 hexane: ethyl acetate, to give 5-(2,4-bis-benzyloxy-5-isobutyl- phenyl)-4-iodo-isoxazole-3-carboxylic acid ethylamide as an oil.
LC retention time 3.089 min [M+H]+ 611.2 Step 9
5-(2,4-Bis-benzyloxy-5-isobutyl-phenyl)-4-(4-formyl-phenyl)-isoxazole-3- carboxylic acid ethylamide
Figure imgf000126_0001
δ-(2,4-Bis-benzyloxy-δ-isobutyl-phenyl)-4-iodo-isoxazole-3-carboxylic acid ethylamide (1 eq) was dissolved in DMF and 1 M Na2CO3 (aq) (3 eq) was added, followed by 4-formylphenylboronic acid (2 eq) and catalytic PdCI2(PPh3)2. Nitrogen was bubbled through the solution for ten minutes at ambient temperature, after which time, the temperature was elevated to 80°C under a nitrogen atmosphere, for 2 hours. The reaction mixture was allowed to cool to room temperature and the reaction mixture was diluted with ethyl acetate. This solution was washed with brine, then dried over magnesium sulfate, filtered and concentrated in vacuo to give an oil which was purified by column chromatography, eluting with 10% EtOAc in hexane, to give δ-(2,4- bis-benzyloxy-δ-isobutyl-phenyl)-4-(4-formyl-phenyl)-isoxazole-3-carboxylic acid ethylamide as a white solid.
LC retention time δ.67 min [M+H]+ 689.1 method B
Step 10
5-(2,4-Bis-benzyloxy-5-isobutyl-phenyl)-4-(4-morpholin-4-ylmethyl- phenyl)-isoxazole-3-carboxylic acid ethylamide
Figure imgf000126_0002
δ-(2,4-Bis-benzyloxy-5-isobutyl-phenyl)-4-(4-formyl-phenyl)-isoxazole-3- carboxylic acid ethylamide (1eq) was dissolved in methanol and powdered 3A sieves were added. Morpholine (2 eq) was added, followed by acetic acid (5 eq). After stirring for 30 minutes, sodium cyanoborohydride (2 eq) was added portionwise and the suspension was stirred under nitrogen at ambient temperature for 16 hours. The reaction mixture was filtered through celite and concentrated to dryness. Column chromatography, eluting with δ% MeOH in DCM gave 5-(2,4-bis-benzyloxy-δ-isobutyl-phenyl)-4-(4-morpholin-4-ylmethyl- phenyi)-isoxazole-3-carboxylic acid ethylamide as a colourless oil.
LC retention time 4.63 min [M+H]+ 660.2 method B
Step 11
5-(2,4-Dihydroxy-5-isobutyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyI)- isoxazole-3-carboxylic acid ethylamide
Figure imgf000128_0001
δ-(2,4-Bis-benzyloxy-δ-isobutyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide (1 eq) was dissolved in an. DCM and under a nitrogen atmosphere, was cooled to 0°C. 1 M BCI3 in DCM (9 eq) was added dropwise and the solution was stirred for 30 minutes. Methanol (2ml) was added and the reaction mixture was concentrated in vacuo. Purification of the sample by preparative LC/MS gave δ-(2,4-dihydroxy-δ-isobutyl-phenyl)-4- (4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide as a white solid.
LC retention time 1.902 min [M+H]+ 480.3
This compound had activity 'A' in the Hsp90 fluorescence polarization assay.
In a similar manner to the preparation of the compound of example 79, example 80 was prepared. Purification of the sample by preparative LC/MS gave the compound as a white solid
Figure imgf000129_0003
Example 81
N-[5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-fluoro-phenyl)-isoxazol-3- ylmethyl]-methanesulfonamide
Figure imgf000129_0001
Example 82
N-[5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-fluoro-phenyl)-isoxazol-3- ylmethyl]-acetamide
5-(2,4-Bis-benzyloxy-5-chloro-phenyl)-4-(4-fluoro-phenyl)-isoxazole-3- carboxylic acid amide
Figure imgf000129_0002
δ-(2,4-Bis-benzyloxy-δ-chloro-phenyl)-4-iodo-isoxazole-3-carboxylic acid amide (0.4δg, O.δOmmol) was cross coupled to 4-fluorophenylboronic acid (0.17g, 1.5 equiv.) using the standard conditions described above. The crude product, an orange solid (0.40g), was taken on to the next step without further purification.
LCMS (LCQ) tR = 8.70, MS m/z 529.1 [M+H]+
C-[5-(2-4-Bis-benzyloxy-5-chloro-phenyl)-4-(4-fluoro-phenyl)-isoxazol-3- yl]-methylamine
Figure imgf000130_0001
To a solution of 5-(2,4-Bis-benzyloxy-δ-chloro-phenyl)-4-(4-fluoro-phenyl)- isoxazole-3-carboxylic acid amide (0.40g, 0.76mmol) in anhydrous THF (20ml) under argon was added 1 M Borane-THF complex (1ml) and the solution refiuxed overnight. After cooling the reaction was quenched with methanol (10ml) and the product purified using a Isolute® SPE Flash SCX-2 δg to provide 0.30g (77% yield) as a powder. LCMS (LCQ) tR = 7.64, MS m/z 616.2 [M+H]+
Figure imgf000130_0002
N-[5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-fluoro-phenyl)-isoxazol-3- ylmethylj-methanesulfonamide
C-[δ-(2,4-Bis-benzyloxy-δ-chloro-phenyl)-4-(4-fluoro-phenyl)-isoxazol-3-yl]- methylamine (100mg, 0.19mmol) was dissolved in DCM (3ml) before the addition of methane sulfonyl chloride (17μl, 1.1 equiv.) and triethylamine (30μl, 1.1 equiv.). The solution was stirred at room temperature overnight before evaporated to dryness in vacuo leaving a the crude benzyl protected product as a blue coloured residue (90mg). This was deprotected using the standard procedure with boron trichloride described above and purified by preparative TLC (10% ethanol in DCM) and soxhlet extraction of the silica by ether gave the pure compound as a near colourless solid (8mg, 10% yield). LCMS (LCQ) tR = 6.66, MS m/z 411.2 [M-H]- δH (d4-MeOH), 7.19 (2H, m, Ar-H), 7.04 (1 H, s, Ar-H), 7.03 (2H, m, Ar-H), 6.34 (1 H. s, Ar-H), 4.27 (2H, s, CH2NH), 2.81 (3H, s, SO2CH3).
Figure imgf000131_0001
N-[5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-fluoro-phenyl)-isoxazol-3- ylmethyl]-acetamide
To a solution of C-[δ-(2,4-Bis-benzyloxy-5-chloro-phenyl)-4-(4-fluoro-phenyl)- isoxazol-3-yl]-methylamine (100mg, 0.19mmol) in DCM was added acetic anhydride (130μl, 7.0 equiv.) and triethylamine (81 μl, 3.0 equiv.). The solution was stirred at room temperature until the amine was consumed. The solvent was removed in vacuo to leave the yellow tinged oily crude benzyl protected product. This was deprotected using the standard procedure with boron trichloride described above and purified by preparative TLC and soxhlet extraction of the silica by ether gave the pure compound as a colourless solid (10mg, 14% yield).
LCMS (LCQ) tR =6.57, MS m/z 377.1 [M+H δH (d4-MeOH), 7.17 (2H, m, Ar-H), 7.01 (1 H, s, Ar-H), 6.98 (2H, m, Ar-H), 6.32 (1H, s, Ar-H), 4.37 (2H, s, CH2NH), 1.77 (3H, s, COCH3).
Examples 83, 84 and 85
5-(5-Ethyl-4-hydroxy-2-methoxy-phenyI)-4-(4-morpholin-4-ylmethyl- phenyl)-isoxazole-3-carboxylic acid ethylamide (83); 5-(5-Ethyl-2- hydroxy-4-methoxy-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide (84); 5-(5-Ethyl-2,4-dimethoxy- phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide (85)
Figure imgf000132_0001
To an argon charged flask containing 5-(δ-Ethyl-2,4-dihydroxy-phenyl)-4-(4- morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide (2δmg, O.Oδδmmol) and N.N-(Diisopropyl)aminomethylpolystyrene [PS-DIEA] (3δmg, 3.83 mmol/g, 2.4 equiv.) was added anhydrous DCM (2.3ml) and anhydrous methanol (0.2δml). During gentle stirring, 2M (Trimethylsilyl)diazomethane in hexanes (28μl, 1.0 equiv.) was added and the solution stirred overnight at room temperature. Argon was bubbled through the solution for 10 mins, the resin filtered off, and the volitiles removed in vacuo. The crude residue was purified by semi-preparative HPLC to yield δ-(5-Ethyl-4-hydroxy-2-methoxy- phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide (83) (5.62mg, 21%), δ-(δ-Ethyl-2-hydroxy-4-methoxy-phenyl)-4- (4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide (84) (1.14mg, 4%), 5-(5-Ethyl-2,4-dimethoxy-phenyl)-4-(4-morpholin-4-ylmethyl- phenyl)-isoxazole-3-carboxylic acid ethylamide (1.46mg, 5%) and the non- methylated starting material. 83: LCMS (LCT) tR = 4.95, MS m/z 466.4 [M+H]+ 84: LCMS (LCT) tR = 5.14, MS m/z 466.4 [M+H]+ (85): LCMS (LCT) tR = 5.46, MS m/z 480.4 [M+H]+
NMR data confirmed the assignments.
Example 86
Ethyl 5-(5-chloro-2-hydroxy-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxam ide
Figure imgf000133_0001
Step l
Methyl 2-benzoyloxy-5-chloro-benzoate
Figure imgf000133_0002
A mixture of methyl 5-chloro-2-hydroxy-benzoate (2.5 g, 13.4 mmol), K2CO3 (3.7 g, 26.8 mmol) and benzyl bromide (2.98 g, 17.4 mmol) in acetone (30 ml) was refiuxed for 12 hours. After cooling, acetone was evaporated. EtOAc (100 ml) was added and filtered. The organic layer was then washed with 1M HCl (1 x 80 ml), brine (2 x 80 ml) and dried with Na2SO4. After filtration and evaporation of the solvent, yellow semi-solids were obtained (3.2 g). 1H NMR (de-acetone) δ = 7.73 (1 H, d); 7.60 - 7.30 (1 H + 5H, m); 7.28 (1 H, d); 5.30 (2H, s) and 3.90 (3H, s).
Step 2
1-(2-Benzyloxy-5-chloro-phenyl)-2-(triphenyl-λ5-phosphanylidene)- ethanone
Figure imgf000133_0003
To a stirred suspension of triphenylphosphonium bromide (2.14 g, 6.0 mmol) in dried THF (30 ml) at room temperature was added 1.6M n-BuLi in hexane (5.26 ml, 8.39 mmol). The orange suspension was stirred for 3 hours. Next, a solution of methyl 2-benzoyloxy-δ-chloro-benzoate (0.83 g, 3.0 mmol) in THF (8 ml) was slowly added. The resulting mixture was stirred at 60 °C for 2 hours and filtered after cooled. DCM (100 ml) was added to the filtrate and the combined organic layers were washed with brine (2 x 80 ml). After filtration and evaporation of the solvent, yellow oil was obtained (2.0 g). They were then purified by chromatography, eluted with EtOAc : hexane / 1 : 1 , yielded 0.97 g solids. Rf = 0.43. 1H NMR (d6-acetone) δ = 7.80 - 7.52 (20H, m); 7.40 - 7.20 (1 H + 1 H + 1H, m); 5.26 (2H, s); 4.72 (1 H, s, trans-H) and 4.62 (1 H, s, c/'s-H). LCMS: (M+1 )+ = 621.2 (RT = 5.94 min.)
Step 3
Ethyl 4-(2-benzyloxy-5-chloro-phenyl)-2,4-dioxo-3-(triphenyl-λ5 phosphanylidene)-butyrate
Figure imgf000134_0001
To a solution of 1-(2-Benzyloxy-5-chloro-phenyl)-2-(triphenyl-λ5- phosphanylidene)-ethanone (0.49 g, 0.94 mmol), NEt3 (96 mg, 0.94 mmol) and DMAP (12 mg, 0.09 mmol) in dry toluene (20 ml) at room temperature, ethyl chlorooxoacetate (0.38 g, 2.78 mmol) in toluene (5 ml) was added. The mixture was stirred for 2 hours and poured into water (60 ml). The organic layer was separated and the aq. layer was extracted with EtOAc (2 x 40 ml). The combined organic layers were then washed with sat. NaHCO3 solution (2 x 40 ml), sat. citric acid (1 x 40 ml), brine (1 x 40 ml) and dried. Crude oil (0.36 g) was purified by chromatography, eluted with EtOAc. Rf = 0.88. 1H NMR (d6- acetone) δ = 7.75 - 7.40 (15H, m); 7.30 (1 H, dd); 7.16 (1 H, d); 7.0δ (1 H, d); δ.10 (2H, s); 3.60 (2H, q) and 1.10 (3H, s). LCMS: (M+1 )+ = 621.2 (RT = 6.49 min.)
Step 4 Ethyl 3-(2-benzoyIoxy-5-chloro-benzoyl)-3-bromo-3H-azirine-2- carboxylate
Figure imgf000135_0001
To a solution of ethyl 4-(2-benzyloxy-δ-chloro-phenyl)-2,4-dioxo-3-(triphenyl- λ5-phosphanylidene)-butyrate (0.143 g, 0.23 mmol) in DCM (8 ml) at room temperature, a mixture of TMSN3 (40 mg, 0.3δ mmol) and NBS (62 mg, 0.36 mmol) in DCM (6 ml) was added. The resulting solution was stirred for 2 hours. After evaporation of the solvent, the crude product was purified by preparative TLC. Yellow solids (38 mg) were obtained. Rf = 0.73 (EtOAc:hexane 1 :2). 1H NMR (d6-acetone) δ = 7.80 (1H, d); 7.60 (1 H, dd); 7.40 (5H, m); 7.30 (1 H, d); 6.20 (2H, s); 4.10 (2H, q) and 1.00 (3H, t). LCMS: (M+1 )+ = 438.0 (RT = 7.32 min.)
Step δ
Ethyl 5-(2-benzoyloxy-5-chloro-phenyl)-4-brorno-isoxazole-3-carboxylate
Figure imgf000135_0002
Ethyl 3-(2-benzoyloxy-δ-chloro-benzoyl)-3-bromo-3H-azirine-2-carboxylate (5δ mg, 0.12 mmol) was heated at reflux in dry toluene for 2 hours. After evaporation of the solvent, crude solids (34 mg) were obtained and purified by preparative TLC (EtOAc: hexane / 1 : 2). Rf = 0.73 (fluorescent). 1H NMR (de- acetone) δ = 7.60 (1 H, d); 7.60 (1 H, dd); 7.40 (1 H, d); 7.30 (5H, m); 5.2δ (2H, s); 4.42 (2H, q) and 1.40 (3H, t). LCMS: (M+1)+ = 438.0 (RT = 7.09 min.)
Step δ Ethyl 5-(2-benzyloxy-5-chloro-phenyl)-4-bromo-isoxazole-3-carboxamide
Figure imgf000136_0001
To a solution of ethyl 5-(2-benzoyloxy-5-chloro-phenyl)-4-bromo-isoxazole-3- carboxylate (30 mg, 6.8 x 10"2 mmol) in EtOH (1 ml), ethylamine (70 % in water, 1 ml) was added. The solution was heated at 100 °C in a CEM® microwave reactor (200W) for one hour. After that, the solvent was evaporated and the compound purified by preparative TLC to yield solids (20 mg). Rf = 0.39 (EtOAc: hexane / 1 : 4). 1H NMR (d6-acetone) δ = 8.10 (1H, s, broad); 7.60 (1 H, d); 7.45 - 7.35 (1 H + 1 H, m); 7.25 (5H, m); 5.20 (2H, s); 3.40 (2H, q) and 1.20 (3H, t). LCMS: (M+1)+ = 437.1 (RT = 6.57 min.)
Step 7
Ethyl 5-(2-benzyloxy-5-chloro-phenyl)-4-(4-morpholin-4-ylmethyl- phenyl)-isoxazole-3-carboxamide
Figure imgf000136_0002
A mixture of ethyl 5-(2-enzyloxy-5-chloro-phenyl)-4-bromo-isoxazole-3- carboxamide (30 mg, 5.6 x 10"2 mmol), Pd(Ph3P)4 (4 mg, 3.5 x 10"2 mmol), 4[4-(4,4,5,5-Tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-benzyl]morpholine (63 mg, 0.2 mmol) and 1 M NaHCO3 solution (0.2 ml) in DME (1 ml) was stirred at 80 °C under Argon gas for 16 hours. After cooling, the solution was diluted with water (8 ml) and extracted with EtOAc (2 x 20 ml). The combined organic layers were washed with brine (1 x 20 ml) and dried. After filtration and evaporation of the solvents, the crude product was purified by preparative TLC, yielded 30 mg solids. Rf = 0.44 (EtOAc). 1H NMR (d6-acetone) δ = 8.25 (1 H, s, broad); 7.60 (1 H, d); 7.55 (1 H, dd); 7.45 (1 H, d); 7.30 - 6.90 (9H, m); 5.00 (2H, s); 3.55 (4H, m); 3.45 (2H + 2H, s + q); 2.30 (4H, m) and 1.20 (3H, t). LCMS: (M+1)+ = 532.2 (RT = 4.39 min.) Step δ
Ethyl 5-(5-chloro-2-hydroxy-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxamide
Figure imgf000137_0001
To a solution of ethyl 5-(2-benzyloxy~5-chloro-phenyl)-4-(4-morpholin-4- ylmethyl-phenyl)-isoxazole-3-carboxamide (25 mg, 4.7 x 10"2 mmol) in DCM (5 ml) at 0 °C, 1 M BCI3 in DCM (0.15 ml) was added. The resulting cloudy yellow solution was then stirred at 0 °C for 15 minutes and room temperature 3 to 4 hours until it became clear. After that, the solution was quenched by MeOH (1 ml). Sat. NaHCO3 (1 ml) was then added and extracted with EtOAc (2 x 2 ml) and dried. After the solvent was filtered and evaporated, the crude oil was purified by preparative TLC (EtOAc: MeOH / 50 : 1), yielded 12 mg solids. 1H NMR (d4-MeOD) δ = 7.60 (2H, d); 7.50 - 7.30 (1 H + 1 H + 1 H, m); 7.00 (2H, d); 3.70 (4H, m); 3.60 (2H, s); 3.50 (2H, q); 2.60 (4H, m) and 1.25 (3H, t). LCMS: (M+1)+ = 442.2 (RT = 3.54 min.)
The 4-hydroxy-isomer was prepared in a similar way as its 2-hydroxy counterpart as follows:
Example 87
Ethyl 5-(3-chloro-4-hydroxy-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxamide
Figure imgf000138_0001
Step l
Methyl 4-benzoyloxy-3-chloro-benzoate
Figure imgf000138_0002
Methyl 3-chloro-4-hydroxy-benzoate (1.0g, 5.36 mmol) gave a crude solid (1.57g). 1H NMR (d6-acetone) δ = 8.00 (1 H, d); 7.95 (1 H, dd); 7.60 - 7.40 (5H, m); 7.35 (1 H, d); 5.40 (2H, s) and 3.90 (3H, s).
Step 2
1-(4-Benzyloxy-3-chIoro-phenyi)-2-(triphenyl-λ5-phosphanylidene)- ethanone
Figure imgf000138_0003
Methyl 4-benzoyloxy-3-chloro-benzoate (1.5 g, 5.40 mmol) gave a crude solid (2.5g). Rf = 0.31 (EtOAc : hexane / 1 : 1). 1H NMR (d6-acetone) δ = 8.05 (1 H, d); 7.90 (1 H, dd); 7.85 - 7.35 (20H, m); 7.20 (1 H, d); 5.30 (2H, s); 4.60 (1 H, s, trans-H) and 4.50 (1 H, s, cis-H). LCMS: (M+1 )+ = 521.2 (RT = 5.29 min.)
Step 3
Ethyl 4-(4-benzyloxy-3-chloro-phenyl)-2,4-dioxo-3-(triphenyl-λ5 phosphanylidene)-butyrate
Figure imgf000139_0001
1-(4-Benzyloxy-3-chloro-phenyl)-2-(triphenyl-λ5-phosphanylidene)-ethanone (1.84 g, 3.53 mmol) gave a crude solid (1.43g). 1H NMR (d6-acetone) δ = 8.00 - 7.35 (22H, m); 7.20 (1 H, d); 5.35 (2H, s); 3.55 (2H, q) and 1.14 (3H, s). LCMS: (M+1)+ = 621.2 (RT = 7.29 min.)
Step 4
Ethyl 3-(4-benzoyIoxy-3-chloro-benzoyl)-3-bromo-3H-azirine-2- carboxylate
Figure imgf000139_0002
Ethyl 4-(4-benzyloxy-3-chloro-phenyl)-2,4-dioxo-3-(triphenyl-λ5 phosphanylidene)-butyrate (0.74 g, 1.19 mmol) gave a solid (0.168 g) after column and preparative TLC purification. Rf= 0.24 (EtOAc : hexane / 1 : 6). 1H NMR (de-acetone) δ = 8.00 (1 H, d); 7.90 (1 H, dd); 7.50 (1 H, d); 7.40 (5H, m); 5.40 (2H, s); 4.05 (2H, q) and 0.95 (3H, t). LCMS: (M+1 )+ = 438.1 (RT = 7.27 min.)
Step 5
Ethyl 5-(4-benzoyloxy-3-chloro-phenyl)-4-bromo-isoxazole-3-carboxylate
Figure imgf000139_0003
Ethyl 3-(4-benzoyloxy-3-chloro-benzoyl)-3-bromo-3H-azirine-2-carboxylate (68 mg, 0.16 mmol) gave a solid (20 mg) after preparative TLC and crystallisation (EtOH). Rf = 0.26 (fluorescent) (EtOAc: hexane / 1 : 4). 1H NMR (d6-acetone) δ = 8.00 (1 H, d); 7.90 (1 H, dd); 7.50 (1 H, d); 7.40 (5H, m); 5.35 (2H, s); 4.45 (2H, q) and 1.40 (3H, t). LCMS: (M+1 )+ = 438.0 (RT = 7.39 min.) Step 6
Ethyl 5-(4-benzyloxy-3-chloro-phenyl)-4-bromo-isoxazole-3-carboxamide
Figure imgf000140_0001
Ethyl 5-(4-benzoyloxy-3-chloro-phenyl)-4-bromo-isoxazole-3-carboxylate (10 mg, 2.3 x 10"2 mmol) gave a crude solid (8 mg). Rf = 0.53 (EtOAc: hexane / 1 : 2). 1H NMR (de-acetone) δ = 8.15 (1 H, s, broad); 8.00 (1H, d); 7.90 (1H, dd); 7.50 (1H, d); 7.40 (5H, m); 5.32 (2H, s); 3.42 (2H, q) and 1.20 (3H, t).
Step 7
Ethyl 5-(4-benzyloxy-3-chloro-phenyl)-4-(4-morpholin-4-ylmethyl- phenyl)-isoxazole-3-carboxamide
Figure imgf000140_0002
Ethyl 5-(4-benzyloxy-3-chloro-phenyl)-4-bromo-isoxazole-3-carboxamide (10 mg, 2.3 x 10"2 mmol) gave a crude solid (10 mg), which was then used in the next step without any further purification.
Step δ
Ethyl 5-(3-chloro-4-hydroxy-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxamide
Figure imgf000140_0003
Ethyl 5-(4-benzyloxy-3-chloro-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxamide (8 mg, 1.5 x 10~2 mmol) gave a crude solid (2 mg) after twice purified by preparative TLC (EtOAc: MeOH / 50 : 1). 1H NMR (d4- MeOD) δ = 7.70 (2H, d); 7.60 (1 H, d); 7.45 (1 H + 1 H, m); 7.00 (2H, d); 3.30 (4H, m); 3.75 (2H, s); 3.50 (2H, q); 2.32 (4H, m) and 1.25 (3H, t). LCMS: (M+1 )+ = 442.2 (RT = 4.47 min.)
Example δδ
3-[4-(4-Bromo-phenyl)-isoxazol-5-yl]-5-chloro-2,6-dihydroxy- benzaldehyde
Figure imgf000141_0001
Step l 3«(4-Bromo-phenyl)-6-chloro-7-hydroxy-4-oxo-4H-chromene-8- carbaldehyde
Figure imgf000141_0002
3-(4-Bromo-phenyl)-6-chloro-7-hydroxy-chromen-4-one (0.35g, Immol) and hexamethyiene tetramine (0.14g, Immol) were dissolved in glacial acetic acid (20ml) and heated overnight at 100°C. Warm 6M HCl (10ml) was added and the mixture heated for a further hour before being poured in to water. The precipitate formed was filtered, washed and dried to provide the pure desired product as a pale brown solid.
LCMS (LCQ) tR = 8.27, MS m/z 377.3 / 379.2 [M-HT
Step 2
3-[4-(4-Bromo-phenyl)-isoxazol-5-yl]-5-chloro-2,6-dihydroxy- benzaldehyde
Figure imgf000142_0001
To a solution of 3-(4-bromo-phenyl)-6-chloro-7-hydroxy-4-oxo-4H-chromene- δ-carbaldehyde 53.5 mg, 0.14 mmol) in EtOH (6 ml), hydroxylamine hydrochloride (100 mg, 1.4 mmol) was added. The resulting mixture was heated at reflux for 16 hours. EtOH was evaporated and EtOAc (20 ml) was added. The organic layer was washed with sat. NaHCO3 and dried. Solids (33 mg) were obtained when the resulting oil was triturated with ether. 1H NMR (de-DMSO) δ = 9.33 (1 H, s); δ.70 (1H, s); 8.21 (1 H, s); 7.78 (2H, d) and 7.68 (2H, s). LCMS: (M+1 )+ = 394.1 (RT = 8.60 min.)
Example δ9
5-(5-Ethyl-2-hydroxy-4-methoxy-phenyl)-4-(4-fluoro-phenyl)-isoxazole-3- carboxylic acid hydroxyamide
Figure imgf000142_0002
Step l 1-(5-Ethyl-2,4-dihydroxy-phenyl)-2-(4-fluoro-phenyl)-ethanone
Figure imgf000142_0003
Ethyl resorcinol (5.37 g, 39 mmol) and 4-fluorophenylacetic acid (6.00 g, 39 mmol) were dissolved in etherate BF3 (40 ml). The solution was heated at δO °C for 4 hours. When cooled, water (100 ml) was added carefully and the solution was extracted with EtOAc (2 x δ0 ml). The organic layers were then washed with sat. NaHCO3 (caution) (2 x 100 ml) and brine (2 x 100 ml) and dried with Na2SO4. After purification with decolourising charcoal, a dark green syrup (10.5 g) was obtained. Rf = 0.4 (EtOAc:n-hexane / 1 :3). The compound was used in the next step without further purification. 1H NMR (d6-acetone) δ = 7.30 (1 H, s); 7.35 (2H, m); 7.00 (1 H, m); 6.35 (1 H, s); 4.35 (2H, s); 2.55 (2H, q) and 1.10 (3H, t).
Step 2
4-(5-Ethyl-2,4-dihydroxy-phenyl)-3-(4-fluoro-phenyl)-2,4-dioxo-butyric acid ethyl ester
Figure imgf000143_0001
To a solution of 1-(5-Ethyl-2,4-dihydroxy-phenyl)-2-(4-fluoro-phenyl)-ethanone (10.3 g, 37.6 mmol) in dried pyridine (100 ml) at 0 °C, ethyl chlorooxoacetate (15.4 g, 112.3 mmol) was added. The solution was stirred at 0 °C for 4 hours and at room temperature for 16 hours. The aq. layer was neutralised with 1M HCl and extracted with DCM (2 x 100 ml). The combined DCM layers were then washed with 2M HCl (2 x δ0 ml), sat. NaHCO3 (1 x 100 ml), brine (1 x 100 ml) and dried with Na2SO4. After filtration and evaporation of the solvent, dark brown oil was obtained (11.4 g). Rf = 0.22 (EtOAc: n-hexane / 1 :2). LCMS shows it is a mixture of desired product [(M-1 )" = 373.1 , RT = 7.27) and the cyclised chromene carboxylate [(M-1 )" = 355.4, RT = 7.33) in a ratio of ca. 6 : 1. A small amount of sample was purified by prep. TLC for spectroscopic analysis. 1H NMR (d6-acetone) δ = 7.75 (1 H, s); 7.30 (2H, m); 7.00 (1 H, m); 6.45 (1 H, s); 4.65 (1 H, s); 4.25 (2H, q); 2.55 (2H, q) and 1.10 (6H, t)
Step 3
6-Ethyl-3-(4-fluoro-phenyl)-7-hydroxy-4-oxo-4H-chromene-2-carboxylic acid ethyl ester
Figure imgf000143_0002
4-(5-Ethyl-2,4-dihydroxy-phenyl)-3-(4-fluoro-phenyl)-2,4-dioxo-butyric acid ethyl ester (3.22 g, 3.6 mmol) was refiuxed in a mixture of O.δM HCl and MeOH (20 ml / 20 ml) for 3 hours at 100 °C. After that, MeOH was evaporated and the aq. layer was extracted with EtOAc (2 x 60 ml). The combined organic layers were washed with sat. NaHCO3 (1 x 30 ml), brine (2 x δO ml), water (1 x δO ml) and dried with Na2SO4. After purification with decolourising charcoal and evaporation of the solvent, brown sticky solids were obtained. They were then extracted with hot ether, dark yellow solids were obtained (0.26 g). Rf = 0.43 (EtOAc:n-hexane / 1:2). LCMS: (M + 1)+ = 357.3 (RT = 7.83). 1H NMR (de-acetone) δ = 9.75 (1H, s); 7.80 (1H, s); 7.25 (2H, m); 7.10 (1H, m); 6.90 (1 H, s); 4.05 (2H, q); 2.70 (2H, q); 1.20 (3H, t) and 0.95 (3H, t).
Step 4
6-Ethyl-3-(4-fluoro-phenyl)-7-methoxy-4-oxo-4H-chromene-2-carboxylic acid ethyl ester
Figure imgf000144_0001
Iodomethane (0.10ml, 12 equiv.) was added to a solution of 6-Ethyl-3-(4- fluoro-phenyl)-7-hydroxy-4-oxo-4H-chromene-2-carboxylic acid ethyl ester (50mg, 0.14 mmol) and potassium carbonate (58mg, 3.0 equiv.) in acetone and the mixture refiuxed overnight. The volatiles were then evaporated in vacuo and the residue partitioned between water (15ml) and EtOAc (15ml). The organic layer was washed with brine, dried over MgSO4 and evaporated to dryness in vacuo to give a white crystalline product (45mg, 37% yield)
δH (CDCIs), 7.96 (1 H, s, Ar-H), 7.27 (2H, m, Ar-H), 7.12 (2H, m, Ar-H), 6.92 (1 H, s, Ar-H), 4.16 (2H, q, CO2CH2CH3 ), 3.95 (3H, s, OCH3), 2.71 (3H, q, CH2CH3), 1.24 (3H, t, CO2CH2CH3), 1.04 (3H, t, CH2CH3)
Step δ
5-(5-Ethyl-2-hydroxy-4-methoxy-phenyl)-4-(4-fluoro-phenyl)-isoxazole-3- carboxylic acid hydroxyamide
Figure imgf000145_0001
To 6-Ethyl-3-(4-fluoro-phenyl)-7-methoxy-4-oxo-4H-chromene-2-carboxylic acid ethyl ester (25mg, O.Oβδmmol) in ethanol (2.5ml) was added hydroxylamine (50% in water, 1 ml) and the solution stirred for 4δh. The volatiles were evaporated off in vacuo and the residue purified by preparative TLC (10% MeOH in DCM) to give the desired product as a light brown solid (3mg, 12% yield).
LCMS (LCT) tR = 6.54, MS m/z 373.17 [M+H]+
δH (de-Acetone), 10.73 (1 H, broad s), 3.59 (1 H, broad s), 7.39 (2H, m, Ar-H), 7.07 (2H, m, Ar-H), 7.00 (1 H, s, Ar-H), 6.55 (1H, s, Ar-H), 3.32 (3H, s, OCH3), 2.43 (2H, q, CH2CH3), 1.30 (1 H, broad s), 1.01 (3H, t, CH2CH3). Example 90
5-(5-Ethyl-2,4-dihydroxy-phenyl)-4-(4-fluoro-phenyl)-isoxazole-3- carboxylic acid hydroxyamide
Figure imgf000145_0002
To 6-Ethyl-3-(4-fluoro-phenyl)-7-hydroxy-4-oxo-4H-chromene-2-carboxylic acid ethyl ester (25mg, 0.070 mmol) in ethanol (2.δml) was added hydroxylamine (60% in water, 1ml) and the solution stirred for 4δhrs. The volitiles were evaporated off in vacuo and the residue purified by preparative TLC (15% MeOH in DCM) to give the desired product as a brown solid (2mg, δ% yield).
LCMS (LCT) tR = 5.63, MS m/z 359.13 [M+H]+ δH (de-Acetone), 10.72 (1H, broad s, CONH), 8.69 (1 H, broad s, Ar-OH), 8.59 (1 H, broad s, Ar-OH), 7.39 (2H, m, Ar-H), 7.06 (2H, m, Ar-H), 6.99 (1H, s, Ar- H), 6.52 (1 H, s, Ar-H), 2.49 (2H, q, CH2CH3), 1.31 (1 H, broad s), 1.08 (3H, t, CH2CH3).
Biological Results
The intrinsic ATPase activity of HSP90 may be measured using yeast HSP90 as a model system. The assay, based on the use of malachite green for the measurement of inorganic phosphate, was used to test the HSP90 inhibitory activity of some of the compounds of the Examples herein.
Malachite Green ATPase Assay Materials
Chemicals are of the highest purity commercially available and all aqueous solutions are made up in AR water. Because of the need to minimise contamination with inorganic phosphate, precautions should be taken with solutions and apparatus used in the assays. Glassware and pH meters are rinsed with double distilled or deionised water before use and, wherever possible, plastic ware should be used. Gloves are worn for all procedures.
(1 ) Greiner 384-well (Greiner 781101 ) or Costar 384-well flat-bottomed polystyrene multiwell plates (VWR).
(2) Assay buffer of (a) 100mM Tris-HCI, pH 7.4, (b) 150mM KCI, (c) 6mM MgCI2. Stored at room temperature.
(3) 0.0812% (w/v) malachite green (M 9636, Sigma Aldrich Ltd., Poole, UK). Stored at room temperature.
(4) 2.32% (w/v) polyvinyl alcohol USP (P 1097, Sigma Aldrich Ltd, Poole, UK) in boiling water (see Comment 1 ), allowed to cool, and stored at room temperature.
(5) 5.72% (w/v) ammonium molybdate in 6 M hydrochloric acid. Stored at room temperature.
(6) 34% (w/v) sodium citrate. Stored at room temperature. (7) 100mM ATP, disodium salt, special quality (47699, Sigma Aldrich).
Stored at -20°C. (δ) E. coli expressed yeast HSP90 protein, purified >95% (see, e.g.,
Panaretou et al., 199δ) and stored in 50uL aliquots at -δO°C .
Method
1. Dilute test compounds to 500μM in AR water (DMSO concentration will be 2.5%). Transfer 2.5μl of these compounds directly from the daughter plate to the assay plate, giving a final assay concentration of 100μM. To obtain 12 point IC50 values, perform serial dilutions 1 :2 to produce a range of assay concentrations from 100μM to 97.6nM (2.5% DMSO), and transfer 2.5μl of each concentration into the assay plate. Column 1 in the assay plate contains no compound, as a negative control. An additional row with no compound is also used as a background.
2. Prepare ATP by diluting 100mM stock to 925μM with assay buffer, and aliquot 5μl of diluted ATP to each well including controls (final assay concentration 370μM).
3. Add 5μl of buffer to background row.
4. Dilute enzyme preparation to 1.05μM with assay buffer, and aliquot 5μl into each compound well and to the negative control column.
5. Collect the reagents to the bottom of the well, cover plate with plate seal and incubate overnight at 37degC.
6. First thing in the morning prepare the Malachite Green Reagent. Add 2parts of Malachite Green Solution, 1 part of Polyvinyl Alcohol Solution, 1 part of Ammonium Molybdate Solution, and 2 parts of AR water.
7. Invert to mix, and leave for approximately 1 hour until the colour turns from brown to golden yellow. δ. Add 40μl of Malachite Green Reagent to each well, allow 5 mins for colour to develop.
9. Add 5μl of Sodium Citrate Reagent to each well (see comment 2)
10. Re-cover with plate seal and shake on plate shaker for at least 15 mins. 11. Measure Absorbance at 620nM using a suitable plate reader (e.g. Victor, Perkin Elmer Life Sciences, Milton Keynes, UK). Under these conditions, the control absorbance is 0.9 to 1.4, and the background is 0.2-0.35 giving a signal to noise ratio of -12. The Z' factor calculated from data obtained using these conditions is between 0.6 and 0.9.
Comments
(1) The polyvinyl alcohol dissolves in boiling water with difficulty and stirring for 2-3 h is required.
(2) The time interval between addition of the malachite green reagent and the sodium citrate should be kept as short as possible in order to reduce the non-enzymatic hydrolysis of ATP. Once the sodium citrate is added, the colour is stable for up to 4 h at room temperature.
(3) Compounds can be added to the assay plates using a Biomek FX Robot (Beckman Coulter). A Multidrop 334 dispenser (Thermo Labsystems, Basingstoke, UK) can be conveniently used to add reagents to the plate.
(4) The assay conditions were optimised with respect to time, protein and substrate concentration in order to achieve minimal protein concentration whilst retaining signal to noise differential.
(5) Signal to noise (S/N) is calculated using the following equation: (S-B)/ (SD of S)2 + (SD of B)2
(6) To determine specific activity of HSP90, a range of inorganic phosphate concentrations (0-10 μM) are prepared and the absorbance at 620 nm measured as described. Specific activity is calculated from the resulting calibration curve.
The compounds tested in the above assay were assigned to one of two activity ranges, namely A = <50μM; B = >50μM, and those assignments are reported above. A growth inhibition assay was also employed for the evaluation of candidate HSP90 inhibitors:
Assessment of cvtotoxicitv by Sulforhodamine B (SRB) assay: calculation of 50% inhibitory concentration (ICRQ).
Day 1
1 ) Determine cell number by haemocytometer.
2) Using an 8 channel multipipettor, add 160μl of the cell suspension (3600 cells/well or 2 x 104 cells/ml) to each well of a 96-well microtitre plate.
3) Incubate overnight at 37°C in a CO2 incubator.
Day 2
4) Stock solutions of drugs are prepared, and serial dilutions of each drug are performed in medium to give final concentrations in wells.
5) Using a multipipettor, 40μl of drug (at 5x final concentration) is added to quadruplicate wells.
6) Control wells are at either side of the 96 well plates, where 40μl of medium is added.
7) Incubate plates in CO2 incubator for 4 days (48 hours).
Day 6
δ) Tip off medium into sink and immerse plate slowly into 10% ice cold trichloroacetic acid (TCA). Leave for about 30mins on ice.
9) Wash plates three times in tap water by immersing the plates into baths of tap water and tipping it off.
10)Dry in incubator. 11)Add 100μl of 0.4% SRB in 1%acetic acid to each well (except the last row
(right hand)of the 96 well plate, this is the 0% control, ie no drug, no stain.
The first row will be the 100% control with no drug, but with stain). Leave for 15 mins. 12)Wash off unbound SRB stain with four washes of 1 % acetic acid. 13)Dry plates in incubator. 14)Solubilise SRB using 100μl of 10mM Tris base and put plates on plate shaker for 5 mins. 15) Determine absorbance at 540nm using a plate reader. Calculate mean absorbance for quadruplicate wells and express as a percentage of value for control, untreated wells. 16)Plot % absorbance values versus log drug concentration and determine
By way of illustration, the compound of Example 2 gave an IC50 in the 'A' range (<50uM) for the SRB growth arrest assay.
A Fluorescence Polarization_assay was also employed for the evaluation of some of the compounds of the Examples:
Fluorescence Polarization Assay
Fluorescence polarization {also known as fluorescence anisotropy} measures the rotation of a fluorescing species in solution, where the larger molecule the more polarized the fluorescence emission.
When the fluorophore is excited with polarized light, the emitted light is also polarized. The molecular size is proportional to the polarization of the fluorescence emission.
The fluoroscein-labelled probe - RBT0045364-FAM -
Figure imgf000150_0001
binds to HSP90 { full-length human, full-length yeast or N-terminal domain HSP90 } and the anisotropy {rotation of the probe:protein complex} is measured.
Test compound is added to the assay plate, left to equilibrate and the anisotropy measured again. Any change in anisotropy is due to competitive binding of compound to HSP90, thereby releasing probe.
Materials
Chemicals are of the highest purity commercially available and all aqueous solutions are made up in AR water.
1 ) Costar 96-well black assay plate #3915
2) Assay buffer of (a)100mM Tris pH7.4; (b) 20mM KCI; (c) 6mM MgCI2. Stored at room temperature.
3) BSA (bovine serum albumen) 10 mg/ml (New England Biolabs # B9001S)
4) 20 mM probe in 100 % DMSO stock concentration. Stored in the dark at RT. Working concentration is 200 nM diluted in AR water and stored at 4 °C. Final concentration in assay δO nM.
5) E. coli expressed human full-length HSP90 protein, purified >95% (see, e.g., Panaretou et al., 199δ) and stored in 50μL aliquots at -δ0°C .
Protocol
1 ) Add 10Oμl 1 x buffer to wells 11 A and 12A (=FP BLNK)
2) Prepare assay mix - all reagents are kept on ice with a lid on the bucket as the probe is light-sensitive.
i. Final Cone"
• 1x Hsp90 FP Buffer 10 ml 1x
• BSA 10mg/ml (NEB) 5.0 μl 5 μg/ml
• Probe 200μM 4.0 μl 80 nM
• Human full-length Hsp90 6.25 μl 200 nM 3) Aliquot 100μl assay mix to all other wells
4) Seal plate and leave in dark at room temp for 20 minutes to equilibrate
Compound Dilution Plate - 1 x 3 dilution series
1 ) In a clear 96-well v-bottom plate - {# VWR 007/008/257} add 10 μl 100% DMSO to wells B1 to H11
2) To wells A1 to A11 add 17.5μl 100% DMSO
3) Add 2.5 μl cpd to A1. This gives 2.5 mM {50x} stock cpd - assuming cpds 20 mM.
4) Repeat for wells A2 to A10. Control in columns 11 and 12.
5) Transfer 5 μl from row A to row B- not column 12. Mix well.
6) Transfer 5 μl from row B to row C. Mix well.
7) Repeat to row G.
8) Do not add any compound to row H - this is the 0 row.
9) This produces a 1x3 dilution series from 50 μM to 0.07 μM. 10)ln well B12 prepare 20 μl of 100 μM standard compound.
11 )After first incubation the assay plate is read on a Fusion™ a-FP plate reader (Packard BioScience, Pangbourne, Berkshire, UK).
12)After the first read, 2 μl of diluted compound is added to each well for columns 1 to 10. In column 11 {provides standard curve} only add compound B11 - H11. Add 2 μl of 100mM standard cpd to wells B12 - H12 {is positive control }
13)The Z' factor is calculated from zero controls and positive wells. It typically gives a value of 0.7 - 0.9.
The compounds tested in the above assay were assigned to one of two activity ranges, namely A = <10μM; B = >10μM, and those assignments are reported above. By way of illustration, the compound of Example 2 gave an IC50 in the 'A' range. REFERENCES
A number of publications are cited above in order to more fully describe and disclose the invention and the state of the art to which the invention pertains. Full citations for these references are provided below. Each of these references is incorporated herein by reference in its entirety into the present disclosure.
Argon Y and Simen BB. 1999 "Grp94, an ER chaperone with protein and peptide binding properties", Semin. Cell Dev. Biol., Vol. 10, pp. 495- 505.
Bijlmakers M-JJE, Marsh M. 2000 "Hsp90 is essential for the synthesis and subsequent membrane association, but not the maintenance, of the Src-kinase p56lck", Molecular Biology of the Cell, Vol. 11(5), pp. 1535- 1595.
Bucci M; Roviezzo F; Cicala C; Sessa WC, Cirino G. 2000 "Geidanamycin, an inhibitor of heat shock protein 90 (Hsp90) mediated signal transduction has anti-inflammatory effects and interacts with glucocorticoid receptor in vivo", Brit. J. Pharmacol., Vol 131(1), pp. 13- 16.
Chen C-F, Chen Y, Dai KD, Chen P-L, Riley DJ and Lee W-H. 1996 "A new member of the hsp90 family of molecular chaperones interacts with the retinoblastoma protein during mitosis and after heat shock", Mol. Cell. Biol., Vol. 16, pp. 4691-4699.
Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, Sepp-Lozenzino L and Rosen N. 2001 "A small molecule designed to bind to the adenine nucleotide pocket of HSP90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells", Chem. Biol., Vol. 8, pp. 289-299.
Conroy SE and Latchman DS. 1996 "Do heat shock proteins have a role in breast cancer?", Brit. J. Cancer, Vol. 74, pp. 717-721.
Felts SJ, Owen BAL, Nguyen P, Trepel J, Donner DB and Toft DO. 2000 "The HSP90-related protein TRAP1 is a mitochondrial protein with distinct functional properties", J. Biol. Chem., Vol. 5, pp. 3305-3312. Fuller W, Cuthbert AW. 2000 "Post-translational disruption of the delta F503 cystic fibrosis transmembrane conductance regulator (CFTR)- molecular Chaperone complex with geidanamycin stabilizes delta F50δ CFTR in the rabbit reticulocyte lysate", J. Biol. Chem.:Vol 275(4δ), pp. 37462-37463.
Hickey E, Brandon SE, Smale G, Lloyd D and Weber LA. 1999 "Sequence and regulation of a gene encoding a human δ9-kilodalton heat shock protein", Mol. Cell. Biol., Vol. 9, pp. 2615-2626.
Hoang AT, Huang J, Rudra-Gonguly N, Zheng J, Powell WC, Rabindron SK, Wu C and Roy-Burman P. 2000 "A novel association between the human heat shock transcription factor I (HSF1) and prostate adenocarcinoma, Am. J. Pathol., Vol. 156, pp. δ57-δ64.
Hostein I, Robertson D, Di Stefano F, Workman P and Clarke PA. 2001
"Inhibition of signal transduction by the HSP90 inhibitor 17-allylamino- 17-demethoxygeldanamycin results in cytostasis and apoptosis", Cancer Res., Vol. 61 , pp. 4003-4009.
Hur E, Kim H-H, Choi SM, Kim JH, Yim S, Kwon HJ, Choi Y, Kim DK, Lee M- O, Park H. 2002 "Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1 α/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol", Mol. Pharmacol., Vol 62(5), pp. 975-982.
Hutter etal, 1996, Circulation, Vol.94, pp.1408.
Jameel A, Skilton RA, Campbell TA, Chander SK, Coombes RC and Luqmani YA. 1992 "Clinical and biological significance of HSPδ9a in human breast cancer", Int. J. Cancer, Vol. 50, pp. 409-415.
Jolly C and Morimoto Rl. 2000 "Role of the heat shock response and molecular chaperones in oncogenesis and cell death", J. Natl. Cancer Inst. Vol. 92, pp. 1564-1572.
Kawanishi K, Shiozaki H, Doki Y, Sakita I, Inoue M, Yano M, Tsujinata T, Shamma A and Monden M. 1999 "Prognostic significance of heat shock proteins 27 and 70 in patients with squamous cell carcinoma of the esophagus", Cancer, Vol. δ5, pp. 1649-1657. Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA and Harrap KR. 1993 "Preclinical antitumour evaluation of bis- acetalo-amino-dichloro-cyclohexylamine platinum (IV): an orally active platinum drug", Cancer Research, Vol. 53, pp. 2531 -25δ6.
Kelland LR, Sharp SY, Rogers PM, Myers TG and Workman P. 1999 "DT- diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90", JL Natl. Cancer Inst., Vol. 91 , pp. 1940-1949.
Kurebayashi J, Otsuki T, Kurosumi M, Soga S, Akinaga S, Sonoo, H. 2001 "A radicicol derivative, KF5δ333, inhibits expression of hypoxia-inducible factor-1 α and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts", Jap. J. Cancer Res., Vol 92(12), 1342-1351.
Kwon HJ, Yoshida M, Abe K, Horinouchi S and Bepple T. 1992 "Radicicol, an agent inducing the reversal of transformed phentoype of src- transformed fibroblasts, Biosci., Biotechnol., Biochem., Vol. 56, pp. 533-539.
Lebeau J, Le Cholony C, Prosperi MT and Goubin G. 1991 "Constitutive overexpression of 39 kDa heat shock protein gene in the HBL100 mammary cell line converted to a tumorigenic phenotype by the EJ/T24 Harvey-ras oncogene", Oncogene, Vol. 6, pp. 1125-1132.
Marcu MG, Chadli A, Bouhouche I, Catelli M and Neckers L. 2000a "The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone", J. Biol. Chem., Vol. 275, pp. 37181-37186.
Marcu MG, Schulte TW and Neckers L. 2000b "Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins", J. Natl. Cancer Inst., Vol. 92, pp. 242-248.
Martin KJ, Kritzman BM, Price LM, Koh B, Kwan CP, Zhang X, MacKay A, O'Hare MJ, Kaelin CM, Mutter GL, Pardee AB and Sager R. 2000 "Linking gene expression patterns to therapeutic groups in breast cancer", Cancer Res., Vol. 60, pp. 2232-2233. Neckers L, Schulte TW and Momnaaugh E. 1999 "Geidanamycin as a potential anti-cancer agent: its molecular target and biochemical activity", Invest. New Drugs, Vol. 17, pp. 361-373.
Page J, Heath J, Fulton R, Yalkowsky E, Tabibi E, Tomaszewski J, Smith A and Rodman L. 1997 "Comparison of geidanamycin (NSC-122750) and 17-allylaminogeldanamycin (NSC-330507D) toxicity in rats", Proc. Am. Assoc. Cancer Res., Vol. 38, pp. 308.
Panaretou B, Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW and Pearl LH. 1998 "ATP binding and hydrolysis are essential to the function of the HSP90 molecular chaperone in vivo", EMBO J., Vol. 17, pp. 4δ29-4δ36.
Plumier etal, 1997, Cell. Stress Chap., Vol.2, pp.162
Pratt WB. 1997 "The role of the HSP90-based chaperone system in signal transduction by nuclear receptors and receptors signalling via MAP kinase", Annu. Rev. Pharmacol. Toxicol., Vol. 37, pp. 297-326.
Prodromou C and Pearl LH. 2000a "Structure and in vivo function of HSP90", Curr. Opin. Struct. Biol., Vol. 10, pp. 46-51.
Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW and Pearl LH. 1997 "Identification and structural characterization of the ATP/ADP-binding site in the HSP90 molecular chaperone", CeJI, Vol. 90, pp. 65-75. Prodromou C, Panaretou B, Chohan S, Siligardi G, O'Brien R, Ladbury JE, Roe SM, Piper PW and Pearl LH. 2000b "The ATPase cycle of HSP90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains", EMBO J., Vol. 19, pp. 4333-4392.
Rajder etal, 2000, Ann. Neurol., Vol.47, pp.732.
Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW and Pearl LH. 1999 "Structural basis for inhibition of the HSP90 molecular chaperone by the antitumour antibiotics radicicol and geidanamycin", J. Med. Chem., Vol. 42, pp. 260-266.
Rutherford SL and Lindquist S. 1998 "HSP90 as a capacitor for morphological evolution. Nature, Vol. 396, pp. 336-342.
Schulte TW, Akinaga S, Murakata T, Agatsuma T, Sugimoto S, Nakano H, Lee YS, Simen BB, Argon Y, Felts S, Toft DO, Neckers LM and Sharma SV. 1999 "Interaction of radicicol with members of the heat shock protein 90 family of molecular chaperones", Mol. Endocrinology,
Vol. 13, pp. 1435-1448. Schulte TW, Akinaga S, Soga S, Sullivan W, Sensgard B, Toft D and Neckers
LM. 1998 "Antibiotic radicicol binds to the N-terminal domain of HSP90 and shares important biologic activities with geldanamcyin", Cell Stress and Chaperones, Vol. 3, pp. 100-108. Schulte TW and Neckers LM. 1998 "The benzoquinone ansamycin
17-allylamino-17-deemthoxygeldanamcyin binds to HSP90 and shares important biologic activities with geidanamycin", Cancer Chemother.
Pharmacol., Vol. 42, pp. 273-279. Sittler etal, 2001 , Hum. Mol. Genet., Vol.10, pp.1307. Smith DF. 2001 "Chaperones in signal transduction", in: Molecular chaperones in the cell (P Lund, ed.; Oxford University Press, Oxford and NY), pp. 165-178. Smith DF, Whitesell L and Katsanis E. 1998 "Molecular chaperones: Biology and prospects for pharmacological intervention", Pharmacological
Reviews, Vol. 50, pp. 493-513. Song HY, Dunbar JD, Zhang YX, Guo D and Donner DB. 1995 "Identification of a protein with homology to hsp90 that binds the type 1 tumour necrosis factor receptor", J. Biol. Chem., Vol. 270, pp. 3574-3581. Stebbins CE, Russo A, Schneider C, Rosen N, Hartl FU and Pavletich NP.
1997 "Crystal structure of an HSP90-geldanamcyin complex: targeting of a protein chaperone by an antitumor agent", Cell, Vol. 89, pp. 239-250. Supko JG, Hickman RL, Grever MR and Malspeis L. 1995 "Preclinical pharmacologic evaluation of geidanamycin as an antitumour agent",
Cancer Chemother. Pharmacol., Vol. 36, pp. 305-315. Tratzelt etal, 1995, Proc. Nat. Acad. Sci., Vol. 92, pp. 2944. Trost etal, 1998, J. Clin. Invest., Vol.101 , pp.855. Tytell M and Hooper PL. 2001 "Heat shock proteins: new keys to the development of cytoprotective therapies", Emerging Therapeutic
Targets, Vol. 5, pp. 267-287. Uehara U, Hori M, Takeuchi T and Umezawa H. 1986 "Phenotypic change from transformed to normal induced by benzoquinoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with
Rous sarcoma virus", Mol. Cell. Biol., Vol. 6, pp. 219δ-2206. Waxman, Lloyd H. Inhibiting hepatitis C virus processing and replication.
(Merck & Co., Inc., USA). PCT Int. Appl. (2002), WO 0207761 Winklhofer etal, 2001 , J. Biol. Chem., Vol. 276, 45160. Whitesell L, Mimnaugh EG, De Costa B, Myers CE and Neckers LM. 1994
"Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation", Proc. Natl. Acad. Sci. U S
A,, Vol. 91 , pp. 6324-3323. Yorgin et al. 2000 "Effects of geidanamycin, a heat-shock protein 90-binding agent, on T cell function and T cell nonreceptor protein tyrosine kinases", J. Immunol., Vol 164(6), pp. 2915-2923. Young JC, Moarefi I and Hartl FU. 2001 "HSP90: a specialized but essential protein-folding tool", J. Cell. Biol., Vol. 154, pp. 267-273. Zhao JF, Nakano H and Sharma S. 1995 "Suppression of RAS and MOS transformation by radicicol", Oncogene, Vol. 11 , pp. 161-173.

Claims

Claims
1. The use of a compound of formula (A) or (B) or a salt, N-oxide, hydrate or solvate thereof, or a prodrug thereof, in the preparation of a composition for inhibition of HSP90 activity:
Figure imgf000159_0001
(A) . (B) wherein
Ri is a group of formula (IA):
-Ar1-(Alk1)p-(Z)r(Alk2)s-Q (IA) wherein in any compatible combination
Ar1 is an optionally substituted aryl or heteroaryl radical,
Alk1 and Alk2 are optionally substituted divalent Cι-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1 ,
Z is -O-, -S-, -(C=O)-, -(C=S)-, -S02-, -C(=O)O-, -C(=O)NRA- ,
-C(=S)NRA-, -SO2NRA-, -NRAC(=O)-, -NRASO2- or-NRA- wherein RA is hydrogen or Ci-Cβ alkyl, and
Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical;
R2 is (i) a group of formula (IA) as defined in relation to R-i;
(ii) a carboxamide radical; or
(iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula -(Alk1)p-(Z)r(Alk2)s-Q wherein Q, Alk1, Alk2, Z, p, r and s are as defined above in relation to group (IA); and
R3 is hydrogen, optionally substituted cycloalkyl, cycloalkenyl, C-ι-C6 alkyl, C-ι-C6 alkenyl, or C Ce alkynyl; or a carboxyl, carboxamide, or carboxyl ester group.
2. The use as claimed in claim 1 wherein the compound is one of formula (A), or a salt, N-oxide, hydrate or solvate thereof, or a prodrug thereof,
3. The use as claimed in claim 1 or claim 2 wherein the radical Ar1 present in Ri has formula (IB)
Figure imgf000160_0001
wherein Alk1, Alk2, p, r, s, Z and Q are as defined in claim 1, and R represents one or more optional substituents.
4. The use as claimed in claim 3 wherein that the ring carbon atom adjacent the hydroxyl group in radical (IB) is unsubstituted.
5. The use as claimed in claim 1 or claim 2 wherein, in R^ each of p, r and s is 0, and Q is hydrogen.
6. The use as claimed in claim 5 wherein Ri is optionally substituted phenyl.
7. The use as claimed in claim 5 wherein R-i is 2-hydroxyphenyl, optionally further substituted by one or more of hydroxy, methyl, ethyl, methoxy, ethoxy , chloro, or bromo.
3. The use as claimed in claim 5 wherein R-i is 2,4-dihydroxyphenyl, substituted in the 5-position by a small lipophilic substituent.
9. The use as claimed in claim δ wherein the small lipophilic substituent methyl, ethyl, isopropyl, isobutyl, tert-butyl, chloro, or bromo.
10. The use as claimed in claim δ or claim 9 wherein the hydroxyl groups in R1 are protected by groups which are cleaved in the body to release the hydroxyl groups.
11. The use as claimed in claim 10 wherein the protecting groups are methylcarbonyloxy, or isopropylamino-carbonyloxy.
12. The use as claimed in claim 1 or claim 2 wherein, in Ri, p, r and s are each 0, and Q is an optionally substituted carbocyclic or heterocyclic ring.
13. The use as claimed in claim 12 wherein Q is an optionally substituted phenyl or pyridyl ring.
14 The use as claimed in claim 1 or claim 2 wherein, in R-i, p and/or s are each 1 and r is 0.
15. The use as claimed in claim 1 or claim 2 wherein, in R-i, each of p, r, and s is 1.
16. The use as claimed in claim 1 or claim 2 wherein, in R-i, p and s are each 0 and r is 1.
17. The use as claimed in any of the preceding claims wherein R2 is a group of formula (IA).
18 The use as claimed in claim 17 wherein R2 is optionally substituted 2-, 3-, or4-pyridyI, 2- or 3-furanyl, 2- or 3-thienyl, or thiazolyl
19. The use as claimed in claim 18 wherein optional substituents present in R2 are selected from methoxy , ethoxy, methylenedioxy, ethylenedioxy, fluoro, chloro, bromo, and trifluoromethyl.
20. The use as claimed in claim 17 wherein R2 is phenyl substituted in the 4 position by methoxy, ethoxy, fluoro, chloro, bromo, piperazinyl, N- methylpiperazinyl, or piperidinyl.
21. The use as claimed in any of claims 1 to 16 wherein R2 has the partial structure:
Figure imgf000162_0001
wherein the substituted amino group -NR10R11 is a solubilising group.
22. The use as claimed in claim 21 wherein the solubilising group is selected from morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, ethylamino, isopropylamino, diethylamino, cyclohexylamino, cyclopentylamino, methoxyethylamino, piperidin-4-yl, N-acetylpiperazinyl, methylsulfonylamino, thiomorpholinyl, thiomorpholinyldioxide, 4-hydroxyethylpiperidinyl, and 4- hydroxypiperidinyl.
23. The use as claimed in any of claims 1 to 16 wherein R2 is a carboxamide group of formula -CONRB(Alk)nRA wherein
Alk is a divalent alkylene, alkenylene or alkynylene radical, for example a — CH2-, — CH2CH -, — CH CH2CH2-, — CH2CH=CH-, or — CH2CCCH2- radical, and the Alk radical may be optionally substituted,
n is 0 or 1 , RB is hydrogen or a C C6 alkyl or C2-C6 alkenyl group, for example methyl, ethyl, n- or iso-propyl, or allyl,
RA is hydroxy or optionally substituted carbocyclic, for example hydroxy and/or chloro-substituted phenyl and 3,4 methylenedioxyphenyl; or heterocyclyl, for example pyridyl, furyl, thienyl, N-piperazinyl, or N- morpholinyl any of which heterocyclic rings may be substituted,
or RA and RB taken together with the nitrogen to which they are attached form an N-heterocyclic ring which may optionally contain one or more additional hetero atoms selected from O, S and N, and which may optionally be substituted on one or more ring C or N atoms, examples of such N-heterocyclic rings including morpholino, piperidinyl, piperazinyl and N-phenylpiperazinyl.
24. The use as claimed in any of the preceding claims wherein R3 is hydrogen, methyl, ethyl, n- or iso-propyl, trifluoromethyl, hydroxyethyl, methylsulfonaminomethyl, or a carboxamide group -CONRB(Alk)nRA as defined in claim 23.
25. The use as claimed in any of claims 1 to 23 wherein R3 is ethylaminocarbonyl or isopropylaminocarbonyl.
26. The use as claimed in claim 1 wherein the compound has formula (ID) or the formula B regioisomer thereof,
Figure imgf000163_0001
(ID) wherein each R independently represents an optional substituent and R3 represents a carboxamide group.
27. The use as claimed in claim 1 wherein the compound has formula (IE) or the formula B regioisomer thereof,
Figure imgf000164_0001
(IE)
wherein R3 represents a carboxamide group; Rg represents -CH2NR10R11 or- NR10R11 wherein the substituted amino group -NR10R11 is a solubilising group; and Rs represents an optional substituent,
28. The use as claimed in claim 27 wherein R3 is ethylaminocarbonyl CH3CH2NHC(=O)-, or isopropylaminocarbonyl (CH3)2CHNHC(=O)-; the substituted amino group -NR10R11 in R9 is morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, ethylamino, isopropylamino, diethylamino, cyclohexylamino, cyclopentylamino, methoxyethylamino, piperidin-4-yl, N-acetylpiperazinyl, N- methylpiperazinyl, methylsulfonylamino, thiomorpholinyl, thiomorpholinyidioxide, 4-hydroxyethylpiperidinyl, or 4-hydroxypiperidinyl); and R8 is ethyl, isopropyl, bromo, or chloro.
29. The use as claimed in claim 1 wherein the compound is selected from:
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-piperidin-1-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
4-(4-Diethylaminomethyl-phenyl)-5-(2,4-dihydroxy-5-isopropyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-[4-(4-methyl-piperazin-1-ylmethyl)- phenyl]-isoxazole-3-carboxylic acid ethylamide
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-ethylaminomethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-[4-(isopropylamino-methyl)-phenyl]- isoxazole-3-carboxylic acid ethylamide
4-(4-Cyclohexylaminomethyl-phenyl)-5-(2,4-dihydroxy-5-isopropyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
4-[4-(tert-Butylamino-methyl)-phenyl]-5-(2,4-dihydroxy-5-isopropyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-{4-[(2-methoxy-ethylamino)-methyl]- phenyl}-isoxazole-3-carboxylic acid ethylamide
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-yimethyl-phenyl)- isoxazole-3-carboxylic acid isopropylamide
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-[4-(4-methyl-piperazin-1-ylmethyl)- phenyl]-isoxazole-3-carboxylic acid isopropylamide
5-(5-tert-Butyl-2,4-dihydroxy-phenyl)-4-[4-(4-methyl-piperazin-1-ylmethyl)- phenyl]-isoxazole-3-carboxylic acid ethylamide 5-(5-tert-Butyl-2,4-dihydroxy-phenyl)-4-(4-piperidin-1-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(2,4-Dihydroxy-5-isobutyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(2,4-Dihydroxy-5-isobutyl-phenyl)-4-(4-piperidin-1-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(5-tert-Butyl-2,4-dihydroxy-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(5-tert-Butyl-2,4-dihydroxy-phenyl)-4-(4-diethylaminomethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
3-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-5-carboxylic acid ethylamide
4-(4-Diethylaminomethyl-phenyl)-5-(4,6-dihydroxy-2'-methyl-biphenyl-3-yl)- isoxazole-3-carboxylic acid ethylamide
4-(4-Diethylaminomethyl-phenyl)-5-(4'-fluoro-4,6-dihydroxy-biphenyl-3-yl)- isoxazole-3-carboxylic acid ethylamide
4-(4-Diethylaminomethyl-phenyl)-5-(4,6-dihydroxy-biphenyl-3-yl)-isoxazole-3- carboxylic acid ethylamide
5-(2'-Fluoro-4,6-dihydroxy-biphenyl-3-yl)-4-(4-pyrrolidin-1-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(4,6-Dihydroxy-biphenyl-3-yl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole- 3-carboxylic acid ethylamide 5-(2,4-Dihydroxy-5-phenethyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-piperidin-1-ylmethyl-phenyl)-isoxazole- 3-carboxylic acid isopropylamide
4-(4-Diethylaminomethyl-phenyl)-5-(5-ethyl-2,4-dihydroxy-phenyl)-isoxazole- 3-carboxylic acid ethylamide
5-(5-Ethyl-2,4-dihydroxy-phenyl)-4-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]- isoxazole-3-carboxylic acid ethylamide
5-(5-Ethyl-2,4-dihydroxy-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole- 3-carboxylic acid ethylamide
5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-diethylaminomethyl-phenyl)-isoxazole- 3-carboxylic acid ethylamide
5-(5-Chloro-2,4-dihydroxy-phenyl)-4-[4-(4-methyl-piperazin-1-ylmethyl)- phenyl]-isoxazole-3-carboxylic acid ethylamide
5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
and salts, hydrates, solvates and prodrugs thereof.
30. A method of treatment of diseases or conditions responsive to inhibition of HSP90 activity in mammals which method comprises administering to the mammal an amount of a compound as defined in any of claims 1 to 29, or a salt, hydrate or solvate thereof, effective to inhibit said HSP90 activity.
31. The use as claimed in any of claims 1 to 29 or a method as claimed claim 23 wherein the disease or condition is cancer; viral disease, rheumatoid arthritis, asthma, multiple sclerosis, Type I diabetes, lupus, psoriasis and inflammatory bowel disease; cystic fibrosis, diabetic retinopathy, haemangiomas, or endometriosis, chemotherapy-induced toxicity; failure to undergo apoptosis; hypoxia-ischemic injury due to elevation of Hsp70 in the heart and brain; scrapie/CJD, Huntingdon's or Alzheimer's disease.
32. A compound of formula (A) or (B) or a salt, N-oxide, hydrate or solvate thereof, or a prodrug thereof, in the preparation of a composition for inhibition of HSP90 activity:
Figure imgf000168_0001
(A) (B) wherein
Ri is a group of formula (IA):
-Ar1-(Alk1 )p-(Z)r-(Alk2)s-Q (IA) wherein in any compatible combination
Ar1 is an optionally substituted aryl or heteroaryl radical,
Alk1 and Alk2 are optionally substituted divalent C Ce alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1 ,
Z is -O-, -S-, -(C=O)-, -(C=S)-, -SO2-, -C(=O)O-, -C(=O)NRA- ,
-C(=S)NRA-, -SO2NRA-, -NRAC(=O)-, -NRASO2- or-NRA- wherein RA is hydrogen or C Ce alkyl, and
Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical;
R2 is (i) a group of formula (IA) as defined in relation to Ri;
(ii) a carboxamide radical; or (iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula -(Alk1)p-(Z)r-(Alk2)s-Q wherein Q, Alk1, Alk2, Z, p, r and s are as defined above in relation to group (IA); and
R3 is hydrogen, optionally substituted cycloalkyl, cycloalkenyl, CrC6 alkyl, CrC6 alkenyl, or CrC6 alkynyl; or a carboxyl, carboxamide, or carboxyl ester group.
PROVIDED THAT the compound is not one of formulae (X), (Y) or (Z):
Figure imgf000169_0001
33. A compound as claimed in claim 32 wherein the compound is one of formula (A), or a salt, N-oxide, hydrate or solvate thereof, or a prodrug thereof,
34. A compound as claimed in claim 32 or claim 33 wherein the radical Ar1 present in Ri has formula (IB)
Figure imgf000169_0002
wherein Alk1, Alk2, p, r, s, Z and Q are as defined in claim 1 , and R represents one or more optional substituents.
35. A compound as claimed in claim 34 wherein that the ring carbon atom adjacent the hydroxyl group in radical (IB) is unsubstituted.
36. A compound as claimed in claim 32 or claim 33 wherein, in R-i, each of p, r and s is 0, and Q is hydrogen.
37. A compound as claimed in claim 36 wherein Ri is optionally substituted phenyl.
38. A compound as claimed in claim 36 wherein Ri is 2-hydroxyphenyl, optionally further substituted by one or more of hydroxy, methyl, ethyl, methoxy, ethoxy , chloro, or bromo.
39. A compound as claimed in claim 36 wherein Ri is 2,4-dihydroxyphenyl, substituted in the 5-position by a small lipophilic substituent.
40. A compound as claimed in claim 39 wherein the small lipophilic substituent methyl, ethyl, isopropyl, isobutyl, tert-butyl, chloro, or bromo.
41. A compound as claimed in claim 29 or claim 40 wherein the hydroxyl groups in R1 are protected by groups which are cleaved in the body to release the hydroxyl groups.
42. A compound as claimed in claim 41 wherein the protecting groups are alkylcarbonyloxy or alkylaminocarbonyloxy groups.
43. A compound as claimed in claim 41 wherein the protecting groups are methylcarbonyloxy, or isopropylamino-carbonyloxy.
44. A compound as claimed in claim 32 or claim 33 wherein, in Ri, p, r and s are each 0, and Q is an optionally substituted carbocyclic or heterocyclic ring.
45. A compound as claimed in claim 44 wherein Q is an optionally substituted phenyl or pyridyl ring.
46 A compound as claimed in claim 32 or claim 33 wherein, in Ri, p and/or s are each 1 and r is 0.
47. A compound as claimed in claim 32 or claim 33 wherein, in R-i, each of p, r, and s is 1.
43. A compound as claimed in claim 32 or claim 33 wherein, in R1 ( p and s are each 0 and r is 1.
49. A compound as claimed in any of the preceding claims wherein R2 is a group of formula (IA).
50 A compound as claimed in claim 49 wherein R2 is optionally substituted 2-, 3-, or 4-pyridyl, 2- or 3-furanyl, 2- or 3-thienyl, or thiazolyl
51. A compound as claimed in claim 50 wherein optional substituents present in R2 are selected from methoxy , ethoxy, methylenedioxy, ethylenedioxy, fluoro, chloro, bromo, and trifluoromethyl.
52. A compound as claimed in claim 49 wherein R2 is phenyl substituted in the 4 position by methoxy, ethoxy, fluoro, chloro, bromo, piperazinyl, N- methylpiperazinyl, or piperidinyl.
53. A compound as claimed in any of claims 32 to 49 wherein R2 has the partial structure:
Figure imgf000171_0001
wherein the substituted amino group -NR10R11 is a solubilising group.
54. A compound as claimed in claim 53 wherein the solubilising group is selected from morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, ethylamino, isopropylamino, diethylamino, cyclohexylamino, cyclopentylamino, methoxyethylamino, piperidin-4-yl, N-acetylpiperazinyl, methylsulfonylamino, thiomorpholinyl, thiomorpholinyidioxide, 4-hydroxyethylpiperidinyl, and 4- hydroxypiperidinyl.
55. A compound as claimed in any of claims 32 to 43 wherein R2 is a carboxamide group of formula -CONRB(Alk)nRA wherein
Alk is a divalent alkylene, alkenylene or alkynylene radical, for example a -CH2-, -CH2CH2-, -CH2CH2CH2-, -CH2CH=CH-, or -CH2CCCH2- radical, and the Alk radical may be optionally substituted,
n is O or 1,
RB is hydrogen or a CrC6 alkyl or C2-C6 alkenyl group, for example methyl, ethyl, n- or iso-propyl, or allyl,
RA is hydroxy or optionally substituted carbocyclic, for example hydroxy and/or chloro-substituted phenyl and 3,4 methylenedioxyphenyl; or heterocyclyl, for example pyridyl, furyl, thienyl, N-piperazinyl, or N- morpholinyl any of which heterocyclic rings may be substituted,
or RA and RB taken together with the nitrogen to which they are attached form an N-heterocyclic ring which may optionally contain one or more additional hetero atoms selected from O, S and N, and which may optionally be substituted on one or more ring C or N atoms, examples of such N-heterocyclic rings including morpholino, piperidinyl, piperazinyl and N-phenylpiperazinyl.
56. A compound as claimed in any of the preceding claims wherein R3 is hydrogen, methyl, ethyl, n- or iso-propyl, trifluoromethyl, hydroxyethyi, methylsulfonaminomethyl, or a carboxamide group -CONRB(Alk)nRA as defined in claim 55.
57. A compound as claimed in any of claims 32 to 55 wherein R3 is ethylaminocarbonyl or isopropylaminocarbonyl.
53. A compound as claimed in claim 32 wherein the compound has formula (ID) or the formula B regioisomer thereof,
Figure imgf000173_0001
(ID)
wherein each R independently represents an optional substituent and R3 represents a carboxamide group.
59. A compound as claimed in claim 32 wherein the compound has formula (IE) or the formula B regioisomer thereof,
Figure imgf000173_0002
(IE)
wherein R3 represents a carboxamide group; Rg represents -CH2NR10R11 or -NR10R11 wherein the substituted amino group -NR10R11 is a solubilising group;; and R8 represents an optional substituent,
60. A compound as claimed in claim 59 wherein R3 is ethylaminocarbonyl CH3CH2NHC(=O)-, or isopropylaminocarbonyl (CH3)2CHNHC(=O)-; the substituted amino group -NR10R11 in Rg is morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, ethylamino, isopropylamino, diethylamino, cyclohexylamino, cyclopentylamino, methoxyethylamino, piperidin-4-yl, N-acetylpiperazinyl, N- methylpiperazinyl, methylsulfonylamino, thiomorpholinyl, thiomorpholinyidioxide, 4-hydroxyethylpiperidinyl, or 4-hydroxypiperidinyl); and R8 is ethyl, isopropyl, bromo, or chloro.
61. A compound as claimed in claim 32 selected from:
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-piperidin-1-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
4-(4-Diethylaminomethyl-phenyl)-5-(2,4-dihydroxy-5-isopropyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-[4-(4-methyl-piperazin-1-ylmethyl)- phenyl]-isoxazole-3-carboxylic acid ethylamide
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-ethylaminomethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-[4-(isopropylamino-methyl)-phenyl]- isoxazole-3-carboxylic acid ethylamide 4-(4-Cyclohexylaminomethyl-phenyl)-5-(2,4-dihydroxy-5-isopropyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
4-[4-(tert-Butylamino-methyl)-phenyl]-5-(2,4-dihydroxy-5-isopropyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-{4-[(2-methoxy-ethylamino)-methyl]- phenyl}-isoxazole-3-carboxylic acid ethylamide
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxylic acid isopropylamide
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-[4-(4-methyl-piperazin-1-ylmethyl)- phenyl]-isoxazole-3-carboxylic acid isopropylamide
5-(5-tert-Butyl-2,4-dihydroxy-phenyl)-4-[4-(4-methyl-piperazin-1-ylmethyl)- phenyl]-isoxazo!e-3-carboxylic acid ethylamide
5-(5-tert-Butyl-2,4-dihydroxy-phenyl)-4-(4-piperidin-1-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(2,4-Dihydroxy-5-isobutyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(2,4-Dihydroxy-5-isobutyl-phenyl)-4-(4-piperidin-1-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(5-tert-Butyl-2,4-dihydroxy-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(5-tert-Butyl-2,4-dihydroxy-phenyl)-4-(4-diethylaminomethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide 3-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-5-carboxylic acid ethylamide
4-(4-Diethylaminomethyl-phenyl)-5-(4,6-dihydroxy-2'-methyl-biphenyl-3-yl)- isoxazole-3-carboxylic acid ethylamide
4-(4-Diethylaminomethyl-phenyl)-5-(4'-fluoro-4,6-dihydroxy-biphenyl-3-yl)- isoxazole-3-carboxylic acid ethylamide
4-(4-Diethylaminomethyl-phenyl)-5-(4,6-dihydroxy-biphenyl-3-yl)-isoxazole-3- carboxylic acid ethylamide
5-(2'-Fluoro-4,6-dihydroxy-biphenyl-3-yl)-4-(4-pyrrolidin-1-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(4,6-Dihydroxy-biphenyl-3-yl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole- 3-carboxylic acid ethylamide
5-(2,4-Dihydroxy-5-phenethyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-piperidin-1-ylmethyl-phenyl)-isoxazole- 3-carboxylic acid isopropylamide
4-(4-Diethylaminomethyl-phenyl)-5-(5-ethyl-2,4-dihydroxy-phenyl)-isoxazole- 3-carboxylic acid ethylamide
5-(5-Ethyl-2,4-dihydroxy-phenyl)-4-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]- isoxazole-3-carboxylic acid ethylamide
5-(5-Ethyl-2,4-dihydroxy-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole- 3-carboxylic acid ethylamide 5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-diethylaminomethyl-phenyl)-isoxazole- 3-carboxylic acid ethylamide
5-(5-Chloro-2,4-dihydroxy-phenyl)-4-[4-(4-methyl-piperazin-1-ylmethyl)- phenyl]-isoxazole-3-carboxylic acid ethylamide
5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)- isoxazole-3-carboxylic acid ethylamide
and salts, hydrates, solvates and prodrugs thereof.
62. A compound claimed in any of claims 32 to 61 , for use in human or veterinary medicine.
63. A pharmaceutical composition comprising a compound as claimed in any of claims 32 to 61 , or a salt hydrate or solvate thereof, together with a pharmaceutically acceptable carrier.
64. A pharmaceutical composition as claimed in claim 63 in the form of a solution or suspension the compound in a sterile, physiologically acceptable carrier, for example aqueous saline.
65. A pharmaceutical composition as claimed in claim 63 in the form of a solution or suspension the compound in a sterile aqueous saline.
66. A method of inhibiting HSP90 activity, comprising bringing into contact, in vitro, an HSP90 enzyme and a compound as claimed in any of claims 32 to 61.
PCT/GB2004/000506 2003-02-11 2004-02-09 Isoxazole compounds as inhibitors of heat shock proteins WO2004072051A1 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
EA200501272A EA009919B1 (en) 2003-02-11 2004-02-09 Isoxazole compounds
KR1020057014738A KR101166749B1 (en) 2003-02-11 2004-02-09 Isoxazole compounds as inhibitors of heat shock proteins
DK04709273.9T DK1611112T3 (en) 2003-02-11 2004-02-09 ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS
BRPI0407403-3A BRPI0407403B1 (en) 2003-02-11 2004-02-09 ISOXAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITION
SI200431954T SI1611112T1 (en) 2003-02-11 2004-02-09 Isoxazole compounds as inhibitors of heat shock proteins
CA2515726A CA2515726C (en) 2003-02-11 2004-02-09 Isoxazole compounds
ES04709273T ES2393483T3 (en) 2003-02-11 2004-02-09 Isoxazole compounds as heat shock protein inhibitors
AU2004210779A AU2004210779B2 (en) 2003-02-11 2004-02-09 Isoxazole compounds as inhibitors of heat shock proteins
MXPA05008335A MXPA05008335A (en) 2003-02-11 2004-02-09 Isoxazole compounds as inhibitors of heat shock proteins.
NZ541479A NZ541479A (en) 2003-02-11 2004-02-09 Isoxazole compounds as inhibitors of heat shock proteins
CN2004800093392A CN1771235B (en) 2003-02-11 2004-02-09 Isoxazole compounds
US10/544,443 US7705027B2 (en) 2003-02-11 2004-02-09 Isoxazole compounds as inhibitors of heat shock proteins
EP04709273A EP1611112B1 (en) 2003-02-11 2004-02-09 Isoxazole compounds as inhibitors of heat shock proteins
JP2006502254A JP4921162B2 (en) 2003-02-11 2004-02-09 Isoxazole compounds as inhibitors of heat shock proteins
NO20054195A NO335001B1 (en) 2003-02-11 2005-09-09 Isoxazole Compounds, and Pharmaceutical Preparations Containing the Compounds, As Inhibitors of Heat Shock Proteins
HK06112447.8A HK1091831A1 (en) 2003-02-11 2006-11-10 Isoxazole compounds as inhibitors of heat shock proteins
US12/708,686 US8507480B2 (en) 2003-02-11 2010-02-19 Isoxazole compounds as inhibitors of heat shock proteins
US13/525,409 US8450310B2 (en) 2003-02-11 2012-06-18 Isoxazole compounds as inhibitors of heat shock proteins
US13/929,098 US9718793B2 (en) 2003-02-11 2013-06-27 Isoxazole compounds as inhibitors of heat shock proteins
US15/631,059 US10413550B2 (en) 2003-02-11 2017-06-23 Isoxazole compounds as inhibitors of heat shock proteins
US16/528,278 US11234987B2 (en) 2003-02-11 2019-07-31 Isoxazole compounds as inhibitors of heat shock proteins

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0303105.1 2003-02-11
GB0303105A GB0303105D0 (en) 2003-02-11 2003-02-11 Isoxazole compounds
GBGB0306560.4A GB0306560D0 (en) 2003-03-21 2003-03-21 Isoxazole compounds
GB0306560.4 2003-03-21
GB0313751.0 2003-06-13
GB0313751A GB0313751D0 (en) 2003-06-13 2003-06-13 Isoxazole compounds

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/544,443 A-371-Of-International US7705027B2 (en) 2003-02-11 2004-02-09 Isoxazole compounds as inhibitors of heat shock proteins
US12/708,686 Division US8507480B2 (en) 2003-02-11 2010-02-19 Isoxazole compounds as inhibitors of heat shock proteins

Publications (1)

Publication Number Publication Date
WO2004072051A1 true WO2004072051A1 (en) 2004-08-26

Family

ID=32872455

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/000506 WO2004072051A1 (en) 2003-02-11 2004-02-09 Isoxazole compounds as inhibitors of heat shock proteins

Country Status (19)

Country Link
US (6) US7705027B2 (en)
EP (1) EP1611112B1 (en)
JP (1) JP4921162B2 (en)
KR (1) KR101166749B1 (en)
CN (1) CN1771235B (en)
AU (1) AU2004210779B2 (en)
BR (1) BRPI0407403B1 (en)
CA (1) CA2515726C (en)
CY (1) CY1113761T1 (en)
DK (1) DK1611112T3 (en)
EA (1) EA009919B1 (en)
ES (1) ES2393483T3 (en)
HK (1) HK1091831A1 (en)
MX (1) MXPA05008335A (en)
NO (1) NO335001B1 (en)
NZ (1) NZ541479A (en)
PT (1) PT1611112E (en)
SI (1) SI1611112T1 (en)
WO (1) WO2004072051A1 (en)

Cited By (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063222A1 (en) * 2003-12-26 2005-07-14 Kyowa Hakko Kogyo Co., Ltd. Hsp90 FAMILY PROTEIN INHIBITOR
EP1638555A1 (en) * 2003-06-27 2006-03-29 Vernalis (Cambridge) Limited Substituted 5-membered ring compounds and their use
WO2006051808A1 (en) * 2004-11-09 2006-05-18 Kyowa Hakko Kogyo Co., Ltd. Hsp90 FAMILY PROTEIN INHIBITORS
WO2006089177A2 (en) * 2005-02-17 2006-08-24 Synta Pharmaceuticals Corp. Isoxazole combretastin derivatives for the treatment of disorders
FR2882361A1 (en) * 2005-02-22 2006-08-25 Aventis Pharma Sa New 3-aryl-1,2-benzisoxazole compounds are heat shock protein 90 inhibitors, useful to treat solid or liquid cancer, preferably cancers resistant to cytotoxic agents
JP2006232705A (en) * 2005-02-23 2006-09-07 Univ Nagoya Anti-polyglutamine disease agent
WO2006101052A1 (en) * 2005-03-22 2006-09-28 Nippon Kayaku Kabushiki Kaisha Novel acetylene derivative
WO2006109075A2 (en) * 2005-04-13 2006-10-19 Astex Therapeutics Limited Hydroxybenzamide derivatives and their use as inhibitors of hsp90
WO2006126751A1 (en) * 2005-05-25 2006-11-30 Korea Research Institute Of Bioscience And Biotechnology New diaryl-isoxazole derivatives, and pharmaceutical compositions containing the same for the prevention and the treatment of cancers
WO2007096194A1 (en) * 2006-02-27 2007-08-30 Novartis Ag Radio-labeled isoxazole derivatives useful for the labeling and diagnostic of hsp90 functionality
WO2007131034A1 (en) * 2006-05-03 2007-11-15 The Regents Of The University Of Michigan Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70
EP1889843A1 (en) * 2005-03-18 2008-02-20 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Bisheterocycle tandem compounds useful as antiviral agents, the uses thereof and the compositions comprising such compounds
WO2008033449A2 (en) * 2006-09-14 2008-03-20 Synta Pharmaceuticals Corp. Compounds for the treatment of angiogenesis
WO2008041610A1 (en) 2006-10-03 2008-04-10 Nippon Kayaku Kabushiki Kaisha Compound of resorcinol derivative with polymer
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
JP2008530149A (en) * 2005-02-17 2008-08-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Triazole derivative
WO2008104595A1 (en) * 2007-03-01 2008-09-04 Novartis Ag Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms
WO2009026658A1 (en) * 2007-08-29 2009-03-05 The University Of Sydney Ppar agonists
WO2009047323A2 (en) * 2007-10-12 2009-04-16 Novartis Ag Organic compounds
AU2008318244A1 (en) * 2007-11-02 2009-05-07 Methylgene Inc. Inhibitors of histone deacetylase
US7534788B2 (en) 2007-07-25 2009-05-19 Hoffmann-La Roche Inc. Benzofuran and benzothiophene-2-carboxylic acid amide derivatives
WO2009066060A2 (en) * 2007-11-19 2009-05-28 Topotarget A/S 4-substituted-6-isopropyl-benzene-1,3-diol compounds and their use
WO2009134110A1 (en) * 2008-04-30 2009-11-05 Biotechnologijos Institutas 5-aryl-4-(5-substituted 2,4-dihydroxyphenyl)-1,2,3-thiadiazoles as inhibitors of hsp90 chaperone and the intermediates for production thereof
WO2010000748A1 (en) * 2008-07-04 2010-01-07 Sigma-Tau Research Switzerland S.A. 5-phenyl-isoxazole-3-carboxamides modulating hsp90 with antitumoral activities
US7652168B2 (en) 2001-07-10 2010-01-26 Synta Pharmaceuticals Corp. Synthesis of taxol enhancers
US7662813B2 (en) 2005-08-18 2010-02-16 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US7671092B2 (en) 2001-07-10 2010-03-02 Synta Pharmaceuticals Corp. Paclitaxel enhancer compounds
US7674795B2 (en) 2005-05-19 2010-03-09 Aventis Pharma Sa Fluorene derivatives, composition containing said derivatives and the use thereof
WO2010060937A2 (en) * 2008-11-28 2010-06-03 Novartis Ag Hsp90 inhibitor combinations
WO2010060939A2 (en) * 2008-11-28 2010-06-03 Novartis Ag Combination of hsp90 and herceptin inhibitors
US7750042B2 (en) 2001-07-10 2010-07-06 Synta Pharmaceuticals Corp. Paclitaxel enhancer compound
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
US7763658B2 (en) 2003-01-15 2010-07-27 Synta Pharmaceuticals Corp. Treatment for cancers
US7795313B2 (en) 2004-06-23 2010-09-14 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) salts for treatment of cancers
US7799954B2 (en) 2006-11-17 2010-09-21 Abraxis Bioscience, Llc Dicarbonyl derivatives and methods of use
WO2010121963A1 (en) 2009-04-21 2010-10-28 Nerviano Medical Sciences S.R.L. Resorcinol derivatives as hsp90 inhibitors
US7825148B2 (en) 2004-11-18 2010-11-02 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
WO2011040421A1 (en) 2009-09-29 2011-04-07 武田薬品工業株式会社 Screening method
WO2011045396A2 (en) 2009-10-16 2011-04-21 Novartis Ag Biomarkers of tumor pharmacodynamic response
US7932279B2 (en) 2007-10-12 2011-04-26 Arqule, Inc. Substituted tetrazole compounds and uses thereof
US7939564B2 (en) 2006-08-31 2011-05-10 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
US7960399B2 (en) 2004-06-08 2011-06-14 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8017654B2 (en) 2005-04-15 2011-09-13 Synta Pharmaceuticals Corp. Combination cancer therapy with bis(thiohydrazide) amide compounds
US8034939B2 (en) 2005-04-08 2011-10-11 Aventis Pharma S.A.. Isoindole derivatives, compositions containing same, preparation thereof and pharmaceutical uses thereof in particular as inhibitors of chaperone protein Hsp90 activities
WO2011102660A3 (en) * 2010-02-17 2012-01-19 Ildong Pharm Co., Ltd. A novel 5-membered heterocycle derivatives and manufacturing process thereof
US8188222B2 (en) 2006-11-08 2012-05-29 Nippon Kayaku Kabushiki Kaisha High molecular weight derivative of nucleic acid antimetabolite
US8277807B2 (en) 2006-10-12 2012-10-02 Astex Therapeutics Limited Pharmaceutical combinations
US8323669B2 (en) 2006-03-28 2012-12-04 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of taxane
US8334364B2 (en) 2006-11-06 2012-12-18 Nipon Kayaku Kabushiki Kaisha High-molecular weight derivative of nucleic acid antimetabolite
WO2013015661A2 (en) * 2011-07-28 2013-01-31 Ildong Pharm Co.,Ltd. Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide
US8383619B2 (en) 2008-04-11 2013-02-26 Astex Therapeutics Limited Pharmaceutical compounds
US8399464B2 (en) 2005-03-09 2013-03-19 Nippon Kayaku Kabushiki Kaisha HSP90 inhibitor
WO2013053833A1 (en) 2011-10-14 2013-04-18 Novartis Ag 2 - carboxamide cycloamino urea derivatives in combination with hsp90 inhibitors for the treatment of proliferative diseases
US8653084B2 (en) 2006-10-12 2014-02-18 Astex Therapeutics Ltd. Hydrobenzamide derivatives as inhibitors of Hsp90
US8703878B2 (en) 2007-09-28 2014-04-22 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of steroids
WO2014074775A1 (en) * 2012-11-09 2014-05-15 Jacobus Pharmaceutical Company, Inc. Heteroaryl derivatives and uses thereof
WO2014074580A1 (en) 2012-11-07 2014-05-15 Novartis Ag Combination therapy
US8779132B2 (en) 2006-10-12 2014-07-15 Astex Therapeutics Limited Pharmaceutical compounds
US8808749B2 (en) 2009-05-15 2014-08-19 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of bioactive substance having hydroxy group
US8920788B2 (en) 2008-03-18 2014-12-30 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of physiologically active substances
US8940332B2 (en) 2006-05-18 2015-01-27 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of podophyllotoxins
US9018323B2 (en) 2010-11-17 2015-04-28 Nippon Kayaku Kabushiki Kaisha Polymer derivative of cytidine metabolic antagonist
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
US9149540B2 (en) 2008-05-08 2015-10-06 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of folic acid or folic acid derivative
US9156783B2 (en) 2006-08-21 2015-10-13 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
US9296696B2 (en) 2012-11-09 2016-03-29 Jacobus Pharmaceuticals Company, Inc. Aryl derivatives and uses thereof
WO2016057841A1 (en) 2014-10-08 2016-04-14 Novartis Ag Compositions and methods of use for augmented immune response and cancer therapy
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US9346923B2 (en) 2011-09-11 2016-05-24 Nippon Kayaku Kabushiki Kaisha Method for manufacturing block copolymer
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors
US9439899B2 (en) 2011-11-02 2016-09-13 Synta Pharmaceuticals Corp. Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
WO2016145102A1 (en) 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
US9730912B2 (en) 2006-10-12 2017-08-15 Astex Therapeutics Limited Pharmaceutical compounds
WO2018001084A1 (en) * 2016-06-29 2018-01-04 广州市恒诺康医药科技有限公司 Heat shock protein inhibitor, and manufacturing method and application thereof
US10040791B2 (en) 2014-10-01 2018-08-07 Daiichi Sankyo Company, Limited Isoxazole derivative as mutant isocitrate dehydrogenase 1 inhibitor
WO2018198076A1 (en) 2017-04-28 2018-11-01 Aduro Biotech, Inc. Bis 2'-5'-rr-(3'f-a)(3'f-a) cyclic dinucleotide compound and uses thereof
EP3514179A1 (en) 2014-01-24 2019-07-24 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
RU2697703C2 (en) * 2015-01-22 2019-08-19 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. Resorcinol derivative as hsp90 inhibitor
US10500193B2 (en) 2011-11-02 2019-12-10 Synta Pharmaceuticals Corporation Combination therapy of HSP90 inhibitors with platinum-containing agents
US10894830B2 (en) 2015-11-03 2021-01-19 Janssen Biotech, Inc. Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses
WO2021152113A1 (en) 2020-01-31 2021-08-05 Bayer Aktiengesellschaft Substituted 2,3-benzodiazepines derivatives
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
EP4324518A2 (en) 2014-01-31 2024-02-21 Novartis AG Antibody molecules to tim-3 and uses thereof
EP4378957A2 (en) 2015-07-29 2024-06-05 Novartis AG Combination therapies comprising antibody molecules to pd-1

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1611112T3 (en) * 2003-02-11 2012-11-19 Cancer Res Inst ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS
PL1748767T3 (en) 2004-05-28 2012-08-31 Unigen Inc 1-(3-methyl-2,4-dimethoxyphenyl)-3-(2',4'-dihydroxyphenyl)-propane as a potent tyrosinase inhibitor
KR101203475B1 (en) 2004-09-22 2012-11-21 니폰 가야꾸 가부시끼가이샤 Novel Block Copolymer, Micelle Preparation, and Anticancer Agent Containing the Same as Active Ingredient
MX2010002258A (en) 2007-08-27 2010-04-22 Helicon Therapeutics Inc Therapeutic isoxazole compounds.
EP2273882A4 (en) * 2008-05-13 2011-07-13 Poniard Pharmaceuticals Inc Bioactive compounds for treatment of cancer and neurodegenerative diseases
JP2011528719A (en) * 2008-07-21 2011-11-24 ユニジェン・インコーポレーテッド Skin whitening (lightening) compound series
CN109180448A (en) 2011-03-24 2019-01-11 尤尼根公司 It is used to prepare the Compounds and methods for of diarylpropane
CN102351655A (en) * 2011-08-18 2012-02-15 杭州澳赛诺化工有限公司 Synthesis method of 4-isopropylresorcinol
CN103086994A (en) * 2011-10-31 2013-05-08 上海壹志医药科技有限公司 Salts of isoxazole derivatives
CA2902699A1 (en) * 2013-03-15 2014-09-18 Novartis Ag Biomarker
EP3013341A4 (en) * 2013-06-26 2017-02-08 Proteostasis Therapeutics, Inc. Methods of modulating cftr activity
WO2015196071A1 (en) * 2014-06-19 2015-12-23 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
CN104725329B (en) * 2015-01-13 2017-01-18 陕西科技大学 Isoxazole carboxylic acid compound with anti-tumor activity and synthesis method of compound
CN106349180B (en) * 2015-07-14 2020-05-19 上海翰森生物医药科技有限公司 4, 5-diphenyl isoxazole derivative and preparation method and application thereof
CN106146466A (en) * 2016-06-30 2016-11-23 珠海赛隆药业股份有限公司（长沙）医药研发中心 Vonoprazan fumarate intermediate, its preparation method and the method for preparation Vonoprazan fumarate
US10851071B2 (en) 2016-07-21 2020-12-01 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. M-dihydroxybenzene derivative crystal and salt, and manufacturing method thereof
CN111217762B (en) * 2018-11-23 2021-08-20 华中师范大学 Polyhalogenated 5- (2-hydroxyphenyl) isoxazole compound and preparation method and application thereof
US20220362276A1 (en) * 2019-05-13 2022-11-17 The Trustees Of Princeton University Small Molecule Inhibitors of Viral Replication
CN110283080A (en) * 2019-07-05 2019-09-27 山西大学 A kind of fluorine-containing benzophenone derivates and its preparation method and application
WO2022075780A1 (en) * 2020-10-07 2022-04-14 광주과학기술원 Pharmaceutical composition for preventing or treating overactive bladder
CN115160250B (en) * 2021-04-02 2024-06-04 沈阳药科大学 4, 6-Biphenol derivative and application thereof
US11324737B1 (en) * 2021-05-25 2022-05-10 Louis Habash Modulating expression level of a gene encoding a heat shock protein by treating a human subject with a nitroxide
US11729925B2 (en) 2021-06-15 2023-08-15 Erico International Corporation Mounting bracket with angled mounting openings for electrical boxes
CN114751870B (en) * 2022-02-28 2023-10-20 贵州医科大学 2- (isoxazole-5-yl) phenyl-3, 4-dihydroxybenzoate and derivative thereof, and synthetic method and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024095A1 (en) * 1993-04-16 1994-10-27 Abbott Laboratories Immunosuppressive agents
WO2000008001A1 (en) * 1998-08-07 2000-02-17 Chiron Corporation Substituted isoxazole as estrogen receptor modulators
WO2001012621A1 (en) * 1999-08-13 2001-02-22 Vertex Pharmaceuticals Incorporated INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES
EP1251126A2 (en) * 2001-04-20 2002-10-23 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
JP2002363079A (en) * 2001-05-31 2002-12-18 National Cancer Center-Japan Medicine for preventing or treating digestive tract polyp and/or digestive tract cancer containing mofezolac as active ingredient

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0418667B1 (en) * 1989-09-22 1995-08-16 BASF Aktiengesellschaft Carboxylic acid amides
CA2102209C (en) * 1991-05-01 1997-11-18 Takashi Shindo Novel isoxazole derivative and salt thereof
DK0932402T3 (en) * 1996-10-15 2004-11-08 Searle Llc Method for the use of cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
ES2196396T3 (en) * 1996-12-23 2003-12-16 Bristol Myers Squibb Pharma Co HETEROAROMATIC COMPOUNDS OF 5 MEMBERS CONTAINING OXYGEN OR SULFUR AS INHIBITORS OF THE XA FACTOR.
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
AU761267C (en) * 1998-09-09 2007-08-09 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
CN100352505C (en) * 1998-12-24 2007-12-05 症变治疗公司 A combination of FBPase Inhibitors and insulin sensitizers for the treatment of diabetes
JP2003519154A (en) * 1999-12-22 2003-06-17 メタバシス・セラピューティクス・インコーポレイテッド Novel bisamidate phosphonate prodrug
JP4399265B2 (en) * 2001-12-21 2010-01-13 ヴァーナリス（ケンブリッジ）リミテッド 3,4-Diarylpyrazoles and their use in the treatment of cancer
DK1611112T3 (en) * 2003-02-11 2012-11-19 Cancer Res Inst ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS
US20110201587A1 (en) * 2010-02-16 2011-08-18 Bio Holding, Inc. Hsp90 inhibitors and methods of use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024095A1 (en) * 1993-04-16 1994-10-27 Abbott Laboratories Immunosuppressive agents
WO2000008001A1 (en) * 1998-08-07 2000-02-17 Chiron Corporation Substituted isoxazole as estrogen receptor modulators
WO2001012621A1 (en) * 1999-08-13 2001-02-22 Vertex Pharmaceuticals Incorporated INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES
EP1251126A2 (en) * 2001-04-20 2002-10-23 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
JP2002363079A (en) * 2001-05-31 2002-12-18 National Cancer Center-Japan Medicine for preventing or treating digestive tract polyp and/or digestive tract cancer containing mofezolac as active ingredient

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"ENAMINE PRODUCT LISTING", 15 November 2001, ENAMINE, KIEV 042, 01042 UKRAINE *
CHEMBRIDGE PRODUCT LIST, 17 January 2002, CHEMBRIDGE, SAN DIEGO, CA, 92127 USA *
DATABASE CHEMCATS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002281467 *
DATABASE CHEMCATS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002281468 *
PATENT ABSTRACTS OF JAPAN vol. 2003, no. 04 2 April 2003 (2003-04-02) *

Cited By (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750042B2 (en) 2001-07-10 2010-07-06 Synta Pharmaceuticals Corp. Paclitaxel enhancer compound
US9107955B2 (en) 2001-07-10 2015-08-18 Synta Pharmaceuticals Corp. Paclitaxel enhancer compounds
US7652168B2 (en) 2001-07-10 2010-01-26 Synta Pharmaceuticals Corp. Synthesis of taxol enhancers
US7671092B2 (en) 2001-07-10 2010-03-02 Synta Pharmaceuticals Corp. Paclitaxel enhancer compounds
US7763658B2 (en) 2003-01-15 2010-07-27 Synta Pharmaceuticals Corp. Treatment for cancers
EP1638555A1 (en) * 2003-06-27 2006-03-29 Vernalis (Cambridge) Limited Substituted 5-membered ring compounds and their use
US7538241B2 (en) 2003-12-26 2009-05-26 Kyowa Hakko Kogyo Co., Ltd. Hsp90 family protein inhibitors
WO2005063222A1 (en) * 2003-12-26 2005-07-14 Kyowa Hakko Kogyo Co., Ltd. Hsp90 FAMILY PROTEIN INHIBITOR
US7960399B2 (en) 2004-06-08 2011-06-14 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US9102653B2 (en) 2004-06-08 2015-08-11 Novartis Ag Substituted quinazolinones as vanilloid antagonists
US8809528B2 (en) 2004-06-08 2014-08-19 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8211902B2 (en) 2004-06-08 2012-07-03 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8461208B2 (en) 2004-06-23 2013-06-11 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) salts for treatment of cancers
US8048925B2 (en) 2004-06-23 2011-11-01 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) salts for treatment of cancers
US7795313B2 (en) 2004-06-23 2010-09-14 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) salts for treatment of cancers
WO2006051808A1 (en) * 2004-11-09 2006-05-18 Kyowa Hakko Kogyo Co., Ltd. Hsp90 FAMILY PROTEIN INHIBITORS
US7781485B2 (en) 2004-11-09 2010-08-24 Kyowa Hakko Kirin Co., Ltd. Hsp90 family protein inhibitors
US9090569B2 (en) 2004-11-18 2015-07-28 Synta Pharmaceuticals Corp. Triazone compounds that modulate HSP90 activity
US7825148B2 (en) 2004-11-18 2010-11-02 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
US8362055B2 (en) 2004-11-18 2013-01-29 Synta Pharmaceuticals, Inc. Triazole compounds that modulate HSP90 activity
US8901308B2 (en) 2004-11-18 2014-12-02 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
TWI385160B (en) * 2005-02-17 2013-02-11 Synta Pharmaceuticals Corp Compounds for the treatment of proliferative disorders
AU2006214164B2 (en) * 2005-02-17 2010-12-09 Synta Pharmaceuticals Corp. Isoxazole combretastin derivatives for the treatment of disorders
US9090603B2 (en) 2005-02-17 2015-07-28 Synta Pharmaceuticals Corporation Compounds for the treatment of proliferative disorders
US7884094B2 (en) 2005-02-17 2011-02-08 Synta Pharmaceuticals Corp. Compounds for the treatment of proliferative disorders
US8269017B2 (en) 2005-02-17 2012-09-18 Synta Pharmaceuticals Corporation Compounds for the treatment of proliferative disorders
US8598366B2 (en) 2005-02-17 2013-12-03 Synta Pharmaceuticals Corporation Compounds for the treatment of proliferative disorders
KR101364762B1 (en) 2005-02-17 2014-02-17 신타 파마슈티칼스 코프. Compounds for the treatment of proliferative disorders
JP2008530149A (en) * 2005-02-17 2008-08-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Triazole derivative
WO2006089177A3 (en) * 2005-02-17 2006-12-14 Synta Pharmaceuticals Corp Isoxazole combretastin derivatives for the treatment of disorders
WO2006089177A2 (en) * 2005-02-17 2006-08-24 Synta Pharmaceuticals Corp. Isoxazole combretastin derivatives for the treatment of disorders
JP2008530240A (en) * 2005-02-17 2008-08-07 シンタ ファーマシューティカルズ コーポレーション Compounds for the treatment of proliferative diseases
FR2882361A1 (en) * 2005-02-22 2006-08-25 Aventis Pharma Sa New 3-aryl-1,2-benzisoxazole compounds are heat shock protein 90 inhibitors, useful to treat solid or liquid cancer, preferably cancers resistant to cytotoxic agents
WO2006090052A1 (en) * 2005-02-22 2006-08-31 Aventis Pharma S.A. Novel 3-aryl-1,2-benzisoxazole derivatives, compositions containing same and use thereof
JP2008531493A (en) * 2005-02-22 2008-08-14 アバンテイス・フアルマ・エス・アー Novel 3-aryl-1,2-benzisoxazole derivatives, compositions containing them and uses thereof
JP2006232705A (en) * 2005-02-23 2006-09-07 Univ Nagoya Anti-polyglutamine disease agent
US8399464B2 (en) 2005-03-09 2013-03-19 Nippon Kayaku Kabushiki Kaisha HSP90 inhibitor
EP1889843A1 (en) * 2005-03-18 2008-02-20 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Bisheterocycle tandem compounds useful as antiviral agents, the uses thereof and the compositions comprising such compounds
KR101177692B1 (en) 2005-03-18 2012-08-29 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 Bisheterocycle tandem compounds useful as antiviral agents, the uses thereof and the compositions comprising such compounds
EP1889843A4 (en) * 2005-03-18 2009-09-02 Shanghai Inst Materia Medica Bisheterocycle tandem compounds useful as antiviral agents, the uses thereof and the compositions comprising such compounds
WO2006101052A1 (en) * 2005-03-22 2006-09-28 Nippon Kayaku Kabushiki Kaisha Novel acetylene derivative
US8034939B2 (en) 2005-04-08 2011-10-11 Aventis Pharma S.A.. Isoindole derivatives, compositions containing same, preparation thereof and pharmaceutical uses thereof in particular as inhibitors of chaperone protein Hsp90 activities
US8101648B2 (en) 2005-04-13 2012-01-24 Astex Therapeutics, Ltd. Hydroxybenzamide derivatives and their use as inhibitors of HSP90
WO2006109085A1 (en) 2005-04-13 2006-10-19 Astex Therapeutics Limited Hydroxybenzamide derivatives and their use as inhibitors of hsp90
JP2008537751A (en) * 2005-04-13 2008-09-25 アステックス、セラピューティックス、リミテッド Pharmaceutical compounds
NO341631B1 (en) * 2005-04-13 2017-12-11 Astex Therapeutics Ltd Hydroxybenzamide derivatives and their use, method of preparation and pharmaceutical compositions
CN101193862B (en) * 2005-04-13 2013-08-21 阿斯特克斯治疗有限公司 Hydroxybenzamide derivatives and their use as inhibitors of HSP90
US8530469B2 (en) 2005-04-13 2013-09-10 Astex Therapeutics Ltd. Therapeutic combinations of hydroxybenzamide derivatives as inhibitors of HSP90
KR101411167B1 (en) 2005-04-13 2014-06-23 아스텍스 테라퓨틱스 리미티드 Hydroxybenzamide derivatives and their use as inhibitors of hsp90
EP2332909A1 (en) 2005-04-13 2011-06-15 Astex Therapeutics Limited Hydroxybenzamide derivatives and their use as inhibitors of HSP90
US7700625B2 (en) 2005-04-13 2010-04-20 Astex Therapeutics Ltd. Hydroxybenzamide derivatives and their use as inhibitors of Hsp90
US8816087B2 (en) 2005-04-13 2014-08-26 Astex Therapeutics Limited Hydroxybenzamide derivatives and their use as inhibitors of Hsp90
WO2006109075A3 (en) * 2005-04-13 2006-11-30 Astex Therapeutics Ltd Hydroxybenzamide derivatives and their use as inhibitors of hsp90
WO2006109075A2 (en) * 2005-04-13 2006-10-19 Astex Therapeutics Limited Hydroxybenzamide derivatives and their use as inhibitors of hsp90
US9914719B2 (en) 2005-04-13 2018-03-13 Astex Therapeutics Ltd. Hydroxybenzamide derivatives and their use as inhibitors of HSP90
US8017654B2 (en) 2005-04-15 2011-09-13 Synta Pharmaceuticals Corp. Combination cancer therapy with bis(thiohydrazide) amide compounds
US7674795B2 (en) 2005-05-19 2010-03-09 Aventis Pharma Sa Fluorene derivatives, composition containing said derivatives and the use thereof
WO2006126751A1 (en) * 2005-05-25 2006-11-30 Korea Research Institute Of Bioscience And Biotechnology New diaryl-isoxazole derivatives, and pharmaceutical compositions containing the same for the prevention and the treatment of cancers
US7662813B2 (en) 2005-08-18 2010-02-16 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
WO2007096194A1 (en) * 2006-02-27 2007-08-30 Novartis Ag Radio-labeled isoxazole derivatives useful for the labeling and diagnostic of hsp90 functionality
US8106057B2 (en) 2006-03-01 2012-01-31 Astex Therapeutics, Ltd. Dihydroxyphenyl isoindolylmethanones
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
US8323669B2 (en) 2006-03-28 2012-12-04 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of taxane
WO2007131034A1 (en) * 2006-05-03 2007-11-15 The Regents Of The University Of Michigan Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70
US8940332B2 (en) 2006-05-18 2015-01-27 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of podophyllotoxins
US9156783B2 (en) 2006-08-21 2015-10-13 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US7939564B2 (en) 2006-08-31 2011-05-10 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
WO2008033449A2 (en) * 2006-09-14 2008-03-20 Synta Pharmaceuticals Corp. Compounds for the treatment of angiogenesis
WO2008033449A3 (en) * 2006-09-14 2008-08-07 Synta Pharmaceuticals Corp Compounds for the treatment of angiogenesis
WO2008041610A1 (en) 2006-10-03 2008-04-10 Nippon Kayaku Kabushiki Kaisha Compound of resorcinol derivative with polymer
US8653084B2 (en) 2006-10-12 2014-02-18 Astex Therapeutics Ltd. Hydrobenzamide derivatives as inhibitors of Hsp90
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
US9428439B2 (en) 2006-10-12 2016-08-30 Astex Therapeutics Ltd. Hydrobenzamide derivatives as inhibitors of Hsp90
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US9730912B2 (en) 2006-10-12 2017-08-15 Astex Therapeutics Limited Pharmaceutical compounds
US8779132B2 (en) 2006-10-12 2014-07-15 Astex Therapeutics Limited Pharmaceutical compounds
US8277807B2 (en) 2006-10-12 2012-10-02 Astex Therapeutics Limited Pharmaceutical combinations
US8334364B2 (en) 2006-11-06 2012-12-18 Nipon Kayaku Kabushiki Kaisha High-molecular weight derivative of nucleic acid antimetabolite
US8188222B2 (en) 2006-11-08 2012-05-29 Nippon Kayaku Kabushiki Kaisha High molecular weight derivative of nucleic acid antimetabolite
US7799954B2 (en) 2006-11-17 2010-09-21 Abraxis Bioscience, Llc Dicarbonyl derivatives and methods of use
AU2008220800B2 (en) * 2007-03-01 2012-02-16 Novartis Ag Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms
US8487095B2 (en) 2007-03-01 2013-07-16 Novartis Ag Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-iso-propyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms
EP2545921A2 (en) 2007-03-01 2013-01-16 Novartis AG Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms
EA017075B1 (en) * 2007-03-01 2012-09-28 Новартис Аг Mesylate, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms
US8163747B2 (en) 2007-03-01 2012-04-24 Novartis Ag Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms
WO2008104595A1 (en) * 2007-03-01 2008-09-04 Novartis Ag Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms
EP2545921A3 (en) * 2007-03-01 2013-04-10 Novartis AG Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms
US7534788B2 (en) 2007-07-25 2009-05-19 Hoffmann-La Roche Inc. Benzofuran and benzothiophene-2-carboxylic acid amide derivatives
WO2009026658A1 (en) * 2007-08-29 2009-03-05 The University Of Sydney Ppar agonists
US8703878B2 (en) 2007-09-28 2014-04-22 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of steroids
USRE46190E1 (en) 2007-09-28 2016-11-01 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of steroids
WO2009047323A3 (en) * 2007-10-12 2009-11-12 Novartis Ag Isoxazole compound for the treatment of cancer
EP2263751A1 (en) 2007-10-12 2010-12-22 Novartis AG Isoxazole compound for the treatment of cancer
AU2008309562B2 (en) * 2007-10-12 2012-01-19 Novartis Ag Isoxazole compound for the treatment of cancer
US7932279B2 (en) 2007-10-12 2011-04-26 Arqule, Inc. Substituted tetrazole compounds and uses thereof
WO2009047323A2 (en) * 2007-10-12 2009-04-16 Novartis Ag Organic compounds
JP2014156475A (en) * 2007-10-12 2014-08-28 Novartis Ag Isoxazole compound for cancer treatment
EP3427797A1 (en) 2007-10-12 2019-01-16 Vernalis (R&D) Limited Isoxazole compound for the treatment of lung cancer
JP2011500535A (en) * 2007-10-12 2011-01-06 ノバルティス アーゲー Isoxazole compounds for cancer treatment
KR101841872B1 (en) 2007-10-12 2018-03-26 노파르티스 아게 Isoxazole compound for the treatment of cancer
US8673911B2 (en) * 2007-11-02 2014-03-18 Methylgene Inc. Inhibitors of histone deacetylase
AU2008318244A1 (en) * 2007-11-02 2009-05-07 Methylgene Inc. Inhibitors of histone deacetylase
US20110021771A1 (en) * 2007-11-02 2011-01-27 Methylgene Inc. Inhibitors of histone deacetylase
WO2009066060A2 (en) * 2007-11-19 2009-05-28 Topotarget A/S 4-substituted-6-isopropyl-benzene-1,3-diol compounds and their use
WO2009066060A3 (en) * 2007-11-19 2009-12-23 Topotarget A/S 4-substituted-6-isopropyl-benzene-1,3-diol compounds and their use
US8920788B2 (en) 2008-03-18 2014-12-30 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of physiologically active substances
US8383619B2 (en) 2008-04-11 2013-02-26 Astex Therapeutics Limited Pharmaceutical compounds
US8664218B2 (en) 2008-04-11 2014-03-04 Astex Therapeutics Ltd. Pharmaceutical compounds
WO2009134110A1 (en) * 2008-04-30 2009-11-05 Biotechnologijos Institutas 5-aryl-4-(5-substituted 2,4-dihydroxyphenyl)-1,2,3-thiadiazoles as inhibitors of hsp90 chaperone and the intermediates for production thereof
US9149540B2 (en) 2008-05-08 2015-10-06 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of folic acid or folic acid derivative
TWI450898B (en) * 2008-07-04 2014-09-01 Sigma Tau Res Switzerland Sa Aryl isoxazole compounds with antitumoural activities
WO2010000748A1 (en) * 2008-07-04 2010-01-07 Sigma-Tau Research Switzerland S.A. 5-phenyl-isoxazole-3-carboxamides modulating hsp90 with antitumoral activities
EA019793B1 (en) * 2008-07-04 2014-06-30 Сигма-Тау Рисерч Свитцерленд С.А. 5-phenyl-isoxazole-3-carboxamides modulating hsp90 with antitumoral activities
AU2009265745B2 (en) * 2008-07-04 2013-07-04 Sigma-Tau Research Switzerland S.A. 5-phenyl-isoxazole-3-carboxamides modulating Hsp90 with antitumoral activities
US8383616B2 (en) 2008-07-04 2013-02-26 Sigma-Tau Industrie Farmaceutiche Riunite Spa Aryl isoxazole compounds with antitumoural activities
CN102083804A (en) * 2008-07-04 2011-06-01 希格马托研究瑞士公司 5-phenyl-isoxazole-3-carboxamides modulating HSP90 with antitumoral activities
AU2009319048B2 (en) * 2008-11-28 2014-01-30 Novartis Ag Pharmaceutical combination comprising a Hsp 90 inhibitor and a mTOR inhibitor
WO2010060939A3 (en) * 2008-11-28 2010-10-07 Novartis Ag Pharmaceutical combinations comprising a pyrido [4, 3-d] pyrimidine derived hsp90-inhibitor and a her2 inhibitor
AU2009319050B2 (en) * 2008-11-28 2014-01-30 Novartis Ag Pharmaceutical combinations comprising a pyrido [4, 3-d] pyrimidine derived Hsp90-inhibitor and a HER2 inhibitor
WO2010060939A2 (en) * 2008-11-28 2010-06-03 Novartis Ag Combination of hsp90 and herceptin inhibitors
WO2010060937A2 (en) * 2008-11-28 2010-06-03 Novartis Ag Hsp90 inhibitor combinations
WO2010060937A3 (en) * 2008-11-28 2011-02-03 Novartis Ag Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor
WO2010121963A1 (en) 2009-04-21 2010-10-28 Nerviano Medical Sciences S.R.L. Resorcinol derivatives as hsp90 inhibitors
US8993556B2 (en) 2009-04-21 2015-03-31 Nerviano Medical Sciences S.R.L. Resorcinol derivatives as HSP90 inhibitors
JP2012524743A (en) * 2009-04-21 2012-10-18 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Resorcinol derivatives as HSP90 inhibitors
US8808749B2 (en) 2009-05-15 2014-08-19 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of bioactive substance having hydroxy group
WO2011040421A1 (en) 2009-09-29 2011-04-07 武田薬品工業株式会社 Screening method
US8563254B2 (en) 2009-10-16 2013-10-22 Novartis Ag Biomarkers of tumor pharmacodynamic response
WO2011045396A2 (en) 2009-10-16 2011-04-21 Novartis Ag Biomarkers of tumor pharmacodynamic response
KR101392086B1 (en) * 2010-02-17 2014-05-07 일동제약주식회사 A novel 5-membered heterocycle derivatives and manufacturing process thereof
WO2011102660A3 (en) * 2010-02-17 2012-01-19 Ildong Pharm Co., Ltd. A novel 5-membered heterocycle derivatives and manufacturing process thereof
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
US9018323B2 (en) 2010-11-17 2015-04-28 Nippon Kayaku Kabushiki Kaisha Polymer derivative of cytidine metabolic antagonist
WO2013015661A2 (en) * 2011-07-28 2013-01-31 Ildong Pharm Co.,Ltd. Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide
WO2013015661A3 (en) * 2011-07-28 2013-05-02 Ildong Pharm Co.,Ltd. Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide
US9346923B2 (en) 2011-09-11 2016-05-24 Nippon Kayaku Kabushiki Kaisha Method for manufacturing block copolymer
WO2013053833A1 (en) 2011-10-14 2013-04-18 Novartis Ag 2 - carboxamide cycloamino urea derivatives in combination with hsp90 inhibitors for the treatment of proliferative diseases
US10500193B2 (en) 2011-11-02 2019-12-10 Synta Pharmaceuticals Corporation Combination therapy of HSP90 inhibitors with platinum-containing agents
US9439899B2 (en) 2011-11-02 2016-09-13 Synta Pharmaceuticals Corp. Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors
WO2014074580A1 (en) 2012-11-07 2014-05-15 Novartis Ag Combination therapy
US9409893B2 (en) 2012-11-09 2016-08-09 Jacobus Pharmaceutical Company, Inc. Heteroaryl derivatives and uses thereof
US9296696B2 (en) 2012-11-09 2016-03-29 Jacobus Pharmaceuticals Company, Inc. Aryl derivatives and uses thereof
WO2014074775A1 (en) * 2012-11-09 2014-05-15 Jacobus Pharmaceutical Company, Inc. Heteroaryl derivatives and uses thereof
EP3514179A1 (en) 2014-01-24 2019-07-24 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
EP4324518A2 (en) 2014-01-31 2024-02-21 Novartis AG Antibody molecules to tim-3 and uses thereof
EP3660050A1 (en) 2014-03-14 2020-06-03 Novartis AG Antibody molecules to lag-3 and uses thereof
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
RU2692782C2 (en) * 2014-10-01 2019-06-27 Дайити Санкио Компани, Лимитед Isoxazole derivative as inhibitor of mutant isocitrate dehydrogenase 1
US10040791B2 (en) 2014-10-01 2018-08-07 Daiichi Sankyo Company, Limited Isoxazole derivative as mutant isocitrate dehydrogenase 1 inhibitor
WO2016057841A1 (en) 2014-10-08 2016-04-14 Novartis Ag Compositions and methods of use for augmented immune response and cancer therapy
EP4245376A2 (en) 2014-10-14 2023-09-20 Novartis AG Antibody molecules to pd-l1 and uses thereof
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
RU2697703C2 (en) * 2015-01-22 2019-08-19 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. Resorcinol derivative as hsp90 inhibitor
WO2016145102A1 (en) 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
US10449211B2 (en) 2015-03-10 2019-10-22 Aduro Biotech, Inc. Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
US11040053B2 (en) 2015-03-10 2021-06-22 Chinook Therapeutics, Inc. Compositions and methods for activating “stimulator of interferon gene”13 dependent signalling
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
EP4378957A2 (en) 2015-07-29 2024-06-05 Novartis AG Combination therapies comprising antibody molecules to pd-1
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
EP3964528A1 (en) 2015-07-29 2022-03-09 Novartis AG Combination therapies comprising antibody molecules to lag-3
US10894830B2 (en) 2015-11-03 2021-01-19 Janssen Biotech, Inc. Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
EP4424322A2 (en) 2015-12-17 2024-09-04 Novartis AG Antibody molecules to pd-1 and uses thereof
WO2018001084A1 (en) * 2016-06-29 2018-01-04 广州市恒诺康医药科技有限公司 Heat shock protein inhibitor, and manufacturing method and application thereof
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
US10975114B2 (en) 2017-04-28 2021-04-13 Chinook Therapeutics, Inc. Bis 2′-5′-RR-(3′F-A)(3′F-A) cyclic dinucleotide compound and uses thereof
WO2018198076A1 (en) 2017-04-28 2018-11-01 Aduro Biotech, Inc. Bis 2'-5'-rr-(3'f-a)(3'f-a) cyclic dinucleotide compound and uses thereof
WO2021152113A1 (en) 2020-01-31 2021-08-05 Bayer Aktiengesellschaft Substituted 2,3-benzodiazepines derivatives

Also Published As

Publication number Publication date
EP1611112A1 (en) 2006-01-04
US9718793B2 (en) 2017-08-01
PT1611112E (en) 2012-11-02
MXPA05008335A (en) 2006-05-04
JP2006517572A (en) 2006-07-27
US11234987B2 (en) 2022-02-01
HK1091831A1 (en) 2007-01-26
US20170326152A1 (en) 2017-11-16
US20190358241A1 (en) 2019-11-28
US8450310B2 (en) 2013-05-28
US20120252797A1 (en) 2012-10-04
CN1771235B (en) 2010-04-28
US20100179138A1 (en) 2010-07-15
CA2515726C (en) 2012-07-10
KR20050103925A (en) 2005-11-01
NO335001B1 (en) 2014-08-18
EA200501272A1 (en) 2006-02-24
JP4921162B2 (en) 2012-04-25
AU2004210779A1 (en) 2004-08-26
NO20054195D0 (en) 2005-09-09
CN1771235A (en) 2006-05-10
KR101166749B1 (en) 2012-07-27
AU2004210779B2 (en) 2010-06-10
NZ541479A (en) 2008-11-28
CY1113761T1 (en) 2016-07-27
SI1611112T1 (en) 2012-12-31
US7705027B2 (en) 2010-04-27
EP1611112B1 (en) 2012-08-22
DK1611112T3 (en) 2012-11-19
US10413550B2 (en) 2019-09-17
NO20054195L (en) 2005-11-09
US8507480B2 (en) 2013-08-13
ES2393483T3 (en) 2012-12-21
EA009919B1 (en) 2008-04-28
US20060241106A1 (en) 2006-10-26
US20130289026A1 (en) 2013-10-31
BRPI0407403A (en) 2006-10-03
CA2515726A1 (en) 2004-08-26
BRPI0407403B1 (en) 2022-07-19

Similar Documents

Publication Publication Date Title
US11234987B2 (en) Isoxazole compounds as inhibitors of heat shock proteins
US7612201B2 (en) Pyrazole compounds
EP1675861B1 (en) Pyrimidothiophene compounds
EP1567151B1 (en) 3-(2-hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer
JP4891904B2 (en) Pyrimidothiophene compound
CN100455586C (en) Pyrimidothiophene compounds
WO2006090094A1 (en) Pyrimidothiophene compounds for use as hsp90 inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 541479

Country of ref document: NZ

Ref document number: 2004210779

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/008335

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1845/CHENP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006502254

Country of ref document: JP

Ref document number: 1020057014738

Country of ref document: KR

Ref document number: 2515726

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2004210779

Country of ref document: AU

Date of ref document: 20040209

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004210779

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005/06836

Country of ref document: ZA

Ref document number: 200506836

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2004709273

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200501272

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 20048093392

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020057014738

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004709273

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006241106

Country of ref document: US

Ref document number: 10544443

Country of ref document: US

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: PI0407403

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10544443

Country of ref document: US